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Abstract  
Retinitis  pigmentosa  (RP)  is  characterized  by  impaired  night  vision  and 
constriction of visual fields, which with disease progression leads to blindness. 
RP can develop as an independent disorder or as a part of a syndrome caused 
by cilia dysfunction, such as Bardet-Biedl syndrome (BBS). Mutations in several 
potential chaperones, similar to cytosolic chaperonin (CCT) subunits, have been 
shown  to  cause  BBS,  such  as  BBS6,  10  and  12.  Furthermore,  mice 
homozygous  for  a  prefoldin  5  (pfdn5)  amino  acid  substitution  have  been 
reported to have retinal degeneration. Prefoldin 5 (PFDN5) is a subunit of the 
prefoldin  chaperone  complex,  which  assists  in  folding  of  tubulin,  and is  thus 
potentially important for microtubule function in the retina.  
Another putative chaperone, RP2, which has homology to another chaperone of 
the  tubulin  folding  pathway,  cofactor  C,  causes  X-linked  RP.  This  protein  is 
ubiquitous as are its currently described interacting partners. The reason why 
RP2  mutations  cause  a retina restricted  phenotype is  not  understood  yet.  A 
study  into  potential  mechanisms  by  which  RP2  could  be  involved  in  retina 
pathways is presented in this thesis. For this purpose RP2 was tested for retina 
specific interactions using two approaches – yeast two-hybrid and proteomic 
screening. During yeast two-hybrid screening of RP2 with a retina cDNA library, 
rod arrestin was identified as a potential interacting partner, binding to the N-
terminus of RP2. Using a proteomic approach of affinity pull down of retinal 
proteins, a retina specific protein, transducin-β subunit, was identified. These 
two novel interacting partners can possibly improve our understanding why RP2 
mutations  lead  to  a  retina  restricted  phenotype.  Several  other  putative 
interacting  partners  with  ubiquitous  expression  were  also  identified  by  yeast 
two-hybrid screening. 
For the genetic screening of PFDN5, two panels of patients were selected, BBS 
of  unknown  aetiology  and  severe  and  early  onset  retinal  degeneration.  No 
disease associated sequence changes were detected in the coding sequence 
or exon/intron boundaries of these patient groups, suggesting that the mutations 
in such a gene could cause another type of ciliopathy or phenotype such as 
embryonic lethality.  
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Chapter I. Introduction 
1.1.  The eye 
The human eye is the organ of vision. It consists of three main layers (figure 
1.1). The first layer is a fibrous coat and includes the cornea and sclera. The 
second layer is called the uvea and is composed of the choroid, ciliary body, 
lens and iris. The choroid is the layer of blood vessels from arteria ophthalmica 
that supplies the eye. The ciliary body is the circumferential tissue inside the 
eye  composed  of  the  ciliary  muscle  and  ciliary  processes.  This  structure  is 
attached to the lens, regulates lens shape and therefore is partially responsible 
for light focus on the retina. When the ciliary muscle relaxes, it flattens the lens, 
generally improving the focus for farther objects and vice versa. The third layer 
of the eye is known as the retina and lines the back of the eye (figure 1.1). 
The eye has three chambers of fluid: anterior chamber (between cornea and 
iris), posterior chamber (between iris, zonule fibers and lens) and the vitreous 
chamber (between the lens and the retina). The first two chambers are filled 
with  aqueous  humour  whereas  the  vitreous  chamber  is  filled  with  a  more 
viscous fluid, the vitreous humour. 
1.2.  The retina 
The retina is composed of neural retina, interphotoreceptor matrix and retinal 
pigment  epithelium  (RPE)  cells  layer  (figure  1.1).  The  adult  human  retina  is 
approximately  42  mm  diameter,  0.5  mm  thick  (Pipe  and  Rapley,  1984).  The 
optic nerve disc near the centre of the retina is a circular to oval white area 
measuring about 2 mm across. Here the optic nerve forms the output of the 
neural retina to the brain. This area does not contain any photoreceptors and is 
known  as  the  “blind  spot”.  From  its  centre  radiate  the  major  blood  vessels. 
Approximately two optic disc diameters to the left of the optic nerve disc, can be 
seen  a  blood  vessel-free  spot,  the  fovea,  which is  at  the  centre  of  the area 
known as the macula (figure 1.2). The retina is a highly organized structure of 
neural retina cells and RPE cells and is composed of a large number of cell 
types, each with a different function (Pipe and Rapley, 1984).   Chapter I 
21 
   
 
 
Figure 1.1. Structure of the human eye 
A cross-sectional view of the human eye (from www.webvision.med.utah.edu) 
 
 
Figure 1.2. A fundus image of a human retina 
 An ophthalmoscopic image of a human retina showing the fovea, optic nerve 
and blood vessels (from www.webvision.med.utah.edu). 
   Chapter I 
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1.2.1.  The retinal pigment epithelium 
A monolayer of epithelial cells separates the neural retina from choroid known 
as the retinal pigment epithelium (RPE) (figure 1.3a). This layer has several 
functions. The RPE nourishes neural retina cells, supplying small molecules, 
such  as  amino  acids,  from  the  blood  vessels  of  the  choroid.  The  RPE  also 
serves as a barrier between blood vessels and neural retina. Third, RPE cells 
recycle  11-cis  retinal  and  thus,  take  part  in  visual  cycle.  RPE  cells  play  an 
important role in the phagocytosis of outer segments (OS) discs. Shed discs 
undergo phagocytosis which occurs through the apical processes of RPE cells 
that  surround  the  photoreceptor  OS  (Andersen  et  al.,  1978).  Each  RPE  cell 
contacts approximately 45 OS and the estimated turnover of outer segments 
discs is 10 % daily (Bosch et al., 1993). The RPE also absorbs scattered light 
as it is rich in melanosomes (LaVail and Gorrin, 1987). 
1.2.2.   The neural retina 
The neural retina is arranged into histologically distinct layers. The outer nuclear 
layer (ONL) contains the cell bodies of the rod and cone photoreceptors (figure 
1.3) The distribution of rods and cones is not even throughout the retina. The 
central retina is cone-dominated and the periphery is a rod rich region. Within 
the macula, cone photoreceptors are highly concentrated. This region includes 
a 200  m fovea pit, where only cones are present (Pipe and Raley, 1984). 
The  first  layer  of  synapses  is  the  outer  plexiform  layer  (OPL).  This  layer 
contains axons of photoreceptor cells and dendrites of the cells from the inner 
nuclear layer (INL). The INL is composed of bipolar, horizontal and amacrine 
cells, which are adjacent to the inner plexiform layer (IPL). This is the second 
layer of synapses in the retina. The IPL has axons of the cells of INL, dendrites 
of the ganglion cells and a second population of amacrine cells which form the 
ganglion cell layer (GCL) (figure 1.3). The GCL contains the ganglion cell nuclei 
and axons of these cells that form the optic nerve conducting the signal to the 
visual cortex of the brain (Pipe and Raley, 1984).  
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Figure 1.3. Structure of the retina 
a. A schematic of the human retina showing the organisation of various cell 
types in the retina. b. Light micrograph of the vertical section through central 
human retina. OLM, outer limiting membrane; ONL, outer nuclear layer; OPL, 
outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, 
ganglion  cell  layer;  ILM,  inner  limiting  membrane  (from 
www.webvision.med.utah.edu). 
 
 
Figure 1.4. Diagrammatic representation of a rod and cone cell 
OS,  outer  segment;  IS,  inner  segment,  D,  discs;  CC,  connecting  cilium;  E, 
ellipsoid; M, myoid; N, nuclear region; ST, synaptic terminal (from Djamgoz and 
Kolb, 1993). 
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The retina has glial cells called Muller cells. Their adherent junctions together 
with the photoreceptor cell inner segments form the outer limiting membrane 
(OLM) of the retina. The inner limiting membrane (ILM) of the retina is likewise 
composed  of  laterally  contacting  Muller  cells  and  the  components  of  the 
basement membrane. The ILM is the inner surface of the retina bordering the 
vitreous humour and thereby forms a diffusion barrier between neural retina and 
vitreous humour (Pipe and Raley, 1984). 
Light travels through the optical systems of the eye and retinal structures before 
striking the photoreceptor outer segments which transform photon energy into 
membrane depolarisation and the visual process begins. 
1.2.2.1.  Rod and cone photoreceptors 
The  human  retina  has  two  basic  types  of  photoreceptors,  rods  and  cones 
(figures 1.3 and 1.4). Rods are highly sensitive photoreceptors and contain the 
visual pigment – rod opsin. This type of photoreceptor is used for vision under 
dark-dim light conditions. Cones contain cone opsins as their visual pigments 
and these have different wavelength sensitivity, forming the basis of trichromatic 
colour perception. The number of rod cells is approximately twenty times higher 
than cones (Curcio et al., 1990). 
Cones are conical-shaped structures that have their cell bodies situated in a 
single row right below the outer limiting membrane (OLM) and their inner and 
outer  segments  protrude  into  the  sub-retinal  space  towards  the  pigment 
epithelium.  Rods  are  slim  rod-shaped  structures  with  their  inner  and  outer 
segments that fill the area between the larger cones in the sub-retinal space 
and stretch to the pigment epithelium cells (figure 1.4).  
Both rods and cones have a similar structure consisting of outer (OS) and inner 
segment (IS) connected by the connecting cilium (CC), cell body and synaptic 
terminal. The outer segments of rods are a stack of numerous membranous 
discs, surrounded by a plasma membrane. They have no connection between 
each  other  or  the  plasma  membrane,  apart  from  the  most  basal  ones.  In 
contrast, in cones all the discs are continuous with one another and the plasma 
membrane (figure 1.4) (Anderson et al., 1978).  Chapter I 
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1.2.2.2.  Outer segment morphogenesis 
The  outer  segments  of  rods  and  cones  are  continually  renewed  through  the 
process of morphogenesis and shedding. They are produced by invaginations 
of the plasma membrane near the connecting cilium and then internalised. At 
the same time old discs are displaced up the outer segment and are pinched off 
at  the  tips  and  engulfed  by  the  apical  processes  of  the  pigment  epithelium. 
These discarded discs become phagosomes in RPE (section 1.2.1) (Steinberg 
et al., 1977).  
There is a burst of disc shedding in the morning in rods (LaVail, 1980) and in 
the  evening  in  cones  (Young,  1978),  judged  by  increased  numbers  of 
phagosomes  in  the  pigment  epithelium  shortly  thereafter.  Outer  segment 
proteins are produced in the inner segment, which is divided into ellipsoid and 
myoid  region.  The  myoid  mainly  contains  organelles  necessary  for  protein 
synthesis and is suggested to be a docking region, whereas the ellipsoid region 
has high density of mitochondria (figure 1.4) (Carter-Dawson and LaVail, 1979).  
1.2.2.3.  The connecting cilium 
The connecting cilium (CC) is a specialised non-motile cilium which connects 
the OS with the IS of photoreceptors. It contains nine pairs of microtubules in 
9+0  arrangement,  and  compared  to  a  motile  cilium  it  lacks  the  central 
microtubule doublet and dynein arms (Rohlich, 1975). The cilium arises from a 
modified  centriole  known  as  the  basal  body,  which  acts  as  a  microtubule 
organising centre for the photoreceptor (Troutt and Burnside, 1988). From the 
basal  body  the axoneme  extends  further  up  into  the  outer  segment  and  the 
cytoskeletal structure extends down into the cell body forming a rootlet (figure 
1.5) (Yang et al., 2002).  
The connecting cilium is essential for the transport of proteins produced in the 
inner  segment  to  the  outer  segment  (Miyaguchi  and  Hashimoto,  1992). This 
type of transport is known as intraflagellar transport (IFT) and is mediated by 
motor proteins such as kinesin II for anterograde traffic (Cole et al., 1998) and 
dynein 1B for retrograde (Pazour et al., 1998).  
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Figure 1.5. The rod connecting cilium structure 
a. A longitudinal profile of a photoreceptor with the connecting cilium structure 
shown as indicated (from Liu et al., 2007a). b. A cross-sectional view through 
the  connecting  cilium  (CC)  and  a  3D  rendition  of  the  photoreceptor  inner 
segment in relation to the connecting cilium are shown. The periciliary ridge 
region is indicated in orange (modified from Liu et al., 2007b). 
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A large number of mutations in genes encoding proteins involved in IFT have 
been  reported  to  date.  The  phenotype  in  such  disorders  usually  affects  the 
retina,  for  example  Bardet-Biedl  syndrome  (described  in  section  1.3.2.2) 
(Bergsma and Brown 1975, Nishimura et al, 2004). Furthermore, other retinal 
disease  proteins  have  been  localized  to  the  connecting  cilium  structure  e.g. 
RPGR (discussed in section 1.3.1.1.1) (Hong et al., 2000), RP1 (Ostrowski et 
al., 2002) (figure 1.5a). 
The connecting cilium is surrounded by a region known as the periciliary ridge 
(Watanabe  et  al.,  1999).  This  is  a  region  of  the  photoreceptor  plasma 
membrane at the apical inner segment that encircles the connecting cilia (figure 
1.5b).  The  connecting  cilia  of  photoreceptors  sit  in  a  recess  formed  by  the 
invagination of apical inner segment plasma membrane. The narrow band of 
periciliary  matrix  materials  separates  the  plasma  membranes  of  the  inner 
segment  and  of  the  connecting  cilium.  Some  retinal  disease  proteins  are 
localised to this region, for example Usherin (Liu et al., 2007b). 
1.2.3.   Visual phototransduction 
Human visual phototransduction occurs in the photoreceptors and is a process 
that converts the light energy into an electric signal.  It is based on guanine 
nucleotide binding protein (G protein) coupled receptor (GPCR) signalling.  
1.2.3.1. G protein coupled receptor signalling 
A  variety  of  processes  in  cells  is  regulated  by  extracellular  signals 
(neurotransmitters, neuromodulators, hormones etc.) that are transmitted into 
the cell via different pathways. The most common pathway is a three step G 
protein  signalling  cascade  (figure  1.6).  The  first  step  is  the  activation  of  a 
GPCR.  Proteins  of  the  superfamily  of  GPCR  have  similar  structure  and  are 
known to have seven transmembrane (TM) domains linked by intracellular and 
extracellular  loops  (Trumpp-Kallmeyer  et  al.,  1992,  Feng  et  al.,  1999). 
Extracellular loops together and/or TM domains are known to be responsible for 
ligand  binding,  and  intracellular  loops  bind  to  guanine  nucleotide  binding 
proteins  (G  proteins)  (reviewed  in  Wess,  1997).  GPCRs  are  conventionally 
divided into six classes A-F (table 1.1). Chapter I 
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Class of GPCR  Distinctive feature  Receptors examples 
Class A (rhodopsin-
like) 
Agonist binds within 
the cavity in the 
heptahelical domain 
and/or extracellular 
loops between the 
helices 
Rhodopsin; 
α and β adrenoreceptors; 
muscarinic cholergic; 
dopamine; 
odorant; 
 
Class B  Large extracellular 
N-terminal ligand 
binding site 
Secretin receptor family: 
Corticotrophin-releasing 
factor receptor; 
parathyroyd  hormone 
receptor; 
Class C  Function only as 
dimers 
Pheromone receptors: 
Homodimeric 
metabotrophic glutamate 
receptor; 
homodimeric 
metabotrophic calcium 
sensing receptor; 
heterodimeric GABAB; 
sweet and umami taste 
receptors; 
Class D  Low sequence 
similarity to other 
GPCRs 
Fungal pheromone 
mating factor receptors: 
STE2, 
STE3 
Class E  Low sequence 
similarity to other 
GPCRs 
Cyclic AMP receptors in 
amoeba  
Class F  transmission and 
interpretation of cell 
polarity information;  
cell density sensing 
Frizzled, 
Smoothened 
Table 1.1. Classes of GPCRs 
 Modified from Breitwieser, 2004; Chen and Struhl, 1996; Vinson et al., 1999 
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Figure 1.6. G protein signalling pathway 
A schematic of the GDP/GTP cycle governing activation of heterotrimeric GPCR 
signaling pathways. In the absence of ligand, the Gα subunit is GDP bound and 
closely associated with the Gβγ heterodimer. This Gα·GDP/Gβγ heterotrimer 
interacts  with  the  cytosolic loops  of  a  seven  transmembrane  domain  GPCR. 
Gβγ  facilitates  the  coupling  of  Gα  to  receptor  and  also  acts  as  a  guanine 
nucleotide  dissociation  inhibitor  (GDI)  for  Gα·GDP,  slowing  the  spontaneous 
exchange of GDP for GTP. Ligand-bound GPCR acts as a guanine nucleotide 
exchange factor (GEF) by inducing a conformational change in the Gα subunit, 
allowing it to exchange GTP for GDP. Gβγ dissociates from Gα·GTP, and both 
Gα·GTP  and  Gβγ  are  competent  to  signal  to  their  respective  effectors.  The 
cycle  returns  to  the  basal  state  when  Gα  hydrolyzes  the  gamma-phosphate 
moiety of GTP, a reaction that is augmented by a GTPase-accelerating protein 
(GAP) such as RGS (modified from McCudden et al., 2005). 
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Ligand binding causes conformational changes in a GPCR that promotes its 
interaction with distinct classes of G protein heterotrimers consisting of α-, β-, 
and  γ-subunits.    Thus,  an  activated  GPCR  acts  as  a  guanine  nucleotide 
exchange factor (GEF) for a G protein α subunit.  
This  process  triggers  the  second  step  of  G  protein  signalling  cascade  -  the 
exchange of GDP for GTP on the α-subunit and this leads to the dissociation of 
the  G  protein  from  the  receptor  (figure  1.6).  The  important  feature  of  this 
cascade step is the signal amplification since one activated molecule of GPCR 
is  able  to  cause  dissociation  of  upto  120  G  protein  heterotrimers  per  one 
activated GPCR molecule per s
-1 (reviewed in Arshavsky et al., 2002). 
Released G protein α subunit and G protein βγ heterodimer are able to interact 
with second messengers, such as distinct effector enzymes and channels. This 
interaction leads  to  a  cellular  response,  which  is  the  third  step  of  G  protein 
signalling cascade (figure 1.6) (reviewed in Neer and Clapham, 1988).  
The  G  protein  activation  becomes  terminated  by  enzymes  called  GTPase 
activating  proteins  (GAP)  which  hydrolyse  GTP  to  GDP  on  the  G  protein  α 
activated subunit. The most extensively studied GAPs are phospholipase C and 
regulators of G protein signalling (RGS) (Ross and Willkie, 2000). 
1.2.3.2. G proteins 
As mentioned above, G proteins are composed of three subunits, αβγ, with the 
GTP  binding  domain  located  on  the  α  subunit.  There  are  four  families  of 
heterotrimeric  G  proteins  classified  by  sequence  homology  of  the  α  subunit 
(figure 1.7).  There are currently 15 Gα genes in the human genome (NCBI and 
UCSC databases) (table 1.2). G protein α subunits are N-terminally modified by 
the covalent attachment of the fatty acids myristate and/or palmitate (Nurnberg 
et al., 1995).  
There are five G protein β and ten G protein γ human subunit genes known to 
date (table 1.3), resulting in a large number of potential combinations of Gβγ 
dimers  and  effector  pathways.  All  G  protein  γ  subunits  are  C-terminally 
prenylated post-translationally: Gγt, Gγ8 and Gγ11 with a 15-carbon farnesyl 
moiety, and the rest with a 20-carbon geranylgeranyl (Nurnberg et al., 1995). Chapter I 
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Gα class  Gα   Gene 
symbol 
and 
locus 
Tissue 
distribution 
 
Other protein names 
Gs; 
stimulates 
the 
production 
of cAMP (or 
cGNP) from 
ATP (or 
GTP) 
Gαs  GNAS1 
20q13.3 
ubiquitous  secretogranin VI; 
GN regulatory protein; adenylate cyclase-
stimulating G α protein; 
G protein α stimulating activity polypeptide1 
Gαolf  GNAL 
18p11.22-
p11.21 
olfactory 
neuro- 
epithelium 
GN binding protein, α -subunit, olfactory 
type; 
GN binding protein (G protein), α activating 
activity polypeptide, olfactory type; 
Gi; 
inhibit the 
production 
of cAMP (or 
cGMP) 
from ATP 
(or GTP) 
Gαi1  GNAI1 
7q21 
brain, spinal 
cord 
Gi1 protein α subunit; 
GN binding protein (G protein), α inhibiting 
activity polypeptide 1; 
Gαi2  GNAI2 
3p21 
blood cells, 
lung, muscle, 
placenta 
GN binding protein (G protein), α inhibiting 
activity polypeptide 2; 
GTP-binding regulatory protein Gi α -2 
chain; 
Gαi3  GNAI3 
1p13 
blood cells  GN binding protein (G protein), α inhibiting 
activity polypeptide 3; 
Gαo  GNAO1 
 
16q13 
brain  GN binding protein, α activating polypeptide 
O, A; CRA-a isoform 
Gαt1  GNAT1 
3p21 
retinal rod 
cells 
transducin α -1 chain; 
transducin, rod-specific; GN binding protein, 
α transducing activity polypeptide 1; 
Gαt2  GNAT2 
1p13.1 
retinal cone 
cells 
transducin α -2 chain; cone-type transducin 
α subunit; transducin, cone-specific, α 
polypeptide; GNB protein G(t), α -2 subunit; 
GN binding protein, α transducing activity 
polypeptide 2; 
Gαz  GNAZ 
22q11.22 
predominately 
brain 
GN binding (G protein), α z polypeptide;  
Gq 
stimulates 
phosphor-
lipase C β 
Gαq  GNAQ 
9q21 
ubiquitous  GN binding protein (G protein), q 
polypeptide 
Gα11  GNA11  prostate, 
thyroid, heart, 
uterus, 
placenta, lung 
GN binding protein (G protein), α 11 
Gα14  GNA14 
9q21 
spinal cord, 
thyroid, liver 
kidney, heart 
GN binding 14 protein 14 
Gα15  GNA15 
19p13.3 
tissues of 
hematopoetic 
lineage 
 
G12 
targets 
Rho family 
GTPase 
signaling 
Gα12  GNA12 
7p22.2 
Ubiquitous  GN binding protein (G protein), α 12 
Gα13  GNA13 
17q24.3  
Ubiquitous  GN binding protein (G protein), α 13 
Table 1.2. G protein α subunits classification and main pathways; guanine 
nucleotide (GN) Modified from Downes and Gautam, 1999. Chapter I 
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G protein 
subunit 
Gene 
symbol 
Locus  Expression   Alternative names 
Gβ1  GNB1        1p36.33  ubiquitous  transducin β; 
guanine nucleotide-
binding protein 
G(I)/G(S)/G(T) β subunit 
1; transducin β chain 1; 
Gβ2  GNB2        7q22  predominantly 
blood cells 
transducin β chain 2 
Gβ3  GNB3       12p13.31  predominantly 
liver, brain   
transducin β chain 3; 
hypertension associated 
protein β 
Gβ4  GNB4       3q26.32  predominantly 
lung, placenta 
transducin beta chain 4; G 
protein β-4 subunit;  
Gβ5  GNB5       15q31.2  brain  GB5; transducin β chain 5; 
G protein, β subunit 5; 
Gβ5L  retina  G protein, β subunit 5L 
Gγ1  GNGT1        7q21.3  rod cells  GNG1 
Gγc  GNGT2     17q21  cone cells, 
olfactory 
neuroepithelium, 
brain 
GNG9; GNGT8; G-
GAMMA-8; G-GAMMA-C; 
GNGT2 
Gγ2  GNG2      14q21.1  brain  G protein γ subunit 2 
Gγ3  GNG3       11p11  brain, testis  NBP gamma-3; G protein 
γ subunit 3 
Gγ4  GNG4       1q42.3  brain, kidney, 
pancreas, 
skeletal muscle; 
G protein γ subunit 4 
Gγ5  GNG5       1p22  blood cells, 
lung, placenta, 
liver, heart 
G protein γ subunit 5 
Gγ7  GNG7      19p13.3  striatum, other 
tissues 
G protein γ subunit 7 
Gγ10  GNG10    9q31.3  ubiquitous  G protein γ subunit 10 
Gγ11  GNG11        7q21  abundantly 
expressed in all 
tissues tested 
except for brain 
GNGT11; G protein γ 
subunit 11 
Gγ12  GNG12     1p31.3  kidney, 
placenta, lung, 
endocrine 
system, uterus, 
heart. 
FLJ31352; G protein γ 
subunit 12 
Table 1.3. Human G protein βγ subunits and their properties Modified from 
Downes and Gautam, 1999. 
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Figure 1.7. Phylogenetic tree of G protein subunits 
Relationships  among  human  G  protein  α  subunits  (a),  β  subunits  (b)  and  γ 
subunits  (c).  The  alignment  was  performed  with  ClustalW.  Subunits  are 
grouped by amino acid identity.  Chapter I 
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This lipid modification of the Gγ polypeptide is believed to be important for the 
membrane localisation of the Gβγ dimer. Gβ subunits have not been shown to 
undergo such modifications, however it was demonstrated that some of them 
(Gβt)  could  be  targeted  to  the  plasma  membrane  independently  of  the  Gγ 
subunit by an uknown mechanism (Chisari et al., 2007). 
Most Gβγ combinations can form functional heterodimers (Jones et al., 2004) 
however, there are exceptions e.g. Gβ2 can pair with Gγ2 but not Gγt (Schmidt 
et  al.,  1992).  Evidence  supporting  the  role  of  specific  Gβγ  combinations  in 
receptor coupling and effector activation is sparse but growing (Jones et al., 
2004). Most in vitro assays show little difference in receptor coupling profile or 
effector activation (reviewed by McCudden et al., 2005).  
However, there are some in vivo examples of the importance of specific Gβγ 
pairs for specific signaling pathways. Inhibition of low-voltage-activated T-type 
calcium channels is mediated selectively by Gβ2γ2 (Wolfe et al., 2003). Gβ3γ3 
was shown to be important for coupling the somatostatin receptor to voltage-
sensitive L-type calcium channels, while Gβ4γ4 was found to be required for 
coupling the muscarinic receptor to the same channels (Kleuss et al., 1993). 
Gβtγt,  also  called  transducin  βγ,  interacts  more  robustly  with  rhodopsin  and 
phosducin than other Gβγ combinations (Muller et al., 1996). The Gαt1 subunit, 
that is alternatively termed as transducin α, binding to the Gβtγt (transducin βγ) 
heterodimer forms a transducin complex (Gαt-GDP-Gβγt) which takes part in 
the phototransduction cascade. 
1.2.3.3. Phototransduction cascade 
Photoreceptors  detect  light  through  activation  of  a  special  type  of  GPCR 
proteins.  In rod cells the GPCR is rod opsin (R), in cones by cone opsins. Like 
all GPCRs they have a typical seven TM domain structure with intracellular and 
extracellular  loops  (Palczewski  et  al.,  2000).  However,  unlike  other  GPCRs, 
they  are  covalently  bound  to  their  ligand  11-cis  retinal  via  a  Schiff  base 
(Koutalos  and  Ebrey,  1986).  11-cis  retinal  is  an  antagonist  for  opsin,  but  it 
becomes an agonist when it undergoes photoisomerisation into all-trans retinal.  
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The phototransduction cascade will be described for the most studied opsin, 
rhodopsin (R) (figure 1.8). 
11-cis  retinal  isomerisation  triggers  a  rhodopsin  conformational  change  and 
thus, starts the second step of the G protein signalling cascade. Activated R 
molecules (R*) interact with the GDP-bound form of a retina specific G protein, 
transducin  αβγ  trimers  (Vuong  et  al.,  1984).  The  R*  activates  transducin  by 
triggering of rapid exchange of GDP for GTP on the transducin α with rapid 
dissociation from the R*. At the same time active transducin α-GTP dissociates 
from transducin βγ (Bruckert et al., 1992) (figure 1.8). 
During  the  third  step  of  the  phototransduction  cascade  transducin  α-GTP 
stimulates  the  activity  of  its  effector  enzyme,  the  cGMP  phosphodiesterase 
(PDE),  also  known  as  PDE6  (Gillespie  and  Beavo,  1989).  The  PDE  is  a 
heterotetramer consisting of two nearly identical catalytic subunits (αβ in rods, 
αα in cones) and two identical regulatory γ subunits (PDEγ) (Hamilton et al., 
1993).  PDEγ  serve  as  inhibitors  of  PDE  activity  and  are  responsible  for 
maintaining basal activity at a low level.  
Activation  of  the  PDE  heterotetramer  results  in  removing  the  inhibitory 
constraint  that  PDEγ  had  imposed  on  the  catalytic  site  of  the  PDE  α  or  β 
subunits (Arshavsky and Bownds, 1992). This process causes a reduction in 
the cytoplasmic concentration of cGMP, which is the second messenger of the 
third step of phototransduction. This reduction in concentration causes closure 
of the cation selective cGMP-gated channels located in the plasma membrane 
(figure 1.8)  
Closure of these channels reduces the steady inward current that is normally 
carried  by  Na
+  and  Ca
2+  ions  in  the  dark.  This  results  in  membrane 
hyperpolarisation and decreased release of the synaptic transmitter glutamate 
in  rods  and  glycine  in  cones  at  the  synaptic  terminal  (Molday  and  Molday, 
1998). The  drop in  the  neurotransmitter  concentration is  detected  by  bipolar 
cells  which  generate  a  signal  that  is  further  processed  in  the  retina  and 
transmitted to the visual cortex (Vaney et al., 1998). 
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Figure 1.8. Phototransduction cascade in rods 
Rhodopsin (R) is activated by light (R*) (i) and causes transducin heterotrimer 
complex  dissociation (GDPαβγ)  with  the  release  of  GTP-bound  transducin  α 
(GTPα)  (ii),  which  in  turn  activates  the  PDE  complex  (iii),  resulting  in  the 
hydrolysis of cGMP to 5′-GMP (iv). The decrease in cGMP levels closes the 
cGMP-gated  Ca2+  channels  (v)  in  the  plasma  membrane  of  photoreceptors 
leading to a decrease in Ca2+ influx and the consequent hyperpolarisation of 
the  cell.  The  desensitisation  of  rhodopsin  (R*→Rn*)  is  mediated  by  the 
phosphorylation  of  rhodopsin  kinase  (RK)  (vi)  with  subsequent  binding  with 
arrestin (Arr) (vii) (adapted from Mendes et al., 2005). 
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The recovery of phototransduction starts when the drop in intracellular calcium 
concentration  activates  rhodopsin  kinase  that  phosphorylates  R*.  Further 
rhodopsin inactivation is completed by arrestin binding to the phosphorylated 
receptor.  
Transducin  inactivation  is  catalysed  by  specific  GAPs,  RGS4  and  RGS9, 
returning  the  G  protein  to  a  GDP-bound  state  (Nekrasova  et  al.,  1997). 
Remarkably, RGS9 acts as a GAP in a complex with another retina specific G 
protein, Gβ5 long isoform (Gβ5L), and R9AP (Makino et al., 1999). This process 
allows PDEα and/or β subunits to bind to γ inhibitory subunits (figure 1.8). 
Moreover,  the  low  calcium  concentration  activates  retinal  guanylate  cyclase 
(RetGC) by its activating protein (GCAP) and thereby restores the concentration 
of cGMP. The cGMP-gated ion channels open and the photoreceptor returns to 
a  depolarised  state  (figure  1.8).  The  intracellular  concentration  of  calcium 
increases and promotes inhibition of rhodopsin kinase by recoverin. 
1.2.3.4. Transducin 
As described above, the G protein taking part in the phototransduction cascade 
is  transducin.  The  synthesis  of  transducin  subunits  begins  in  the  IS  of  the 
photoreceptors  and  are  then  transported  to  the  OS  in  the  dark  (IS→OS) 
(described in section 1.2.3.5).  
Structurally the transducin α subunit is composed of two domains: a nucleotide 
binding  domain  with  high  structural  homology  to  the  Ras-superfamily  of 
GTPases,  and  an  all-α-helical  domain  that,  in  combination  with  the  Ras-like 
domain,  helps  to  form  a  deep  pocket  for  binding  guanine  nucleotide  (figure 
1.9a) (reviewed in Sprang, 1997). Transducin α contains three flexible regions 
designated switch-I, -II and -III that change conformation in response to GTP 
binding and hydrolysis (Lambright et al., 1996). The GTP-bound conformation of 
transducin α results in decreased affinity for transducin βγ.  
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Figure 1.9. Structure of the transducin complex and its subunits 
a. Ribbon diagram of the transducin α subunit (green) with the switch region 
highlighted in blue and a bound nucleotide is shown in pink (protein databank 
(PDB)  1TAD).  b.  Ribbon  diagram  of  transducin  βγ  heterodimer  where  the 
transducin  β  subunit  is  yellow  and  the  transducin  γ  is  red  (PDB  1TBG).  c. 
Ribbon diagram of transducin αβγ heterotrimer (subunits are colour coded as α 
– green, β – yellow, γ – red) (PDB 1GOT) (modified from Sondek et al., 1996). 
 
 
Figure 1.10. Rod arrestin structure and oligomerisation 
a. Ribbon diagram of rod arrestin monomer with the N-domain shown in pink 
and C-domain in green (PDB 1CF1). b. One of the rod arrestin dimer states is 
shown with each arrestin monomer colour coded. c. Model of a representative 
structure from the rod arrestin largest cluster, which was identified as the best 
structural model. Kd are as indicated for dissociation of  monomer/dimer and 
dimer/tetramer (Modified from Hirsch et al., 1999 and Hanson et al., 2008a).  
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Transducin βγ is a functional heterodimer that forms a stable structural unit. The 
transducin β subunit contains seven WD-40 repeats, a tryptophan-aspartic acid 
sequence  that  repeats  about  every  40  amino  acids  and  form  antiparallel  β 
strands (Neer et al., 1994). Crystal structures of the transducin βγ dimer and 
transducin trimer revealed that the seven WD-40 repeats of the transducin β 
subunit folds into a seven-bladed β-propeller or torus-like structure, while the N-
terminus forms an α-helix (figure 1.9b) (Wall et al., 2005; Sondek et al., 1996). 
Transducin γ folds into two α-helices. The N-terminal helix forms a coiled-coil 
with  the  α-helix  of  transducin  β,  while  the  C-terminal  helix  makes  extensive 
contacts  with the  base  of  the  transducin  γ-torus.  Unlike the  conformationally 
flexible  transducin  α  subunit,  the  transducin  βγ  dimer  does  not  change 
conformation when it dissociates from the G protein heterotrimer (figure 1.9c) 
(Sondek et al., 1996).  
After synthesis, transducin undergoes lipid modifications. Rod transducin α is 
fatty acetylated at the extreme N-terminus Gly residue by lauroyl, myristoyl and 
tetradecaenoyls moieties (Neubert et al., 1992) whereas cone transducin α is 
only myristoylated (Rosenzweig et al., 2007). Transducin γ subunit is known to 
be  prenylated  and  this  modification  is  suggested  to  serve  as  a  membrane 
anchor for transducin βγ (Lai et al., 1990; Saini et al., 2007; Chisari et al., 2007).  
1.2.3.5. Arrestin 
Arrestins  are  a  family  of  proteins  which  shut  down  the  G  protein  signalling 
pathway (described in 1.2.2.2). There are four types of arrestin in mammals 
reported by date: arrestin1 (called visual or rod arrestin, S-antigen or 48 kDa 
protein),  arrestin2  (also  known  as  β-arrestin  or  β-arrestin-1),  arrestin3  (β-
arrestin-2) and arrestin4 (cone arrestin or X-arrestin) (Gurevich and Gurevich 
2006).  Structurally  and  functionally  the  family  can  be  divided  into  two 
subfamilies: visual or sensory (arrestin1 and arrestin4) and non-visual (arrestin2 
and arrestin3) (Gurevich and Gurevich 2006). 
In vertebrates, arrestins are encoded by large genes containing 14-17 exons, 
some of which are only 10 nucleotides long (Yamaki et al., 1990). The multi-
exon structure of vertebrate arrestins gives rise to splice variants of rod arrestin Chapter I 
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and both non-visual subtypes (Sterne-Marr et al., 1993). The protein products 
usually consist of two domains and a variable carboxyl-terminal tail.  
Rod arrestin (p48) also has a short splice variant (p44) that lacks most of the 
carboxyl-terminal tail and has functional characteristics distinct from the longer 
variant, such as binding to unphosphorylated activated rhodopsin (Palczewski 
et al., 1994).  Other non-visual arrestins have been shown to have long and 
short forms which differ by 8 or 11 residues in the proximal carboxyl-terminal tail 
(Gurevich et al., 1995). The functional significance of this is unclear.  
Rod  arrestin  is  the  only  arrestin  from  this  family  of  proteins  that  invariably 
crystallises  as  a  tetramer  (Wacker  et  al.,  1987;  Granzin  et  al.,  1998).  Each 
monomer is composed of two domains: an N domain (residue 8–180) and a C 
domain  (residue  188–362)  (figure  1.10a).  Each  rod  arrestin  domain  is 
constructed from a seven-stranded β sandwich and isolated N and C domains 
are functional (Gurevich et al., 1993). 
The  N  domain  has  a  single  α  helix,  while  the  C  domain  contains  two  short 
helices  in  a  long  loop  that  provides  some  of  the  interface  between  the  two 
domains. The very carboxyl terminus of the protein or “C tail” (residues 372–
404) is connected by a flexible linker (residues 362–371) to the C domain. The 
C “tail” contains a short stretch that forms a parallel β sheet interaction with the 
lateral strand of the N domain. In addition, the C tail makes other interactions 
with various parts of both the N and C domains (Hirsch et al., 1999). Recently 
the  crystal  structure  of  the  rod  arrestin  tetramer  was  solved  (Hanson  et  al., 
2008).  It  demonstrated  different  conformational  states  of  arrestin 
monomer/dimer/tetramer and described the final “diamond” crystal of arrestin 
tetramer (figure 1.10). 
Rod  arrestin  is  a  soluble,  predominantly  cytoplasmic  protein.  Binding  to 
phosphorylated  active  rhodopsin  and  termination  of  the  phototransduction 
cascade  was  the  first  arrestin  function  described  (Kuhn  and  Wilden,  1987). 
Phosphorylation of rhodopsin is the key to the interaction with arrestin: a single 
attached phosphate does not facilitate arrestin binding, two are necessary to 
induce  high  affinity  interaction,  and  three  phosphates  fully  activate  arrestin 
(Vishnevetsky et al., 2007).  Chapter I 
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Interestingly, rod arrestin binds to microtubules and rod arrestin domains have 
been demonstrated to have higher affinity to microtubules than full-length rod 
arrestin  (Hanson  et  al.,  2006).  The  role  of  such  binding  to  cytoskeleton 
elements is not clear, however it has been suggested to be a storage form of 
arrestin (Hanson et al., 2008). The p44 isoform, lacking the C “tail” is known to 
have higher affinity for microtubules than the full-length protein (p48). Enhanced 
microtubule binding of p44 is suggested to underlie preferential localisation of 
p44 to detergent-resistant membrane microdomains, where it is anchored via 
membrane-associated microtubules in a rhodopsin-independent fashion (Nair et 
al., 2002; Nair et al., 2004). 
1.2.3.6.  Light  dependent  translocation  of  phototransduction  cascade 
components 
In  order  to  prevent  rod  photoreceptor  cells  from  over  activating  signal 
transduction  under  intense  light,  adaptation  is  necessary.  Light  driven 
translocations  of  signalling  molecules  have  been  suggested  to  contribute  to 
photoreceptor  cell  adaptation  in  vertebrates  and  invertebrates  (reviewed  in 
Slepak and Hurley, 2008).  
In vertebrate rod photoreceptor cells, recoverin (Strissel et al., 2005), arrestin 
and transducin undergo light dependent translocation into and out of the OS 
(Broekhuyse et al., 1985; Brann and Cohen, 1987). This phenomenon was first 
noted  about  two  decades  ago  and  has  developed  into  an  active  field  in 
photoreceptor  cell  biology.  The  adjustment  of  the  protein  composition  in  the 
outer segment may optimise the sensitivity and efficiency of the photoresponse 
(Strissel et al., 2004). 
It is known that 80-90 % of transducin in the dark state concentrates in the OS 
(Sokolov et al., 2002). Within minutes of sufficient light illumination, 80 % of 
transducin  moves  from  the  outer  segment  to  the  inner  segment  of  rod 
photoreceptor cells (OS→IS). In contrast, the return of transducin subunits to 
the outer segment in the dark takes much longer (Sokolov et al., 2002). This 
process  is  more  typical  for  rod  rather  than  for  cone  transducin  which  was 
demonstrated to translocate only in responce to very high intensity light (Chen 
et al., 2007). Reciprocal to transducin movement, arrestin translocated during Chapter I 
42 
   
dark adaptation into the inner segment and during light adaptation into the outer 
segment (IS→OS). 
While  the  functional  role  of  light  dependent  translocation  is  starting  to  be 
decrypted  (Calvert  et  al.,  2006),  the  molecular  and  cellular  mechanisms 
governing  these  adaptive  movements  through  the  cytoplasm  is  still  elusive 
(Slepak and Hurley, 2008). There are reports of conflicting mechanisms. Two 
principle distinct mechanisms are possible by which signalling proteins could 
change their cellular compartment: by diffusion or by active transport mediated 
by molecular motors along with actin filaments or microtubules.  
1.2.3.6.1. Diffusion hypothesis 
Recent  studies  have  suggested  molecular  diffusion  as  the  major  force  for 
driving  the  intersegmental  exchange  of  arrestin  and  transducin.  Diffuse 
translocation of arrestin from IS→OS upon light illumination could be explained 
by its high affinity for activated phosphorylated rhodopsin (Strissel et al., 2006). 
However, studies in mice deficient in rhodopsin phosphorylation and transducin 
activation demonstrated unaffected arrestin translocation upon light illumination 
(Mendez et al., 2003). 
For transducin the diffusion could be driven by membrane affinity to the disc 
membranes,  which  is  very  high  in  OS.  Therefore,  to  translocate  upon  light 
exposure  from  OS→IS,  transducin  should  lower  its  affinity  for  membrane 
binding. This process is suggested to be mediated by phosducin (figure 1.11) 
(Gaudet et al., 1996).  
Phosducin  is  abundant  in  the  IS  and  has  been  shown  to  reduce  affinity  of 
transducin  βγ  to  the  membrane  by  burying  the  C-terminal  farnesyl  group  of 
transducin  γ  in  a  cleft  of  transducin  β,  preventing  membrane  localisation 
(Gaudet  et  al.,  1996;  Loew  et  al.,  1998).  Moreover,  phosducin  has  been 
demonstrated  to  prevent  re-association  of  transducin  α  with  βγ  and  thus,  to 
facilitate transducin translocation (Sokolov et al., 2004).    Chapter I 
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Figure 1.11. A model of phosducin function in transducin translocation 
Upon light exposure, Ca
2+ and cAMP concentrations in rod photoreceptors fall, 
resulting in dephosphorylation of phosducin by PP2A and PP1. Phosducin binds 
transducin  βγ  and  maintains  it  in  a  soluble  form,  assisting  its  diffusion 
throughout the rod cell. Upon return to the dark, Ca
2+ and cAMP concentrations 
rise,  and  phosducin is  phosphorylated.  Upon  phosphorylation,  14-3-3  protein 
binds to phosducin and transducin βγ is released from complex with phosducin. 
Transducin βγ then reassociates with transducin α and either binds membranes 
in the ellipsoid region that are trafficking to the outer segment, or diffuses to the 
outer segment before binding to disc membranes there. R - rhodopsin; Gt α, β 
or    γ  –  transducin  subunits  as  indicated;  Pdc  -  phosducin;  P  –  phosphate 
(adapted from Willardson and Howlett, 2007). 
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1.2.3.6.2. Active transport hypothesis 
Several studies support the hypothesis of an active molecular motor mediated 
mode  of  transducin  transport  during  dark  adaptation  (IS→OS).  It  has  been 
shown that transducin and arrestin translocation may be an energy-dependent 
process  (Nair  et  al.,  2005;  Reidel  et  al.,  2008;  Marszalek  et  al.,  2000), 
suggesting  it  is  motor-mediated.  It  was  also  demonstrated  that  siRNA  of 
GAPDH  in  photoreceptors  slowed  transducin  translocation  during  dark 
adaptation (Chen et al., 2008). GAPDH is present in OS at high concentration 
and the energy required for ATP and GTP synthesis is likely to be derived from 
glycolysis  in  OS  (Hsu  and  Molday,  1990).  Therefore,  the  effect  of  GAPDH 
knock-down on transducin translocation could be due to an energy-dependent 
mechanism.  
Using  cytoskeleton  disrupting  drugs,  it  was  proposed  that  the  transport  is 
dependent on microtubules and/or actin (Peterson et al., 2005). The loss of the 
KIF3A subunit of kinesin-II caused impaired transport of arrestin (Marszalek et 
al., 2000), suggesting it is mediated by IFT. Rod arrestin has been shown to be 
localised to the connecting cilium in dark adapted rods suggesting a role of this 
structure in dark adaptation (McGinnis et al., 2002).  
Active transport of transducin through the cilium has also been proposed. In 
dark  adaptation  (IS→OS),  transducin-carrying  vesicles  or  protein  complexes 
may  fuse  at  the  periciliary  ridge  plasma  membrane  (described  in  section 
1.2.2.3).  The  membrane  surface in  this  region  could  then  be  utilised  by  IFT 
complexes to move transducin to the OS (reviewed in Roepman and Wolfrum, 
2007). Diffusion of transducin through the inner lumen of the cilium is proposed 
to be controlled by Ca
2+ binding proteins, centrins. They bind to transducin βγ in 
a Ca
2+ dependent manner (Giessl et al., 2006).  
Recent  reports  on  testing  cytoskeleton  disrupting  drugs in  ex  vivo  retina  co-
cultivated  with  RPE  demonstrated that  the  translocation  of  both  arrestin  and 
transducin was disrupted only in dark adaptation and not in light adaptation. 
However, the drug which was used to destabilize microtubules (thiabendazole) 
surprisingly  was  not  found  to  affect  cilia  (Reidel  et  al.,  2008),  suggesting  a 
possible role of other unknown non-cilia mediated mechanisms.  Chapter I 
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Interestingly,  along  with  transducin,  the  RGS9--Gβ5L  complex  was  found  to 
translocate  to  the  detergent-resistant  membrane  (DRM)  microdomains  upon 
light illumination (Nair et al., 2002). It was demonstrated that the transducin α - 
RGS9 - Gβ5L complex had the highest affinity to detergent resistant membrane 
microdomains in the transition state of the GTPase. Phosphorylation of RGS9 
was found to occur exclusively in such microdomains. Many other proteins of 
the phototransduction cascade were also found in DRM’s. Rhodopsin and PDE 
were identified in DRM and non-DRM portions of the photoreceptor membrane 
whereas guanylate cyclase was present exclusively in the raft. Distribution of 
these proteins did not change in the light or dark (Nair et al., 2002). 
1.2.3.6.3. Calcium-myristoyl switch mechanism 
Another protein that translocates from the OS to the IS upon light exposure in 
the retina is recoverin (Strissel et al., 2005). Recoverin is a component of the 
phototransduction  cascade  and  is  responsible  for  the  inhibition  of  rhodopsin 
kinase  (figure  1.8)  (Tanaka  et  al.,  1995).  Recoverin  has  been  shown  to 
translocate via a calcium-myristoyl switch mechanism (Ames et al., 1997). High 
levels of intracellular Ca
2+ in the dark induce conformational changes leading to 
extrusion of the N-terminal myristoyl group on recoverin, enabling it to interact 
with the lipid bilayer membrane of OS discs (Tanaka et al., 1995). When the 
calcium level drops upon phototransduction cascade activation, it causes the 
reverse effect and recoverin translocates to the IS. 
1.3. Inherited retinal dystrophies 
Inherited retinal dystrophies are both clinically and genetically heterogeneous 
disorders which affect 1 in 2000 people worldwide (Rivolta et al., 2002). There 
are  currently  192  loci  with  144  disease  causing  genes  identified  (RetNet, 
http://www.sph.uth.tmc.edu/Retnet/,  November  2008).  Autosomal  dominant, 
autosomal recessive, X-linked, digenic, mitochondrial and complex patterns of 
inheritance have been reported (Daiger et al., 2007). Retinal dystrophies can 
also be classified by their clinical symptoms such as age of onset, severity and 
pattern of visual loss. Chapter I 
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Genes in which mutations have been shown to result in retinal dysfunction or 
degeneration can be characterised by their expression profile. Some of them 
are  expressed  exclusively  in  the  eye  and  are  the  components  of  the 
phototransduction  cascade  or  visual  cycle.  Another  group  of  proteins  with 
ubiquitous expression patterns have been shown to cause retinal dysfunction 
alone or as a part of a syndromic disorder. A summary of some of the genes 
and the affected pathways implicated in retinal diseases is shown in table 1.4. 
1.3.1. Retinitis pigmentosa 
Retinitis  pigmentosa  (RP;  OMIM  #268000)  is  a  subtype  of  retinal  dystrophy 
featuring  retinal  pigment  deposits  and  the  loss  of  photoreceptors.  The 
prevalence  of  RP  is  approximately  1/4000  people  (Hamel,  2003).  Non-
syndromic forms of retinitis pigmentosa comprise approximately 65 % of all RP 
cases (Daiger et al., 2007). There are currently 41 loci for non-syndromic RP 
with  32  causative  genes  identified  (RetNet,  November  2008).  RP  can  be 
inherited  as  an  autosomal  dominant  (approximately  20  %),  an  autosomal 
recessive (approximately 25 %) or X-linked condition (approximately 10-15 %). 
The  remaining  40–55  %  cases  of  RP  are  still  to  be  classified  (Wang  et  al., 
2005a).  
Night  blindness  is  the  earliest  symptom  of  RP  which  appears  before 
morphological signs. Later as the disease progresses, morphological signs in 
the fundus occur.  The fundus of patients with RP shows pigmentary deposits 
resembling bone spicules predominantly in peripheral retina where the rod cells 
are concentrated, attenuation of retinal blood vessels and waxy pallor of the 
optic  disc.  Clinically,  patients  suffer  from  visual  field  constriction  with  tunnel 
vision. As disease progresses, cone photoreceptors also degenerate resulting 
in blindness (Bird, 1975).  
The first linkage study of RP revealed an XLRP locus, later identified as RP2 
(Bhattacharya et al., 1984; Schwann et al., 1998). The first RP causing gene 
identified was RHO, encoding rhodopsin (Driya et al., 1990).  
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Pathway/ 
Function 
Gene  Expression 
profile 
Disease  First identified by  
Visual cycle  LRAT  retina  arRP/arLCA  Thompson et al., 2001 
ABCA4  retina  arRP/arCRD 
ar Stargadrt 
Cremers et al., 1998 
 
RPE65  RPE  arRP/arLCA  Gu et al., 1997 
Photo 
Transduction 
PDE6A  retina  arRP  Dryja et al., 1999 
PDE6B  retina  arRP  Bayes et al., 1995 
RHO  retina  adRP/arRP/ 
adCSNB 
Dryja et al., 1990 
SAG  retina  arRP/Oguchi  Yoshii et al., 1998 
photoreceptor 
structure 
RDS  retina 
 
adRP  Kajiwara et al., 1994 
retinal polarity  CRB1  retina, brain  arRP/arLCA  den Hollander et al., 
1999 
extracellular 
matrix 
USH2A  broad but 
not 
ubiquitous 
ar Usher/arRP  Rivolta et al., 2000 
Transcription  NRL  retina  adRP/arRP  Bessant et al., 1999 
TULP1  retina, brain  arRP/arLCA  Banerjee et al., 1998 
CRX  retina, 
pineal gland 
arLCA/adCRD  Freund et al., 1997 
cilia function  RPGRIP  retina, testis  arCRD/arLCA  Dryja et al., 2001 
RP1  retina  adRP/arRP  Bowne et al., 1999 
BBS1-12  ubiquitous  BBS  see table 1.5 
mRNA splicing  PRPF31  ubiquitous  adRP  Vithana et al., 2001 
PRPF8  ubiquitous  adRP  McKie et al., 2001 
PRPF3  ubiquitous  adRP  Chakarova et al., 2002 
PAP1  ubiquitous  adRP  Maita et al., 2005 
unknown 
function 
RP2  ubiquitous  XLRP  Schwann et al., 1998 
RPGR  ubiquitous  XLRP  Meindl et al., 1995 
 
Table  1.4.  Examples  of  genes  and  pathways  implicated  in  retinal 
degeneration 
arRP – autosomal recessive retinitis pigmentosa; adRP - autosomal dominant  
retinitis pigmentosa; arLCA - autosomal recessive Leber congenital amaurosis; 
BBS – Bardet-Biedl syndrome (detailed table of mutations 1.3), XLRP- X-linked 
retinitis pigmentosa. 
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1.3.1.1. X-linked retinitis pigmentosa 
X-linked retinitis pigmentosa (XLRP) is the most severe form of RP with early 
onset and fast disease progression leading to blindness by 40 years of age 
(Bird, 1975). There are six RP loci on the X-chromosome and for four of them 
the causative gene is not known. However, causative genes were found for two 
loci.  The  retinitis  pigmentosa  2  gene  (RP2)  (Schwann  et  al.,  1998)  will  be 
described  in  section  1.5.  The  other  identified  XLRP  gene  is  the  retinitis 
pigmentosa GTPase regulator (RPGR, RP3) (Meindl et al., 1995; Roepman et 
al., 1996). 
1.3.1.1.1. Retinitis pigmentosa GTPase regulator 
The retinitis pigmentosa GTPase regulator (RPGR, RP3) protein is encoded by 
the RPGR gene spanning approximately 60 kb on the X-chromosome (locus 
Xp11.4). Originally, RPGR was described to have 19 exons and RPGR protein 
was found to be ubiquitously expressed (Meindl et al., 1995).  However, later 
studies revealed the presence of an alternative exon, ORF15, where most of 
the disease causing mutations are located (Vervoort et al., 2000). The isoform 
produced  by  alternative  splicing  to  contain  ORF15  was  demonstrated  to  be 
expressed preferentially in the retina and testis, suggesting a possible retina 
specific role (Vervoort et al., 2000). This isoform was shown to be able to fully 
substitute for RPGR in vivo (Hong et al., 2003). 
The  RPGR  protein  contains  three  ‘regulator  of  chromosome  condensation’ 
domains (RCC1) in its N-terminus (protein families database (PFAM) 00415) 
within one large α-tubulin suppressor domain (ATS1) (PFAM COG5184). RCC1 
is a guanine nucleotide exchange factor (GEF) for a small GTP-binding protein 
RAN. Some of the XLRP causing mutations, which are not located in ORF15, 
were found in this domain, suggesting its importance for disease pathogenesis 
(Meindl et al., 1995).  
The  region  of  RPGR  homologous  to  RCC1  was  investigated  for  interacting 
partners using a yeast-two hybrid approach. It was revealed that RPGR bound 
to  a  retina  and  testis  specific  protein  named  retinitis  pigmentosa  GTPase 
regulator interacting protein 1 (RPGRIP1) (Roepman et al., 2000; Boylan et al., Chapter I 
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2000). Later, mutations in the gene encoding this protein were found to cause 
Leber congenital amaurosis (LCA) and cone-rod dystrophy (CRD) (Driya et al., 
2001; Gerber et al., 2001; Hameed et al., 2003).  
RPGR  and  RPGRIP1  have  been  shown  to  localise  to  the  photoreceptor 
connecting cilia (described in section 1.2.3.2) (Hong et al., 2003; Hong et al., 
2005;  Shu  et  al.,  2005).  Studies  in  mice  demonstrated  that  knock-down  of 
Rpgrip1 disrupted cilia localization of RPGR (Pawlyck et al., 2005), suggesting 
that RPGRIP1 tethers RPGR to this structure highlighting the importance of the 
interaction  with  this  retina  specific  protein.  RPGR  was  also  shown  to  bind 
nucleophosmin  1  (NPM),  a  nuclear  chaperone  involved  in  chromosome 
duplication (Shu et al., 2005). 
Recently, a homologue of RPGRIP1 was identified RPGRIP1-like (RPGRIP1L) 
(Arts et al., 2007). It was shown to localise to the cilia although it demonstrated 
a ubiquitous expression level. Mutations in the gene encoding this protein were 
found to cause Joubert syndrome, a ciliopathy with developmental defects and 
mainly affecting the kidneys (described in 1.3.2) (Delous et al., 2007).  
Mutations  in  RPGR  were  also  demonstrated  to  cause  a  syndromic  form  of 
retinitis pigmentosa with impaired hearing and sinorespiratory infections (Zito et 
al., 2003). Interestingly, mutations in RPGR also cause cone cell death resulting 
in cone-rod dystrophy (Demicri et al., 2002; Yang et al., 2002).  
Thus, the mechanism by which mutations in RPGR result in RP remains to be 
discovered but the data suggest is that RPGR has a role in an important retina 
specific cilia mediated pathway. 
1.3.2. Syndromic forms of retinitis pigmentosa 
Syndromic RP comprises approximately 35 % of all RP cases and can be found 
as  a  part  of  hereditary  syndrome  such  as  Bardet-Biedl  syndrome  (OMIM 
209900),  Fahr  disease  (OMIM  213600),  Usher's  syndrome  (OMIM  276900), 
Refsum’s  disease  (OMIM  266500),  Senior-Loken  syndrome  (OMIM  266900), 
Alstrom  syndrome  (OMIM  203800),  Sjogren-Larsson  syndrome  (OMIM 
270200),  mitochondrial  encephalomyopathy  (OMIM  256000),  Kearns-Sayre Chapter I 
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syndrome  (OMIM  530000),  medullary  cystic  renal  disease  (OMIM  174000), 
Mirhosseini-Holmes-Walton  syndrome  (OMIM  268050),  and  tapetochoroidal 
dystrophy (OMIM 303100). This group of disorders is very heterogeneous and 
implicates a variety of molecular/cellular pathways.  
1.3.2.1. Ciliopathies 
It is now recognised that certain forms of syndromic RP can be classified as 
ciliopathies. Primary cilia are found not only in photoreceptors but in a number 
of  organs,  such  as  the  liver  and  pancreas,  as  well  as  numerous  cell  types, 
including endothelial cells, the myocardium, cortical and hypothalamic neurons 
(list  of  cells  and  tissues  containing  cilia 
http://members.global2000.net/bowser/cilialist.html).  Consistent  with  the  broad 
and  varied  tissue  and  cellular  distribution,  dysfunction  of  cilia  and  the  basal 
body has been implicated in numerous human diseases. Diseases in which the 
motile and/or sensory cilia are affected, such as Bardet-Biedl syndrome (BBS), 
Usher’s, Alstrom (ALMS), Senior-Loken syndromes and medullary cystic renal 
disease, include retinitis pigmentosa as part of their phenotype. 
1.3.2.2. Bardet–Biedl syndrome 
Bardet–Biedl  syndrome  (OMIM  209900)  is  an  autosomal  recessive  inherited 
disorder and one of the most studied ciliopathies. It is characterised by renal 
abnormalities,  central  obesity,  postaxial  polydactyly,  mental  retardation, 
hypogonadism, anosmia and RP. Other features, not always present, include 
hepatic fibrosis, diabetes mellitus, endocrinological disturbances, short stature, 
developmental delay, and speech deficits (Beales et al., 1999). 
There  are  twelve  disease  causing  genes  identified  to  date,  BBS1-12 
(summarised in table 1.5).  Protein products of genes causing BBS6, BBS10 
and BBS12 belong to a novel branch of the type II chaperonin superfamily, but 
they  are  considered  unlikely  to  assemble  in  a  complex,  similar  to  cytosolic 
chaperonin (CCT) (described in section 1.5.2) (Stoetzel et al., 2007).  Chapter I 
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Causing  
Gene 
Locus  Protein feature  Reference  
BBS1  11q13  unknown function  Leppert et al., 1994 
BBS2  16q21  unknown function  Kwitek-Black et al., 1993 
BBS3 (Arl6)  3p13-p12  small GTPase  Sheffield et al., 1994; 
Ghadami et al., 2000 
BBS4  15q22.3-
q23 
adaptor for p150 
subunit of dynein 
complex cilia 
localisation 
Carmi et al., 1995 
Kim et al., 2004 
BBS5  2q31  unknown  Young et al., 1999 
BBS6  20p12  chaperonin-like  Slavotinek et al., 2000 
BBS7 
(BBS2-like) 
4q26-q27  homologue of BBS1 
and BBS2 
Badano et al., 2003 
BBS8 
(TTC8) 
14q32.11  contains 8 TPR 
domains, involved in 
centriolar replication 
during ciliogenesis 
Ansley et al., 2003 
Kubo et al., 1999 
BBS9 
(PTHB1) 
7p14  PTH-responsive  Nishimura et al., 2005 
BBS10 
(C12ORF58) 
12q 21.2  chaperonin-like  Stoetzel et al. 2006  
BBS11 
(TRIM32) 
9q31-
q34.1 
putative E3 ligase  Chiang et al., 2006 
Kudryashova et al., 2005 
BBS12 
(C4ORF24) 
4q27  chaperonin-like  Stoetzel et al. 2007  
 
Table 1.5. Genetic heterogeneity of Bardet-Biedl syndrome 
TPR – tetratricopeptide repeat, PTH – parathyroid hormone. 
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BBS6,  10  and  12  are  thought  to  perform  cilia-related  functions  with  special 
importance for the photoreceptor connecting cilia. BBS6 was also shown to be a 
centrosomal component required for cytokinesis (Kim et al., 2005). Apart from 
homology to CCT, BBS10 also has an ATP binding site suggesting that it is a 
bona  fide  chaperonin  (Stoetzel  et  al.,  2006).  Recently,  another  putative 
chaperone,  BBS12,  causing  Bardet-Biedl  syndrome  was  identified.  BBS12 is 
highly  similar  to  group  II  chaperonins  except  the  ATP-binding  region  is  not 
conserved, similar to the BBS6 protein (Stoetzel et al., 2007). Suppression of 
each  BBS6,  10  or  12  in  zebrafish  yielded  gastrulation-movement  defects 
characteristic of other BBS morphants, whereas simultaneous supression of all 
three  chaperonin-like  BBS  proteins  resulted  in  severely  affected  embryos, 
possibly  hinting  at  partial  functional  redundancy  between  these  proteins 
(Stoetzel  et  al.,  2007).  Thus,  some  of  the  proteins  causing  BBS  have  high 
homology  to  group  II  chaperonins,  demonstrating  the  conservation  with  the 
cytosolic  chaperonin  domain  architecture.  Meanwhile,  they  have  specific 
insertions,  probably  giving  these  proteins  another  chaperone  function  that  is 
critical for ciliated cells. 
1.3.3. Oguchi disease 
Mutations  in  the  SAG  gene,  encoding  rod  arrestin,  cause  an  autosomal 
recessive  form  of  RP  (Yoshii    et  al.,  1998)  and  a  special  type  of  a  rare 
autosomal  recessive  congenital  stationary  night  blindness,  Oguchi  disease 
(OMIM 258100). The condition is associated with golden fundus discolouration 
and abnormally slow dark adaptation. After 2 or 3 hours in total darkness, the 
normal colour of the fundus returns (Usui et al., 2004).  
Fuchs  and  colleagues  (1995)  first  reported  that  a  homozygous  frame  shift 
mutation  (1147delA) in  the  SAG  gene  was  detected in  5  out  of  6  unrelated 
Japanese  patients  with  Oguchi’s  disease.  The  condition  is  more  frequent  in 
Japanese than other nationalities, however it was also found in an Indian family 
with a stop codon mutation at codon 193 in SAG (Maw et al., 1998). However, it 
was  shown  later  that  a  more  frequent  cause  of  this  disease  is  mutations in 
rhodopsin kinase gene GRK1 (Yamamoto et al., 1997).  Chapter I 
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The reason why the same mutation in the SAG gene leads to Oguchi disease in 
one patient and to retinitis pigmentosa in another patient is not identified. There 
was a case reported that one male patient had the typical Oguchi phenotype in 
both his eyes, however, his brother had a typical Oguchi phenotype in one eye 
and retinitis pigmentosa in the other eye (Yoshii et al., 1998). Therefore, the 
mechanism  of  retinal  degeneration  caused  by  mutations  in  arrestin  is  to  be 
elucidated. 
1.3.4. Cone-rod dystrophy 
Cone-rod dystrophies (CRD) (prevalence 1/40,000) belong to a group of central 
retinal  disorders  with  pigmentary  deposits  predominantly  localized  to  the 
macular region (Hamel, 2007). Symptomatically, CRD is different to RP. The 
first symptom of CRD is usually decreased visual acuity (age of onset ranging 
from first decade to the sixties), hypersensitivity to bright lights, and poor color 
vision. Color vision testing usually reveals many errors on both red-green and 
blue-yellow plates (reviewed in Hamel, 2007). Therefore, patients see better at 
dusk and have progressive difficulty with daytime vision. Visual acuity usually 
deteriorates  gradually,  but  it  can  deteriorate  rapidly.  Later,  in  more  severe 
cases, it drops to “counting fingers” vision. Usually with disease progression 
patients suffer from a loss in peripheral vision and night blindness as a result of 
rod cell death.  
CRDs  are  most  frequently  non  syndromic,  but  they  have  been  reportedly 
associated  with  several  syndromes  such  as  Bardet  Biedl  syndrome  and 
Spinocerebellar  Ataxia  Type  7  (Beales,  1999;  Aleman  et  al.,  2002).  Non 
syndromic CRDs are genetically heterogeneous. There are currently 8 known 
causative  genes  for  CRD  identified  and  14  loci  mapped  (RetNet,  November 
2008). The most studied causative genes involved in the pathogenesis of CRDs 
is ABCA4, which causes Stargardt disease and also 30 to 60 % of autosomal 
recessive CRDs (Cremers et al., 1998, Hamel, 2007). Other genes are cone-rod 
homebox-contaning  gene  CRX  and  retinal  guanylate  cyclase  (GUCY2D), 
responsible for many reported cases of autosomal dominant CRDs (Freund et 
al.,  1997;  Gregory-Evans  et  al.,  2000).  RPGR  is  known  to  cause  an 
undetermined percentage of X-linked CRDs (described in 1.3.2.1.1).  Chapter I 
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1.3.4.1. Unc 119 
Higashide  and  colleagues  (1996)  identified  a  retina-specific  cDNA  (HRG4, 
human retinal gene-4) that is now known as UNC119. Sequence comparison 
between  species  revealed  that  the  human  gene  had  57  %  homology  with
 
Caenorhabditis elegans Unc-119 (Higashide et al., 1998). The UNC119 gene 
was mapped to chromosome 17q11.2 and was shown
 to consist of five exons 
(Higashide et al., 1999).
 The 240-amino-acid encoded protein (NP 005139) has 
a  two-domain  structure  consisting  N-terminal  region  (amino  acids  1-78) 
predicted  to  interact  with  other  proteins  (Higashide  et  al.,  1998)  and  PDEδ 
subunit homology domain (amino acids 79-198) (PFAM 05351), which is highly 
conserved between species. 
Unc119  protein  was  localised  to  the  synaptic  termini  of  rod  and  cone 
photoreceptors (Higashide et al., 1998) and to the basal body of the connecting 
cilium (Li et al., 2004). Unc119 was found to bind at least two small GTPases 
ADP-ribosylation factors 2 and 3 (Arl2 and Arl3, described in 1.7) (Kobayashi et 
al., 2003; Linari et al., 1999). Interestingly, both GTPases bind to PDE δ, which 
is homologous to Unc119 (Linari et al., 1999).  
An UNC119 heterozygous mutation creating a stop codon was associated with 
late  onset  cone-rod  dystrophy  in  one  family  (Kobayashi  et  al.,  2000).  This 
Unc119  mutation  was  reproduced  in  a  knock-in  mouse  model  and  the 
transgenic  animals  exhibited  retinal  degeneration  (Kobayashi  et  al.,  2000; 
Ishiba et al., 2007). 
1.3.5. Leber congenital amaurosis 
Leber  congenital  amaurosis  (LCA)  (OMIM  204000)  is  a  rare  autosomal 
recessive severe retinal dystrophy with an incidence of approximately 1/80,000 
(Sohocki et al., 2000). The disease is genetically and clinically heterogeneous 
with  9  known  loci  of  which  7  have  the  causative  genes  identified  (RetNet, 
reviewed in Kaplan, 2008). These disease genes causing LCA are diverse and 
include  ones  of  the  visual  cycle  and  phototransduction  such  as  RPE65 
(Morimura  et  al.,  1998)  and retinal  guanylate  cyclase  (Perrault  et  al.,  2004). Chapter I 
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Recently, another LCA causing gene was identified, LCA5 (den Hollander et al., 
2007). The protein product of this gene, lebercilin, is ubiquitous and is localised 
to cilia, and the reason why mutations in this gene do not cause syndromic form 
of retina degeneration is not yet known (den Hollander et al., 2007). 
Another LCA causing gene is AIPL1. The AIPL1 protein is expressed only in the 
pineal gland and retinal photoreceptors (van der Spuy et al., 2002). AIPL1 is 
named  based  on  its  similarity  (49  %  amino  acid  identity)  with  the  aryl 
hydrocarbon  receptor  (AhR)-interacting  protein  (AIP)  (Kuzhandaivelu  et  al., 
1996;  Carver  and  Bradfield,  1997).  These  proteins  share  the  common  co-
chaperone  tetratricopeptide  repeat  (TPR)  motif  that  mediates  protein-protein 
interactions, suggesting that AIPL1 may be a member of the family of TPR co-
chaperones.  
This suggestion was supported by a recent study showing that AIPL1 interacted 
with the molecular chaperones Hsp90 and Hsp70 (described in section 1.4.1). 
Mutations within the TPR domain of AIPL1 or removal of the chaperone TPR 
acceptor site abolished the interactions. Importantly, LCA-causing mutations in 
AIPL1  also  compromised  these  interactions,  suggesting  that  the  essential 
function of AIPL1 in photoreceptors may involve the interaction with Hsp90 and 
Hsp70 (Hidalgo-de-Quintana et al., 2008). The client proteins of AIPL1 remain 
to be defined but studies in mouse models suggest that cGMP PDE subunits 
are possible retina specific candidates (Liu et al., 2004).  
1.4.  Molecular chaperones 
Molecular  chaperones  are  a  class  of  proteins  that  assist  the  non-covalent 
folding and assembly of other macromolecular structures without being part of 
the  finished  product  (Ellis  &  van  der  Vies  1991).  One  major  function  of 
molecular chaperones is to prevent both newly synthesised polypeptide chains 
and  assembled  proteins  from  aggregating  into  nonfunctional  structures.  The 
primary amino acid sequence of a polypeptide contains sufficient information to 
direct its folding to the native state (Anfinsen, 1973). However, under cellular 
conditions, which feature high macromolecular solute concentrations, misfolding 
can occur. Misfolding usually results in exposure of hydrophobic surfaces that Chapter I 
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should  have  become  buried  in  the  interior  of  a  protein  in  its  native  state. 
Molecular  chaperones  bind  such  exposed  surfaces  through  their  own 
hydrophobic  binding  sites,  thus  preventing  misfolding  and  aggregation  and 
ultimately releasing bound proteins to allow them to proceed with further steps 
of biogenesis (reviewed in Ellis, 2007). 
1.4.1.  Heat shock proteins 
A study by Tissieres and colleagues (1974) demonstrated a rapid and selective 
increase in the expression of a group of proteins, following heat exposure of 
Drosophila  melanogaster  larvae.  These  proteins  were  termed  heat-shock 
proteins  (Hsps)  and  were  annotated  by  molecular  weight;  Hsp100,  Hsp90, 
Hsp70, Hsp60, Hsp40, and small heat-shock protein (sHsp) families (Chang et 
al. 2007a; Tang et al. 2007). Many subsequent studies revealed that a large 
number  of  other  cell  stresses  could  lead  to  very  similar  changes  in  gene 
expression (figure 1.12) (reviewed in Georgopoulos and Welch, 1993).  
Genes  encoding  chaperone  proteins  are  of  three  regulatory  classes:  i) 
constitutively  expressed  and  regulated  during  growth  and  development,  ii) 
constitutive and inducibly regulated, and iii) strictly inducible. The expression of 
some  chaperones  is  essential  for  normal  growth  and  development  and  to 
survive  stress  (reviewed  in  Morimoto,  2008).  One  of  the  best  characterised 
stress proteins is the Hsp70 family.  
1.4.1.1. Heat shock proteins 70 kDa. 
The 70 kDa heat shock proteins (Hsp70s, HSPA) are a family of ubiquitously 
expressed  heat  shock  proteins  found  in  most  living  organisms.  Prokaryotes 
express  three  Hsp70  proteins:  DnaK,  HscA  (Hsc66),  and  HscC  (Hsc62). 
Eukaryotic organisms express several slightly different Hsp70 proteins and they 
share a common domain structure. The family of Hsp70 proteins in humans is 
currently described to have 12 members (Kampinga et al., 2008). 
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Figure 1.12.  Conditions that induce the heat shock response 
Heat  shock  gene  expression  is  activated  by  heat  shock  factors  (HSF)  and 
binding to heat shock effectors (HSE) results in the elevated expression of heat 
shock proteins (from Morimoto, 2008). 
 
Figure 1.13. The Hsp70 protein-folding cycle 
Hsp70 is shown in gray, with the substrate-binding domain on top. The hinged 
lid is shown open or closed to indicate low- and high-affinity substrate-binding 
states. Substrate protein is depicted as an extended line in the “unfolded" state, 
and a compact shape in the "folded," or native state. Hsp70 ATPase activating 
proteins (40) are depicted as circles, nucleotide exchange factor proteins are 
shown as rectangles (from Morano, 2007).    Chapter I 
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All Hsp70 molecules share a conserved architecture consisting of an N-terminal 
44 kDa adenine nucleotide-binding domain (NBD, ATPase domain) and a 27 
kDa  carboxy-terminal  substrate/peptide-binding  domain  (SBD,  or  PBD).  This 
region can be further divided by an 18 kDa domain, “lid”, whose conformation 
dictates  substrate-binding  affinity  (Morshauser  et  al.,  1999).  The  interdomain 
linker connecting the NBD and SBD is highly conserved and plays an important 
role in the allosteric switch mechanism controlling Hsp70 chaperone function 
(Vogel et al., 2006). Hsp70s are known to exist in two stable conformations, 
regulated  by  ATP  binding  to  the  NBD.  Cycling  between  these  two  states  is 
controlled  by  nucleotide  binding,  hydrolysis  and  release  results  in  substrate 
folding (figure 1.13). 
A number of co-chaperones have been described that modulate Hsp70 ATPase 
activity.  The  best  studied  among  these  are  Hsp40  proteins,  containing  a  J-
domain.  J-domain  proteins  bind  to  EEVD  motif  at  the  C-terminus  of  Hsp70 
(Freeman et al., 1995). This interaction stimulates Hsp70 ATPase activity, thus 
accelerating substrate-folding reactions (Cheetham et al., 1994; Minami et al., 
1996).    Hsp40  proteins  also  bind  substrates  and  in  at  least  some  folding 
scenarios  are  responsible  for  initial  presentation  of  the  unfolded  protein  to 
Hsp70 (reviewed in Morano, 2007). Another group of co-chaperones of Hsp70 
function  as  nucleotide  exchange  factors  (NEFs),  stimulating  the  release  of 
bound ADP for ATP to release a client protein and to initiate a new folding cycle 
(figure 1.13).  
Hsp70s have also been found to have non-folding roles. It has been reported 
that  together  with  the  co-chaperone,  CHIP,  Hsp70  promotes  protein 
degradation by 26S proteasome (Elliot et al., 2007). Hsp70 proteins have also 
been shown to be a crucial component in chaperone-mediated autophagy (Dice 
et al., 1990). Hsp70 is known to inhibit caspase activation and thus, protect from 
apoptotic cell death (Zhou et al., 2001).  
Hsp70  can  also  be  excreted  by  some  cells  upon  heat  shock  and  could  be 
internalised by other cells protecting them from cell death (Guzhova et al., 2001; 
Novoselova et al., 2005). Extracellular Hsp70 can act as cytokine binding to 
Toll-like receptors (TLR)-2 and -4 on antigen presenting cells (Arnold-Schild et Chapter I 
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al.,  1999;  Asea  et  al.,  2002).  Numerous  publications  support  the  theory  that 
Hsp70 is a chaperokine acting as an initiator of immune response (reviewed in 
Asea, 2008). 
1.4.2.  Cytosolic chaperonin 
The  chaperonins,  a  sub-group  of  molecular  chaperones  found in  virtually  all 
organisms,  comprise  a  family  of  ATPases  of  approximately  60  kDa  that 
assemble  into  twin  rings,  stacked  back-to-back,  with  a  large  central  cavity 
where unfolded polypeptides may bind and undergo productive folding  (Ranson 
et al., 1998). Based on their evolutionary origin, chaperonins can be grouped 
into two distinct classes. Type I chaperonins, found in the bacterial cytosol and 
in endosymbiont-derived organelles of eukaryotes, form heptameric rings and 
are  represented  by  bacterial  GroEL,  mitochondrial  hsp60,  and  chloroplast 
cpn60.  Type  II  chaperonins,  present  in  the  eukaryotic  cytoplasm  and  in 
archaea,  include  the  archaeal  thermosome  and  the  eukaryotic  cytosolic 
chaperonin (CCT, chaperonin containing TCP-1) (Frydman et al., 1992).  
CCT is composed of two rings of eight different subunits. Each subunit consists 
of three domains: an equatorial domain containing a nucleotide binding site; an 
intermediate connector domain; an apical domain responsible for binding to the 
target protein and closure of the chaperonin cavity. CCT adopts at least two 
conformations,  an  ADP  or  nucleotide  free  conformation  and  an  ATP-bound 
state when its cavity is closed (Gao et al., 1992; Llorca et al., 1998).  
In  mammalian  cells,  the  main  function  of  CCT  is  folding  of  cytoskeletal 
components such as actin and α-, β- tubulins. Unlike most other chaperones, 
which recognise substrates only by exposed hydrophobic residues, CCT is able 
to bind the substrate via discrete binding determinants, which explains the high 
substrate  specificity  of  CCT-mediated  folding  (Llorca  et  al.,  1999;  Ritvo-
Vonsovici and Willinson, 2000). CCT does not function in isolation but works in 
conjunction with another molecular chaperone named prefoldin (PFDN; GimC) 
(Vainberg et al., 1998) and the tubulin folding cofactors (see section 1.4.4). 
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1.4.3.  Prefoldin 
Prefoldin (PFDN) is a heterohexameric protein that exists in archaebacterial and 
eukaryotic organisms (Stirling et al., 2006a). In the case of archaeal PFDN, the 
chaperone  contains  two  different  proteins  (i.e.  two  α-subunits  and  four  β-
subunits). However, in eukaryotes, PFDN exists as a more complex oligomer 
assembled from six different proteins, two of which are α-like and four of which 
are β-like (Leroux et al., 1999).  
The complex is arranged into an “octopus”-like structure where α-like subunits 
(PFDN3 and PFDN5) are located in the centre, while the four β-like subunits 
(PFDN1, PFDN2, PFDN4 and PFDN6) are at the periphery (Martin-Benito et al., 
2002). The coiled-coils of PFDN subunits form “tentacles” of the complex, which 
capture the substrate, non-native α-, β-, γ- tubulins, actin, or Cdc20 (Leroux et 
al., 1999). The non-native substrate is bound by PFDN without using chemical 
energy (e.g. ATP) and transported to CCT which transforms the substrate into a 
native state by rounds of ATP-dependent folding (Siegert et al., 2000).  
Recently,  an  antagonist  to  PFDN  complex  was  identified.  It  is  a  novel  co-
chaperone of the CCT complex phosducin-like protein 3 (PhLP3). It binds CCT 
and significantly diminishes the chaperonin ATPase activity, and accordingly, 
excess PhLP3 perturbs actin or tubulin folding in vitro (Stirling et al., 2006b). 
1.4.4.  Tubulin folding cofactors and tubulin folding pathway 
Tubulin,  a  major  component  of  microtubules,  is  a  heterodimer  of  α-  and  β- 
tubulin. The initial steps of tubulin folding are assisted by CCT and PFDN as 
described above. After folding by CCT, tubulin subunits require the action of 
cofactors to form the tubulin heterodimer. In mammals five such cofactors have 
been identified which are involved in the folding and association of tubulin in 
vitro (Tian et al., 1995; Lewis et al., 1997, Bartolini et al., 2005). The specific 
role  of  each  cofactor  in  tubulin  folding  is  yet  not  fully  understood,  but  the 
following model has been proposed (figure 1.14) (Bhamidipati et al., 2000).  Chapter I 
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Nascent chains of tubulin polypeptides are captured by the PFDN complex and 
then guided to CCT for ATP-dependent folding. Cofactor A (CoA) then binds to 
β-tubulin  and  cofactor  B  (CoB)  to  α-tubulin  monomers.  These  cofactors  are 
suggested  to  be  a  reservoir  for  excess  β-  and  α-tubulin.  These  complexes 
transfer the tubulin subunits to cofactors E and D (CoE and CoD) (figure 1.14).  
At this point cofactor C (CoC) binds to the CoE, CoD and β-tubulin complex.  
Hydrolysis of GTP to GDP acts as a switch mechanism for the release of the 
native tubulin heterodimer that can polymerise into microtubules once GDP has 
been exchanged for GTP (figure 1.14). Cofactor D (CoD), cofactor E (CoE) and 
cofactor C (CoC) are also able to disrupt tubulin dimers and thus depolymerise 
microtubules (Bhamidipati et al., 2000).  
The tubulin folding pathway is proposed to be regulated by ADP-ribosylation 
factors (Arf)-like proteins such as Arl2 (figure 1.14). Arl2 was shown to regulate 
the  binding  of  CoD  to  tubulin  and  microtubule  destabilisation  induced  by 
overexpression of CoD in mammalian cells could be rescued by co-expression 
of Arl2 (Bhamidipati et al., 2000).  
Another  protein  which  is  proposed  to  be  involved  in  tubulin  folding  pathway 
regulation is gigaxonin. Mutations in the gene encoding this protein were shown 
to cause giant axonal neuropathy (Bomont et al., 2000). One of the features of 
disease is reduced levels of microtubules (Bomont et al., 2003). Gigaxonin was 
shown to interact with CoB and to target it for proteasomal degradation (figure 
1.14) (Wang et al., 2005b).  
Tubulin folding cofactors are described to have homologues. For instance, a 
homologue  of  cofactor  E,  cofactor  E-like  protein,  is  known  to  depolymerise 
microtubules by commiting tubulin to proteosomal degradation (Bartolinini at al., 
2005). Cofactor C is suggested to have several homologues (Stephan et al., 
2007) and one of them is retinitis pigmentosa 2 (RP2) protein (Bartolini et al., 
2002).  
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Figure 1.14. Model of the tubulin heterodimer assembly 
Schematic showing the proposed mechanism by which nascent chains of α and 
β tubulin are folded and incorporated to form microtubules. The nascent chains 
of  tubulin  polypeptides  are  shown  as  blue  and  red  lines.  PFDN  complex  is 
shown as yellow octopus-like shape. PFDN delivers tubulin peptides to CCT for 
further ATP-dependent folding. This step is regulated by phosducin-like protein 
3  (PhLP3).  CCT is  depicted as  a  ring  of  eight  subunits (blue  circles).    After 
folding by CCT, tubulin folding cofactors (shown as blue, green, yellow or purple 
colour-coded  boxes  as  indicated)  assist  in  formation  of  tubulin  heterodimers 
from  tubulin  monomers.  Red  boxes  indicate  tubulin  heterodimers.  The 
involvement of Arl2 and gigaxonin in the regulation of cofactor activity is also 
shown. Modified from Bhamidipati et al., 2000; Vainberg et al., 1998; Wang et 
al., 2005b; Stirling et al., 2006b. 
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1.5.  RP2 
RP2 mutations cause X-linked retinitis pigmentosa (XLRP) and are responsible 
for between 7-20 % cases of XLRP (section 1.3.1.1, Hardcastle et al., 1999; 
Sharon et al., 2003; Vorster et al., 2004). Mutations in RP2 have also been 
shown to cause macular and peripapillar atrophy, thus expanding the clinical 
phenotype to the central retina (Dandekar et al., 2004). 
1.5.1. RP2 gene 
RP2 maps to Xp11.4 and is composed of 5 exons (figure 1.15a). There are 53 
disease mutations reported to date (table 1.6). The majority of these mutations 
(67  %)  are  predicted  to  result  in  a  truncated  protein.  Missense  mutations 
account for 22 % while the remaining 11 % of mutations are located in splice-
sites, or are caused by large deletions and insertions. 
Most  of  the  missense  mutations  cluster  in  exon  2,  encoding  the  N-terminal 
region of the RP2 protein (figure 1.15a). However, two  mutations have been 
described  which located  at  the  C-terminal  region  of  the  protein (R211H  and 
L253R). The  most common  mutation is the Arg120 stop (Arg120X) mutation 
found in several families with different ethnicities (Voster et al., 2004), resulting 
in no detectable protein in RP2 patients lymphoblasts (Grayson et al., 2002a). 
Currently  there  is  no  apparent  correlation  between  genotype  and  patient 
phenotype (Pelletier et al., 2007).  
1.5.2. RP2 protein 
RP2 is a 350 amino acid protein with a predicted molecular weight 39 kDa and 
a pI 4.94. The protein consists of an N-terminal cofactor C (CoC) homology 
domain  (1-228)  and  a  C-terminal  nucleoside  diphosphate  kinase  (NDPK) 
homology domain (229-317) (Kuhnel et al., 2006) (figure 1.15b).  
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Figure 1.15. Position of pathogenic missense and nonsense mutations in 
the RP2 gene and RP2 protein domain organisation 
a.  Schematic  of  the  human  RP2  gene.  Exons  are  shown  as  boxes  and  are 
numbered as indicated. Introns are black lines. Shaded exon boxes indicate the 
coding regions and unfilled boxes are untranslated regions. Patient missense 
mutations  identified  are  shown  above  the  gene  schematic  and  nonsense 
mutations are below. b. Schematic of the domain structure of RP2 showing CoC 
homology domain (residues 42-192) and C-terminal NDPK homology domain 
(229-317).  The  N-terminal  acylation  motif  (MGCFFS)  is  shown  by  two  tags 
representing the myristoylation and palmitoylation that target RP2 to the plasma 
membrane.  
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Intron/Exon  Position  Change  Consequence  Primary reference 
All    Gene deletion    Pelletier et al., 2007 
Exon 1    Exon deletion    Bader et al., 2003 
Exon 1  16-18  3bp deletion  ∆S6  Schwann et al., 1998 
Exon 1  77/78  Insertion CA  Frameshift,  305 
AA missing 
Mears et al., 1999 
Intron 1    IVS1+3A>T  Splice site 
alteration 
Sharon et al., 2000 
Intron 1    IVS1+3A>G  Splice site 
alteration 
Breuer et al., 2002 
Intron 1    retrotransposition  Not known  Schwann et al., 1998 
Intron 1    IVS1-2A>G  Splice site 
alteration 
Miano et al., 2001 
Exon 2  292  A insertion  G98fsX123  Pelletier et al., 2007 
Exon 2  297  5 bp insertion  S99fsX114  Pelletier et al., 2007 
Exon 2  305  T deletion  F102fsX11  Pelletier et al., 2007 
Exon 2  302  T insertion  F101fsX22  Miano et al., 2001 
Exon 2  330-342  12 bp deletion  C110fsX40  Mears et al., 1999 
Exon 2  350-351  2 bp deletion  F117fsX38  Breuer et al., 2002 
Exon 2  409  3 bp deletion  ∆I137  Sharon et al., 2000 
Exon 2  419-426  8 bp deletion  S140fsX151  Pelletier et al., 2007 
Exon 2  453  1 bp deletion  Y151fsX1  Schwann et al., 1998 
Exon 2  483/484  7 bp insertion  D161fsX13  Mears et al., 1999 
Exon 2  515  1 bp inserion  S172fsX1  Breuer et al., 2002 
Exon 2  538-539  2 bp deletion  V180fsX38  Pelletier et al., 2007 
Exon 2  670  1 bp insertion  R225 fsX9  Breuer et al., 2002 
Exon 2  688-692  5 bp deletion  Q229fsX2  Hardcastle et al., 
1999 
Exon 2  723  1 bp deletion  F241fsX12  Thiselton et al., 2000 
Intron 2    IVS2-1G>A  Splice site 
alteration 
Pelletier et al., 2007 
Exon 3  796-799  4bp deletion  V265fsX3  Thiselton et al., 2000 
Exon 3  801-804  4 bp deletion  T267fsX4  Pelletier et al., 2007 
Exon 3  834  2 bp inserion  Q278fsX15  Mashima et al., 2000 
Exon 3  853  1 bp insertion  F284fsX4  De Luca et al., 2001 
Exon 4    Exon deletion    Schwann et al., 1998 
Exon 4  925/926  2 bp insertion  V308fsX7  Mears et al., 1999 
Exon 4  929  1 bp insertion  E309fsX18  Hardcastle  et  al., 
1999 
Intron 4    IVS4+3A>G  Splice site 
alteration 
Sharon et al., 2003 
 
Table 1.6. Reported pathogenic mutations in RP2 
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1.5.2.1. Cofactor C homology domain  
As the majority of patient missense mutations are located in the N-terminus of 
RP2 suggesting its importance for XLRP pathogenesis. The N-terminal β-helix 
domain from residue 42 to 192 shares 30.4 % of sequence identity and 43.7 % 
similarity with cofactor C (CoC) (figure 1.16) (Bartolini et al., 2002). This parallel 
β-helix domain has a rectangular barrel shape and consists of three stacked β-
sheets numbered PB1, PB1a and PB2 according to the nomenclature for β-helix 
domains (Kuhnel et al., 2006) (figure 1.17). The fold of this region of RP2 is 
similar to that of C-terminal domain of cyclase associated protein (368-508) (C-
CAP) of S. cerevisiae despite only 11 % of sequence identity (Dodatko et al., 
2004,  Evans  et  al.,  2005).  However,  the  proteins  differ  in  their  in  vitro 
oligomerisation  states;  CAP  forms  a  homodimer  whereas  RP2 is  monomeric 
(Kuhnel et al., 2006). Within the CoC homology region of RP2 lie two potential 
actin-binding domains known as CARP (figure 1.15b). Tandem repeats of such 
domains are found in the C-terminal region and CAPs are known to be involved 
in  the  regulation  of  actin  polymerisation  (Stevenson  and  Theurkauf,  2000; 
Ponting  et  al.,  2001).  The  presence  of  these  CAP  domains  suggests  the 
potential ability of RP2 and its homologue CoC to bind actin. However, there is 
no experimental evidence to support this hypothesis.  
1.5.2.2. Nucleoside diphosphate kinase homology domain 
The C-terminal α/β domain has a ferredoxin-like fold and forms a three layered 
α+β  sandwich  (figure  1.17)  (Kuhnel  et  al., 2006). This  domain  is  structurally 
similar to the nucleoside diphosphate kinase (NDPK) domain (figure 1.18) with 
22 % of the sequence identity. NDPK catalyses phosphorylation of nucleoside 
diphosphates  to  triphosphates  and  thus,  is  involved  in  a  variety  of  cellular 
processes  (Morera  et  al.,  1994a).  However,  the  alignment  of  RP2  to  NDPK 
indicates  that  the  active  catalytic  residue  His  122  is  not  conserved  in  RP2 
(figure 1.18) and RP2 failed to bind ADP or GDP in vitro (Kuhnel et al., 2006).  Chapter I 
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Figure 1.16. Sequence conservation between the N-terminus of RP2 and 
the C-terminal domain of cofactor C 
Alignment of amino acid sequences of human RP2 (CAA 07577), mouse RP2 
(Q9EPK2), rat RP2 (XM 346266), Xenopus RP2 (BC 04122), and cofactor C 
(CoC) of human (AAB 17539), chimpanzee (XM 518477), dog (XM 538923) and 
chicken (XM 426123). Conserved residues are highlighted with green, with the 
degree of conservation between species decreasing from dark green to yellow. 
The catalytically important residue in RP2 Arg118 is labelled with red asterisk 
(from Kuhnel et al., 2006). 
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Figure 1.17. Structure of the human RP2 protein 
Ribbon diagram of RP2 with β strands shown in green, red α helixes, and grey 
loop regions. In the N-terminus strands a, b and c that form β sheets PB1, PB1a 
and PB2 are indicated. The structural model includes residues 34-347 (from 
Kuhnel et al., 2006). 
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Figure 1.18. Comparison of the C-terminus of RP2 with NDPK 
a. Protein sequence alignment of the C-terminal region of human RP2 (200-
350) with mouse NDPK1, human NDPK1, testis specific human NDPK5 and 
NDPK  of  Dictyostelium  discoideum.  The  residues  that  match  RP2  are 
shadowed in red. Asterisk highlights the catalytic His in NDPK. The alignment is 
performed by Clustal W. b. Crystal structure of the C-terminus of human RP2 
(AA 229-350) showing structural homology to NDPK (PDB 2BX6, Kuhnel et al., 
2006). c. Crystal structure of NDPK of Dictyostelium discoideum (PDB 1NPK, 
Morera et al., 1994b). 
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1.5.3. Localisation of RP2 protein 
RP2 has a MGCXXS motif at its N-terminus, which facilitates myristoylation at 
position G2 and palmitoylation at position C3 resulting in dual acylation. As a 
result RP2 protein is targeted predominantly to the plasma membrane (figure 
1.19) (Chapple et al., 2000; Chapple et al., 2002; Grayson et al., 2002b). It has 
been demonstrated that a patient mutation ∆S6 prevented normal targeting of 
RP2  to  the  plasma  membrane  (Chapple  et  al.,  2000),  suggesting  the 
importance  of  acyl  modifications  for  XLRP  pathogenesis.  Mutation  of  G2  for 
alanine (G2A) abolished the plasma membrane localisation of RP2 (Chapple et 
al., 2000). This residue was later reported to be mutated in XLRP patients with 
the substitution for valine (G2V) (Pelletier et al., 2007). In the retina, RP2 was 
predominantly localised to the plasma membrane in all retinal cells, including 
photoreceptors  (figure  1.19)  (Grayson  et  al.,  2002b).  However,  many  patient 
mutations  outside  of  the  acylation  motif,  such  as  R118H,  did  not  alter  the 
plasma membrane localisation of RP2 (figure 1.19, Chapple et al., 2000). 
Recently  Li  et  al.  (2004)  in  their  flagella  and  basal  body  proteome  study 
suggested that the C. elegans homologue of RP2 was localised to the basal 
body (described in section 1.2.2.3) along with other proteins involved in ciliary 
and basal body biogenesis, such as Arl3, RPGRIP and Unc119. However, the 
C. elegans RP2 lacks a myristoylation signal (G2) and therefore is unlikely to be 
targeted to the plasma membrane like human RP2. A trypanosome homologue 
of CoC and RP2, also lacking a myristoylation motif, was localized to the region 
around  the  basal  body  of  the  flagellum  and  appeared  to  recruit  carboxyl-
tyrosinated  α  tubulin  to  the  basal  body.  This  protein,  named  tbRP2,  was 
suggested to act as a chaperone to monitor the quality of tubulin prior to cilia 
assembly (Stephan et al., 2007).  
Therefore, RP2 could cause XLRP through lack of plasma membrane targeting 
and potentially impaired chaperoning of components of the primary cilia. This 
hypothesis  requires  further  investigation  and  currently  does  not  explain  why 
RP2 mutations do not lead to syndromic forms of retinitis pigmentosa. Chapter I 
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Figure 1.19. Localisation of RP2 protein 
a. Immunohistochemistry of RP2 in human retina using anti-RP2 antibody. NFL, 
nerve fibre layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner 
nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; IS, inner 
segments; OS, outer segments. Arrowheads highlight the plasma  membrane 
localization.  Scale  bar  is  10  mm  (from  Grayson  et  al.,  2002b).  b.  RP2  is 
localised  predominantly  at  the  plasma  membrane  of  retinal  cells.  Confocal 
microscopy image of peripheral human retina using anti-RP2 antibody (red) and 
wheat germ agglutinin (WGA, green). IS, inner segments; OS, outer segments 
(from Grayson et al., 2002b). c. Mutations of N-acylation motif, but not R118H 
mutation, alter the subcellular localisation of RP2 protein. Confocal microscopy 
images of CHO cells transfected with wild type RP2-GFP and its mutants as 
indicated. The images are 102  m
  x 102  m (from Chapple et al., 2000). 
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1.5.4. RP2 function 
RP2  protein  function  is  unknown.  The  role  of  RP2  in  different  intracellular 
compartments is not clear. However, the strongest clue to the RP2 function lies 
in  its  homology  to  CoC  and  NDPK.  RP2  was  shown  to  exhibit  functional 
homology to CoC. It was found that RP2 stimulates the GAP activity of tubulin in 
combination with CoD and thus, substituting for CoC in this function (Bartolini et 
al.,  2002).  As  described  above,  the  N-terminus  of  RP2  and  CoC  have 
conserved Arg residues (figure 1.16). When these arginines on CoC (Arg262) 
and RP2 (Arg118) were mutated in both proteins, their tubulin GAP activity was 
abolished  (Bartolini  et  al.,  2002).  Such  Arg  residue  is  commonly  called  an 
“arginine finger” and it is often found in other GTPase activating protens (GAPs) 
(Rittinger  et  al.,  1997;  Vetter  and  Wittinghofer,  2001,  Pan  et  al.,  2006), 
suggesting that RP2 is a GAP.  
Due to a structural homology of the C-terminus of RP2 to NDPK, a functional 
overlap between these two proteins has also been suggested. RP2 has been 
reported to exhibit exonuclease activity, similar to NDPK (Yoon et al., 2006). 
Possibly, the key to uncovering of RP2 may also lie in its interactions. The only 
published  interacting  partner  for  RP2  is  ADP-ribosylation  factors  (Arf)-like  3 
(Arl3) (described below in 1.6) (Bartolini et al., 2002). 
1.5.4.1. Interaction of RP2 with Arl3 
The interaction of RP2 with a small GTPase Arl3 was discovered in 2002 by 
Bartolini and colleagues who demonstrated that RP2 bound to the GTP-locked 
conformation  of  Arl3  (Q71L  substitution).  Several  studies  revealed  that 
pathogenic  mutations  of  RP2  could  decrease  the  affinity  of  this  interaction 
(Bartolini et al., 2002, Evans et al., 2005, Kühnel et al., 2006), highlighting its 
importance. 
Arl3  binds  to  the  N-terminal  CoC  homology  domain  of  RP2  (described  in 
1.5.2.1).  The  interaction  occurs  via  the  PB1  sheet  of  RP2  and  includes  β-
strands  5a  and  6a.    Residues  that  are  responsible  for  binding  have  been 
identified, including residues mutated in XLRP, such as Glu138 (Veltel et al., Chapter I 
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2008a). It was also revealed that RP2 contacts the bound nucleotide of Arl3 by 
four other residues including the catalytically important Arg118 (Bartolini et al., 
2002; Veltel et al., 2008a). Biochemical studies demonstrated that Arl3’s slow 
intrinsic GTP hydrolysis rate upon addition of RP2 was accelerated 1400-fold 
(Veltel et al., 2008a). In the same study it was shown that an “arginine finger” 
mutation in RP2 (R118A) and another pathogenic mutation E138G drastically 
reduced the GTP hydrolysis stimulation.  
Interestingly,  CoC  was  able  to  act  as  a  GAP  towards  Arl3  even  at  a  low 
concentration,  although  with  slightly  less  efficiency  than  the  wild  type  RP2 
(Veltel et al., 2008a). Therefore, the functional overlap between RP2 and CoC 
to act as a GAP seems to be reciprocal. 
1.6. ADP-ribosylation factors (ARF)-like GTPases 
The ADP-ribosylation factors (Arf)-like GTPases (Arl) family of proteins are part 
of  the  Ras  family  of  small  GTPase  proteins  (Fan  et  al.,  2004).  There  are 
currently eight members of this family described, Arl1-8. Mammalian Arls have 
up to 40-60 % of protein sequence identity with Arfs, however they do not share 
function and are separated in two families. For instance Arf proteins are able to 
activate cholera-toxin catalysed ADP ribosylation, activate phospholipase D and 
complement the lethal arf1-/arf2- mutation in S.cerevisiae, whereas Arls do not 
possess such characteristics (Tamkun et al., 1991; Amor et al., 2001). Only Arl1 
is an exception, which has a weak ability to act as an Arf (Hong et al., 1998). 
Small GTPases are known to adopt two conformational states that depend on 
the bound nucleotide. They adopt an “active” conformation when GTP bound 
and “inactive” when bound with GDP (Burd et al., 2004). Arfs are known to have 
a  myristoylation site, targeting protein to the plasma  membrane. It has been 
shown that Arl1, Arl4 and Arl5 undergo such a posttranslational modification 
(Lee et al., 1997; Randazzo et al., 1995). 
The in vivo functions of members of the Arl family are relatively unexplored. Arl 
4, 6 and 7 are suggested to belong to a sub-group, characterised by a nuclear 
subcellular localisation and a nucleotide exchange rate higher than other Arls Chapter I 
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(Jacobs et al., 1999). Disruption of Arl4 in mice causes retardation in normal 
germ cell development, showing that Arl4 is required for the progression of cells 
through meiosis (Lin et al., 2000; Schurmann et al., 2002). Arl5 also is localised 
to the nuclei and nucleoli and is developmentally regulated (Lin et al., 2002).  
Arl6  is  known  to  be  a  causative  gene  for  BBS  type  3  (described  in  section 
1.3.3.2) (Fan et al., 2004). It was shown that the worm orthologue of Arl6 is 
expressed  in  sensory  neurons  and  is  proposed  to  traffic  along  cilia  by 
intraflagellar transport (IFT) (Fan et al., 2004). A role for Arl6 in ciliary functions 
has also been suggested by at least two comparative genomic searches (Li et 
al., 2004; Avidor-Reiss et al., 2004). These searches identified genes implicated 
in  ciliogenesis  or  ciliary  function  that  included  both  Arl3  and  Arl6.  Together, 
these results point to a role for Arl6 in cilia or flagella function. The presence of 
Arl6  in  flagella  was  confirmed  in  a  study  of  the  flagellar  proteome  of  the 
biflagellated green alga Chlamydomonas (Pazour et al., 2005). 
1.6.1.   Arl3 
Arl3 has 45 % identity to Arf1 protein and structural analysis revealed that Arl3-
GDP is very similar to Arf1-GDP and Arl1-GDP (Amor et al., 1994). Arl3 was 
found to be a microtubule associated protein (MAP) (Grayson et al., 2002b). 
Arl3 was co-purified with microtubules from bovine brain, exhibited enhanced 
microtubule decoration upon tubulin stabilisation with taxol and redistributed to 
the nuclear membrane when the tubulin was depolymerised. The localisation of 
Arl3 in the retina was also studied and it was revealed that Arl3 was enriched in 
the photoreceptor connecting cilium of both rod and cone cells (Grayson et al., 
2002b).  
There  is  further  evidence  for  connecting  cilium  localisation  of  Arl3  and  its 
importance.  A  study in  Leishmania  demonstrated  that  over  expression  of  an 
Arl3  homologue  (LdArl3A)  was  required  for  normal  flagella  development 
(Cuvillier et al., 2000). However, LdArl3A is different to mammalian Arl3 due to 
myristoylation (Randazzo et al., 1995). Several cilia proteome studies (Li et al., 
2004;  Avidor-Reiss  et al.,  2004)  have identified  Arl3  as  a  component  of  the Chapter I 
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basal  body  structure,  thus  confirming  the  data  of  Grayson  and  colleagues 
(2002a).  
A recent report of Arl3 knock-out mice further implicated Arl3 as a cilia protein 
(Schrick et al., 2006). These  mice exhibited abnormal development of renal, 
hepatic, and pancreatic epithelial tubule structures, which is characteristic of the 
renal-hepatic-pancreatic  dysplasia  found  in  autosomal  recessive  polycystic 
kidney disease (Zerres et al., 1998). Absence of Arl3 was also associated with 
abnormal epithelial cell proliferation and cyst formation. Moreover, mice lacking 
Arl3 exhibited photoreceptor degeneration as early as postnatal day 14. These 
results  demonstrated  involvement  of  Arl3  in  a  ciliary  disease  similar  to  BBS 
(Schrick et al., 2006). Furthermore, a proteomic screen of the photoreceptor 
mouse cilium detected Arl3 in this structure (Liu et al., 2007).  
1.6.2. Arl2  
Arl2 is the closest homologue of Arl3 and they share 56 % identity however a 
recent study suggested different microtubule-associated roles for Arl2 and Arl3 
(Zhou et al., 2006). As described in section 1.4.4, Arl2 modulates the tubulin 
GAP  activity  of  cofactors  C  and  D  and  thus  has  a  role in  regulating  tubulin 
dynamics (figure 1.16). Arl2 is essential for tubulin biogenesis (Steinborn et al., 
2002; Antoshechkin et al., 2002). Genetic studies of a putative yeast homologue 
demonstrated  that  lack  of  Arl2  affected  microtubule  stability  (Stearns  et  al., 
1990;  Hoyt  et  al.,  1990).  Interestingly,  Arl2  has  not  been  detected  in  the 
photoreceptor cilium proteome unlike Arl3, suggesting Arl3 and Arl2 may have 
divergent  functions  in  this  specialised  cytoskeletal  compartment  (Liu  et  al., 
2007a). Arl2 has been identified with a number of interactors, and Arl2 shares 
some of these with Arl3. 
1.6.3. Interacting partners of Arl2 and Arl3 
Arl3  and  Arl2  have  been  shown  to  interact  with  the  ubiquitously  expressed 
proteins such as the δ subunit of cGMP phosphodiesterase (PDEδ) and BART1 
(Linari et al., 1999; Sharer et al., 1999). Both Arls were demonstrated to bind 
PDEδ  predominantly  in  their  GTP-bound  “active”  state  (Hanzal-Bayer  et  al., Chapter I 
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2002). PDEδ in turn was shown to increase the affinity of Arl3 to GTP (van 
Valkenburgh et al., 2001).  
Although PDEδ function is not fully understood yet, it is suggested to be an 
effector  of  Arls  (Hanzal-Bayer  et  al.,  2002).  It  has  also  been  proposed  that 
PDEδ has a more general function as a prenyl binding protein interacting with 
several  other  small  GTPases  which  are  prenylated  (Zhang  et  al.,  2004). 
However, Arl3 and Arl2 have not been reported to be prenylated, suggesting 
that prenylation is not essential for Arl3 binding to PDEδ (Zhang et al., 2004). 
Arl3 and Arl2 have been shown to interact with Unc119 (HRG4) (described in 
section 1.3.4.1) (van Valkenburgh et al., 2001; Kobayashi et al., 2003). The C-
terminus of Unc119 shares 30 % identity and 40 % similarity to PDEδ. Recently, 
the crystal structure of a ternary complex formed by Arl3, Unc119 and RP2 was 
described (Veltel et al., 2008b). It was revealed that Arl3 is able to bind both 
Unc119 and RP2 at the same time, although RP2 and Unc119 residues that 
would  interact  directly  were  not  found.  Thus,  the  formation  of  the  ternary 
complex and its role in the retina need further investigation. 
Arl3 has also been shown to interact with Golgin-245, a GRIP domain protein 
recruited to trans-Golgi network (van Valkenburgh et al., 2001) and the function 
of this interaction remains unclear. 
1.7. Potential mechanisms of XLRP caused by RP2 
The key to one of the possible mechanisms of XLRP caused by RP2 mutations 
may  lie  in  the  disruption  of  RP2  GAP  activity  towards  Arl3.  As  described in 
1.6.1.1 and 1.6.1.3., Arl3 has retina specific interacting partners and is localised 
to  the  photoreceptor  cilium,  suggesting  a  potential  pathogenic  mechanism. 
However,  Arl3  knockout  mice  exhibited  a  syndromic  form  of  retinitis 
pigmentosa, unlike RP2 patients with the retina restricted phenotype. Moreover, 
due to the functional overlap in the catalytic activity of RP2 and CoC it is unclear 
whether  disruption  of  RP2  GAP  activity  to  Arl3  is  the  crucial  step  in  the 
pathogenesis of XLRP since CoC does not compensate for loss of RP2 function 
in patients (Grayson et al., 2002a). Chapter I 
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Another possible hypothesis of XLRP pathogenesis suggests that cilia function 
is  compromised  by  RP2  mutations.  However,  primary  cilium  is  a  ubiquitous 
structure (described in 1.2.2.3) and its dysfunction would cause a syndromic 
form of RP rather than the retina restricted phenotype.  
Pathogenic mutations in acyl modifications motif of RP2 have been shown to 
abolish  RP2  plasma  membrane  localisation,  highlighting  an  important  retina 
functional role for RP2 on the plasma membrane.  
1.8. Aims of this study 
The aim of this study was to find retina specific interacting partners of RP2, 
which would link RP2 with the retinal physiology.  
For  this  purpose  RP2  was  tested  for  protein-protein  interactions  using  two 
approaches. The first approach employed yeast two-hybrid screening of RP2 
with the retinal cDNA library. The second method involved using of a proteomic 
affinity  assay  with  mass  spectrometry  analysis  of  potential  novel  interactors. 
Other biochemical and molecular biology methods were also applied in order to 
verify novel putative RP2 intertactions. They were also used to elucidate the 
consequences of novel RP2 interactions in vivo.  
Another purpose of this study was to further investigate the role of potential 
chaperones  in  the  retina  by  testing  whether  prefoldin  5  (PFND5)  mutations 
could cause syndromic or non-syndromic retinal dystrophy. 
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Chapter II. Materials and methods 
2.1. Basic molecular biology techniques 
2.1.1. Polymerase chain reaction 
The polymerase chain reaction (PCR) was used to amplify selected regions of 
DNA  for  subsequent  cloning  or  sequencing.  PCR  uses  in  vitro  enzyme-
catalysed  DNA  synthesis  to  create  copies  of  a  specific  region  of  DNA.  The 
oligonucleotide  primers  are  extended  towards  one  another  under  chosen 
conditions  by  a  thermostable  DNA  polymerase  in  a  three  step  reaction: 
denaturation, primer annealing and extension.  
For cloning a 25 µl PCR mix of 50 ng DNA, 2  M of forward and reverse primer, 
0.2  mM  of  each  dNTP  (Promega),  1.5  mM  MgCl2,  1  µl  of  Taq  polymerase 
(GoTaq®,  Promega)  and  distilled  water.  For  PFDN5  gene  fragments 
amplification consisted of 12.5 µl of 2x Abgene
® Master Mix (Appendix), 100 ng 
of DNA, 2 nM of each primer and distilled water. The sequences of primers with 
integrated  restriction  sites  used  for  cloning  are  shown  in  table  2.1.  The 
sequences of primers designed for amplifying and sequencing PFDN5 exons 
are  shown  in  table  5.1.  PCRs  were  performed  using  Techne  Genius  PCR 
thermocycler (Jencons-PLS). When PCR was performed for subsequent cloning 
the  conditions  were  as  follows:  initial  denaturation  at  95ºC  for  5  minutes 
followed by 12-15 cycles of 95ºC for 30 sec, TaºC for 30 sec and 72ºC for 35 
sec.  
When PCR was carried out to amplify PFDN5 fragments for further sequencing, 
the PCR conditions were as follows: initial denaturation at 95ºC for 5 minutes 
and 30 cycles of 95ºC for 30 sec, annealing temperature (TaºC) incubation for 
30  sec  (see  chapter  5.2.1,  table  5.1)  and  72ºC  for  45  sec  with  the  final 
extension step at 72ºC for 5 minutes. All the PCR products if stored were kept 
at -20ºC.    Chapter II 
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Table  2.1.  Sequences  of  primers  used  in  this  study  for  cloning  (the 
restriction sites are underlined) 
 
Exon  Primer sequence  Ta(ºC) 
used 
Amplicon 
size 
1 forward  5’TCTGGCCGAGCGAGGCCTG3’  58  243 bp 
1 reverse   5’GGCGCGAGAGTACGCGTG3’ 
2 forward  5’TATCCGATCCCAGGACCTG3’  58  288 bp 
2 reverse  5’GGATTTTCTCGTTTCAGGTAAG3’ 
3 forward  5’TAACGTCTTACGTTGGAGCC3’  55  197 bp 
3 reverse  5’GAGAGGGTAATCTGAAGTAAT3’ 
4 forward  5’GGCGGAATCATGGCTCATGC3’  60  438 bp 
5 reverse  5’TGGTTCACACTGCAATCCATG3’ 
6 forward  5’GTTAGTCGGTCGCCTGTCC3’  58  271 bp 
6 reverse  5’AGACCAACATTCTGCCCAGC3’ 
Table  2.2.  Sequences  of  primers  used  for  PFDN5  amplification  and 
sequencing 
Primer  Sequence 5’-3’  Restriction 
site 
Ta 
(ºC) 
Arl3 F  GAATTCCGATGGGCTTGCTCTCAATTTT
G 
EcoRI  58 
Arl3 R  CGGTCGACTCCCGCAGCTCCTGCATC  SalI 
PFN5 F  GAATTCGGATCCATGGCGCAGTCTATT
AACATCACG 
EcoRI, 
BamHI 
60 
PFN5 R  GGATCCAAGCTTGAATTCTCAGGCCTT
AGCAGTAGCCTG 
BamHI, 
HindIII 
pMyr PFN5 F  GAATTCATGGCGCAGTCTATTAAC  EcoRI  58 
pMyr PFN5 R  CTCGAGTCAGGCCTTAGCAGTAG  XhoI 
pSos PFN5 F  GGATCCATGGCGCAGTCTATTAAC  BamHI  58 
pSos PFN5 R  GTCGACTCAGGCCTTAGCAGTAG  SalI 
pCMV 46 F  CCCGGGCAGGGCAGAACAAGC  SmaI  55 
pCMV 46 R  GATATCGGCACGAGGCCTGAC  EcoRV Chapter II 
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2.1.2. TA cloning 
PCR products were TA cloned into pGEM® -T Easy vector (Promega). pGEM® 
-T Easy vector is cut with EcoRV resulting in a 3´ terminal thymidine (T) to both 
ends. These single 3´-T overhangs at the insertion site improve the efficiency of 
ligation of a PCR product into the plasmids by preventing recircularization of the 
vector  and  providing a  compatible overhang  for  PCR  products generated  by 
certain thermostable DNA polymerases. These polymerases often add a single 
deoxyadenosine (A), in a template-independent fashion, to the 3´-ends of the 
amplified fragments. 
A ligation reaction consisted of 10 units of T4 DNA ligase, 1 µl 10x rapid ligase 
buffer (0.3 M Tris-HCl (pH 7.8), 0.1 M MgCl2 , 0.1 mM DTT and 10 mM ATP), 1 
µl  of  pGEM®  -T  Easy  vector,  3  µl  of  PCR  product  and  4  µl  of  water.  The 
reaction mix was then incubated overnight at 4ºC.  
2.1.3. E.coli transformation 
100 µl of JM109 competent cells, high efficiency (Promega), were mixed with 
the ligation reaction and incubated on ice for 30 minutes, heat shocked at 42ºC 
for 45 sec in a water bath and then incubated on ice for 2 min. After that, 900µl 
of 37ºC SOC medium (Appendix) was added and the transformed cells were 
incubated  at  37ºC  with  shaking  for  1  hour,  followed  by  plating  on  50  µg/ml 
ampicillin Luria Broth (LB) agar (Appendix) and incubation overnight at 37° C.  
For E.coli transformation with a ligation reaction into pGEM® -T Easy vector, a 
colour selection method was used. The pGEM® -T Easy vector contains contain 
T7  and  SP6  RNA  polymerase  promoters  flanking  a  multiple  cloning  region 
within the α-peptide coding region of the enzyme β-galactosidase. Insertional 
inactivation of the α-peptide allows recombinant clones to be directly identified 
by color screening on indicator plates.  
Such plates were prepared by speading 50 µl of 1 M IPTG and 50 µl of 20 
mg/ml X-Gal on LB plates with 50 µg/ml ampicillin. Transformed JM109 cells 
were then spreaded onto the plates and incubated overnight at 37° C. The white 
colonies were then selected for further experiments. Chapter II 
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2.1.4. Plasmid purification and DNA quantification 
Colonies from plates with cells transformed as described above were picked 
and used to inoculate 5 ml of LB with ampicillin (50µg/ml, Appendix) followed by 
incubation  at  37ºC  with  shaking  for  16-18  hours.  Cells  from  1.5  ml  of  each 
culture were centrifuged at 6,000 g for 5 minutes and the DNA was extracted 
using  GenElute  Miniprep  kit  (Sigma)  according  to  the  manufacturer’s 
instructions.  The  kit  is  based  on  alkaline  lysis  of  bacteria  with  alkaline  lysis 
buffer. The lysate is neutralised by addition if a neutralising buffer containing 
acid and centrifuged for 10 minutes at 16100 g at 22ºC. The cleared lysate is 
loaded  on  a  DNA  -  binding  column  and  is  passed  through  a  DNA  binding 
membrane  of  the  column  followed  by  washing  of  the  column  with  the  wash 
buffer, containing 70 % (v/v) ethanol. After that the DNA is eluted with 60  l of 
sterile distilled water.  
To  determine  the  DNA  concentration  spectrophotometric  analysis  was  used. 
The DNA was diluted in ddH2O and the absorbance was measured in a quartz 
cuvette at 260 nm wavelength. To calculate the concentration of DNA in the 
sample, an absorbance of 1 indicates 50 µg/ml of DNA.  
2.1.5. Restriction enzyme digestion  
For analytical routine digests 250 ng of DNA was mixed with at least 1 unit of 
restriction  enzyme  in  a  10  µl  volume  with  the  appropriate  buffer  as 
recommended and provided by the manufacturer. The reaction was incubated 
at 37ºC for 1 hour. For excision of inserts from plasmid DNA for cloning, 2 µg of 
DNA  was  digested  in  a  25  µl  reaction  volume  with  at  least  10  units  of 
appropriate enzyme. The DNA was then digested for 2 hours at 37ºC. A list of 
enzymes and buffers used for cloning of plasmids constructed during this study 
is shown in table 2.3. 
2.1.6. Alkaline phosphatase vector treatment 
Vectors used for cloning were treated with calf intestinal alkaline phosphatase 
(CIAP, Promega) to dephosphorylate the 5’ end of the cut vector after restriction 
digest to prevent self-ligation.  Chapter II 
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A typical reaction consisted of 2 µg of digested DNA, 10 µl of 10x CIAP reaction 
buffer, 1 unit of CIAP and nuclease free water to a final volume of 100 µl. The 
reaction was incubated for 1 hour at 37ºC. To remove CIAP so it would not 
interfere  with  subsequent  ligation  by  acting  on  insert,  DNA  clean  up  was 
performed  using  QIAquick  PCR  Purification  Kit  (Qiagen)  according  to  the 
manual. The kit involves using of a silica-membrane based purification of DNA. 
2.1.7. Analysis of PCR products and restriction digests 
Products  of  PCR  and  restriction  digests  were  analysed  by  agarose  gel 
electrophoresis and ethidium bromide staining. Generally, 1 % (w/v) agarose in 
1X tris-acetate (TAE) buffer was used (Appendix). Samples were prepared for 
loading by adding 6X dye (0.4 % (w/v) orange G; 0.03 % (w/v) bromophenol 
blue, 0.03 % (w/v) xylene cyanol FF, 15 % (v/v) Ficoll® 400, 10mM Tris-HCl (pH 
7.5) and 50mM EDTA (pH 8.0)) to a final concentration of 1X. Ethidium bromide 
was added to the TAE buffer to a final concentration of 0.5 µg/ml prior to loading 
the samples. The bands were visualised by ultraviolet irradiation using Gene 
Genius Bio imaging system with GeneSnap software (Syngene).  
2.1.8. Vectors and constructs 
The  human  Arl3  coding  sequence  was  amplified  as  described  in  2.1.1  from 
plasmids  previously constructed in our lab containing mutants of Arl3 (T31N 
and  Q71L)  in  pCMV  tag  3B  vector  and  specific  primers  (table  2.1).  Human 
PFDN 5 coding DNA was amplified as in 2.1.1 with appropriate specific primers 
(table 2.1) from IMAGE clone 6458093 (Geneservice Ltd).   
The PCR products were TA cloned as in 2.1.2. The pGEM
® - T Easy plasmids 
were digested as described in 2.1.5 with enzymes as shown in table 2.4. The 
target  vectors  (table  2.3)  were  CIAP  treated  as  in  2.1.6.  Ligation  and 
transformation procedures are the same as described in 2.1.2 and 2.1.3. 
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Vector  Company  Expression 
system 
Fusion of tag  Antibiotic  
Selection 
pGem
® - T 
Easy 
Promega  E.coli  -  Ampicillin 
pSos  Stratagene  S. cerevisiae   N-terminal 
hSos 
Ampicillin/ 
Leucine 
pMyr  Stratagene  S. cerevisiae   N-terminal 
myristoylation  
Chloramphenicol/ 
Uracil 
pCMV Tag 
3a,b 
Stratagene  mammalian  N-terminal 
myc 
neomycin/ 
kanamycin 
pEGFP C1  Clontech  mammalian  N-terminal 
GFP 
neomycin/ 
kanamycin 
pTrc His (-A)  Invitrogen  E.coli  N-terminal 
6Xhis 
Ampicillin 
pGEX-2T  Pharmacia  E.coli  N-terminal 
GST 
Ampicillin 
 
Table 2.3. Vectors used in this study and their characteristics 
 
Table 2.4. Plasmids made in this study 
The enzymes labeled “I” were used for digest the insert at the 5’ end and “II” for 
the 3’ end.  
Plasmid  Enzyme I  Enzyme II 
pGex-2T Arl3 T31N  EcoRI  EcoRI 
pGex-2T Arl3 Q71L 
pCMV-Tag 3a clone 46 
pCMV-Tag 3b PFN5  BamHI  HindIII 
pGex-2T PFN5  BamHI  EcoRI 
pTrc-HisA PFN5 
pMyr PFN5  EcoRI  XhoI 
pSos PFN5  BamHI  SalI 
pCMV-Tag 3(b) Unc119  EcoRI  SalI 
pEGFP-C1 clone 46  HindIII  EcoRI Chapter II 
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Other plasmids used in this study were either constructed in our lab before or 
were purchased/ gifted (table 2.5).  
Plasmid  Source  Expression   Tag 
pSos RP2 constructs   Evans, 2007.  S. cerevisiae  N-terminal hSos 
pSos MAFB  Stratagene  S. cerevisiae  N-terminal hSos 
pMyr Lamin C,  
pMyr SB 
pMyr MAFB 
pMyr cDNA retinal library 
Stratagene  S. cerevisiae  N-terminal 
myristoylation 
signal 
pcDNA-FLAG Gβ1, Gβ3, 
Gβ5 and Gβ5L 
Missouri S&T 
cDNA Resource 
Center 
Mammalian  N-terminal FLAG 
pcDNA arrestin1 
pcDNA arrestin 3 
Dr. Vsevolod V. 
Gurevich 
Mammalian  no tag 
pcDNA arrestin 1 - FLAG 
pcDNA arrestin 3 - FLAG 
Dr. Vsevolod V. 
Gurevich  
Mammalian  C-terminal FLAG 
pGEX-2T RP2  Prof. Michael 
Cheetham 
E.coli  N-terminal GST 
pEGFPN1RP2 constructs  Dr PJ Chapple  
Dr R Evans 
Mammalian  C-terminal GFP 
Table 2.5. Provided plasmids used in this study 
2.1.9. Short interfering RNA 
The  siRNA  to  human  Arl3  and  RP2  were  designed  and  synthesised  by 
Dharmacon. All four siRNAs for Arl3 were mixed to create a combined pool of 
siRNA  to  achieve  a  good  protein  suppression  level.  A  negative  control 
scrambled siRNA was also obtained from Dharmacon. The RNA sequences are 
represented  in  table  2.6.  The  cells  were  then  transfected  with  siRNA  as 
described in 2.3.3. 
siRNA  sequence 5’-3’  
Arl3 siRNA 1  AAUUCCGCUAGUUCCUGACUU 
Arl3 siRNA 2  UAUUAGCAAAGAUGAGCACUU 
Arl3 siRNA 3  UAUGCAGGUUCAGUCCUUCUU  
Arl3 siRNA 4  AUUUACAGAGGCCGUUAUCUU 
 Table 2.6. siRNA sequences used in this study Chapter II 
85 
   
2.2. CytoTrap® yeast-two hybrid 
2.2.1. Cdc25-H yeast strain long term storage and resuscitation 
The S.cerevisiae cdc25-H yeast strain (MATαura3-52 his3-200 ade2-101 lys2-
801  trp1-901  leu2-3  112  cdc25-2  Gal+)  was  obtained  from  Stratagene  and 
spread onto an YPAD plate (Appendix) and grown for 96 hours at 24° C. To 
ensure that the yeast phenotype had not reverted to allow growth at the 37° C 
restrictive temperature, the strain was streaked out on YPAD plate, placed at 
37° C and examined for growth after 144 hours of incub ation. 
To create a frozen stock of yeast culture, 12 ml of YPAD broth (Appendix) was 
inoculated  with  a  single  colony  and  grown  at  24° C  with   250  rpm  shaking 
overnight until saturation (OD600>1). The cells were harvested by centrifuging at 
3000  g  for  2  minutes,  the  supernatant  was  discarded  and  the  pellet  was 
resuspended in 12 ml of YPAD broth, containing 50 % glycerol. 1 ml aliquots 
were immersed in liquid nitrogen for 5 minutes, then placed at -70° C and kept 
until needed. To resuscitate, defrosted cells were spread by a 10 µl loop onto 
YPAD agar plate and grown for 96 hours.  
2.2.2. Yeast transformation 
10 ml of YPAD broth was inoculated with a single colony of yeast and incubated 
overnight at 24ºC with shaking at 250 rpm. This culture was used to inoculate 
50 ml of YPAD broth in 250 ml flask to a final OD600 = 0.2 and incubated at 24° C 
with  shaking  until  OD600  =  1.0.  Cells  were  centrifuged  at  3000  g  for  2  min, 
washed with 10 ml of water, resuspended, centrifuged again under the same 
conditions and washed with 5 ml of LiOAc/TE (10 mM LiOAc in TE, Appendix). 
The pellet was resuspended in 250 µl of LiOAc/TE and incubated for 15 minutes 
at room temperature.  
50  µl  of  the  yeast  suspension  was  added  to  2  µg  DNA  of  a  1:1  mixture  of 
appropriate pSos and pMyr constructs (section 2.1.8), combined with 5 µl of 
DMSO  (Sigma)  and  5  µl  of  salmon  sperm  DNA  boiled  for  5  minutes 
(Stratagene).  Next,  300  µl  of  40  %  PEG  4000  in  LiOAc/TE  (Appendix)  was Chapter II 
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added to the cells, mixed gently by several inversions and incubated for 1 hour 
at 24° C, followed by heat shock for 10 minutes at 42 ° C  in a water bath. The 
cells  were  then  centrifuged  at  800  g  for  2  minutes,  washed  with  water  and 
resuspended in 200 µl of water. The cells were plated on SD / glucose agar with 
amino acids (BD Biosciences), but lacking uracil and leucine (-UL) (Appendix).  
2.2.3. Library screening 
Yeast  cells  were  co-transformed  with  pSosRP2  or  pSos1-200RP2  with  pMyr 
bovine  retinal  cDNA  library  as  in  2.2.2.  For  a  positive  control  these  pSos 
constructs  were  also  co-transformed  with  a  positive  control pMyrSB  and  the 
negative control pMyr LaminC (section 2.1.8) in the same way as the library. An 
additional  control  of  pMyr  bovine  retinal  cDNA  library  was  transformed  into 
yeast  and  plated  on  SD  /  glucose  agar  (-U)  to  monitor  the  number  of 
temperature  revertants.  Every  screen  consisted  of  25-30  co-transformations 
which were plated on SD / glucose agar (-UL) and incubated for 36 hours at 
24ºC. The colonies were then replica-plated with a clear orientation mark onto a 
selective  SD/galactose  (-UL)  plates  and  incubated  at  37° C.  A  library  control 
plate was replica plated on SD/galactose (-U) plate at 37° C. Visible colonies 
were picked up during the following 144-240 hours until more than 20 colonies 
appeared on the negative control plates. 
2.2.4. Total yeast DNA isolation 
To isolate total yeast DNA, each colony was resuspended in 3 ml of SD/glucose 
broth with amino acids without uracil added and incubated at 24ºC for 48 hours 
with shaking at 250 rpm. The yeast cultures were then centrifuged at 1000 g for 
2  min  at  room  temperature,  supernatants  discarded  and  the  pellets  were 
resuspended in 100 µl of 3 % SDS in 0.2 N NaOH. The cells were lysed for 15 
min at room temperature with occasional mixing. After this 500 µl of TE buffer 
was mixed with the lysate and 60 µl of 3 M sodium acetate added (Appendix). 
Next 600 µl of phenol/chloroform/isoamylalcohol (25:24:1) (Sigma) was added 
and the tubes were mixed using vortex for 2 min each at maximum speed.  Chapter II 
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The samples were then centrifuged at 16200 g for 2 min at room temperature, 
the upper layers of the supernatants were transferred into fresh tubes with 600 
µl  of  phenol/chloroform/isoamylalcohol,  followed  by  vortexing  at  maximum 
speed for 2 minutes. After that the tubes were centrifuged at 16200 g again as 
above, upper layers were taken into clean tubes containing 600 µl of ice-cold 
100 % isopropanol (Sigma) and mixed. The samples were incubated for 20 min 
at -20ºC with subsequent centrifugation for 5 min at 16200 g.  
The supernatant was discarded, 100 µl of 70 % (v/v) ethanol was added and the 
tubes were centrifuged for 5 min at 16200 g. All the supernatants were then 
carefully discarded and the pellets were air-dried and resuspended in 15 µl of 
distilled water to solubilise the DNA from the pellet. 
2.2.5. pMyr plasmids isolation 
5 µl of total yeast DNA from section 2.2.4 was used to transform E.coli JM109 
competent cells as described in 2.1.2 section with the difference that the cells 
with added DNA were incubated for 40 min on ice before the heat pulse. The 
transformed  cells  were  selected  on  LB  agar  plates  with  34  µg/ml 
chloramphenicol (Sigma) and incubated at 37° C for 16-1 8 hours.  
A single colony from each plate was picked and grown at 37° C for 16-18 hours 
with shaking at 250 rpm. The cells were collected and the plasmid DNA was 
purified  using  GenElute™  Plasmid  Miniprep  kit  (Sigma)  according  to  section 
2.1.4.  To  check  that  the  plasmid  DNA  was  pMyr  with  an  insert,  restriction 
enzyme digestion was used as described in 2.1.5. 
2.2.6.  Protein-protein  interaction  verification  by  yeast  two-
hybrid 
To verify that isolated pMyr plasmids still allowed growth at 37° C only upon co-
transformation with the pSos construct used for the library screening, they were 
co-transformed in yeast as described in 2.2.4. After transformation cells were 
plated on SD/glucose (-UL) media and incubated for 96 hours at 24ºC. Several 
single medium size colonies were resuspended in 100 µl of distilled water and 5 
µl  of  each  suspension  was  spotted  onto  a  SD/galactose  (-UL)  plate  and Chapter II 
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incubated  at  37° C  and  24ºC.  Growth  was  observed  over  the  next  144-168 
hours.   
2.3. Cell based techniques 
2.3.1. Cell culture maintenance and storage 
ARPE19  human  retinal  pigment  epithelial  cells  and  SK-N-SH  human 
neuroblastoma cell line from ATCC collection (Cat.   HTB-11) were grown in 
DMEM/NUT.MIX.F12 with Glutamax-I (Invitrogen), 10 % (v/v) heat inactivated 
foetal bovine serum (FBS), 50 U/ml penicillin and 50  g/ml streptomycin (all 
from Invitrogen) in a humidified atmosphere of 6 % (v/v) CO2 at 37° C. HeLa 
human cervical carcinoma cells were grown in DMEM with Glutamax-I, 10 % 
(v/v) heat inactivated FBS and 50  g/ml gentamycin under the same conditions.  
When confluent ,cells were washed with Hank’s Buffered Salt Solution (HBSS) 
(Invitrogen)  and  treated  with  enough  trypsin  to  cover  the  cell  monolayer 
(Invitrogen)  at  37ºC  until  cells  changed  shape  under  light  microscopy 
examination.  The  reaction  then  was  blocked  by  addition  of  full  media  and 
resuspension. Cell counts were performed using Neubauer chamber (Sigma) 
according  to  the  manual.   All  cell lines  were  not  subjected  to  more  than  25 
passages.  
For storage 2 X 10
5 cells were resuspended in 0.5 ml of freezing media (20 % 
v/v FBS, 72 % v/v DMEM/NUT.MIX.F12, 8 % v/v dimethyl sulfoxide (DMSO)) 
and the tubes were then put at -70° C in an alcohol/  isopropanol bath (VWR) for 
24 hours. After that the tubes were transferred to liquid nitrogen storage. To 
resuscitate the cells the aliquots were rapidly warmed to 37° C,  washed with 
HBSS, appropriate media was added and cells were cultivated as above. 
2.3.2. Transfection procedure 
Cells  were  cultivated  as  in  2.2.1  and  grown  until  60  %  confluence.  The 
transfection  of  cells  was  performed  using  liposome  DNA  delivery.  The 
proportion of reagents for transformation was as recommended by Invitrogen for 
the type of flasks (Falcon) or chamber slides (Lab-TekTM) (table 2.7).  Chapter II 
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Flask  Number 
of cells 
Plus
®   Lipofect
amine®  
DNA 
( g) 
Total 
mixture 
volume  
Cultivation 
media 
volume 
chamber 
slide well 
2 X 10
4  1  l  0.5  l  0.1  125  l  250  l 
well of a 
6 well 
plate 
6 X 10
5  6  l  3  l  0.5  800  l  2 ml 
25 ml 
flask 
1 X 10
6  12  l  6  l  1.5  1.5 ml  5ml 
 Table 2.7. Transfection of mammalian cells with DNA 
For this purpose diluted in serum-free media DNA was combined with Plus
® 
Reagent (Invitrogen) and incubated for 15 min at room temperature. After that 
Lipofectamine  (Invitrogen)  was  added  to  the  mixture  of  DNA  and  Plus
®  and 
incubated for 15 minutes at room temperature. Cells were then washed twice 
with  HBSS  and  once  with  DMEM/NUT.MIX.F12/Glutamax-I.  The  transfection 
mixture  was  added  to  the  cells  and  incubated  for  3  hours  in  a  humidified 
atmosphere of 6 % (v/v) CO2 at 37° C.  
After  that  the  transfection  mixture  was  discarded  and  the  fresh  10  %  FBS 
DMEM/NUT.MIX.F12/Glutamax-I was added. Cells were then incubated for 24 
hours under the same conditions and then used for further experiments. 
 2.3.3. Transfection with short interfering RNA (siRNA) 
Cells were cultivated in chamber slides as described in 2.3.1 and grown until 
40-50 % of confluence. The cells were then washed twice with serum free and 
antibiotic  free  DMEM/NUT.MIX.F12/Glutamax-I  media.  100  nM  of  each 
combined siRNA (table 2.5) in siRNA buffer (Appendix) was diluted 2 X in the 
serum  free  media  and  incubated  for  5  minutes  at  room  temperature. 
Dharmafect® reagent (Dharmacon) was diluted 20 X in the serum free media 
and incubated for 5 minutes at room temperature. Both reagent mixtures were 
combined, incubated for 15 minutes at room temperature and cultivating media 
was added up to a final volume 200 µl for each chamber slide well. The cells Chapter II 
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were then incubated for 96 hours in a humidified atmosphere of 6 % (v/v) CO2 
at 37° C and analysed further as in 2.3.4. 
2.3.4. Immunocytochemistry 
Approximately  80000  cells  per  ml  were  cultivated  on  Permanox™  chamber 
slides for 24 hours and then the cells underwent transfection procedure as in 
2.2.2.  Slides  were  washed  with  phosphate  buffered  saline  (PBS)  and  fixed 
using two different methods (table 2.8).  
 First method was fixing with 3.7 % (v/v) paraformaldehyde (PFA) (Sigma) for 
15  minutes  at  room  temperature  with  subsequent  permeabilising  with  0.2  % 
Triton X 100 (v/v) for 10 minutes.  
The  second  fixation  method  was  incubation  of  cells  with  ice-cold  100  % 
methanol (Sigma) for 5  minutes at room temperature. After fixation the cells 
were  washed  and  blocked  in  PBS  with  10  %  normal  donkey  serum  (w/v) 
(Invitrogen)  and  3  %  bovine  serum  albumin  (w/v)  (Sigma)  for  20  minutes  at 
room temperature.  
 The primary antibodies were diluted in the blocking solution as in table 2.7, 
incubated for 1 hour at room temperature, discarded and wells were washed 3 
times with PBS. The cells were incubated further with appropriate secondary 
antibody Cy2- or Cy3- conjugate (all raised in donkey, Jackson) diluted to 1:100 
in the blocking solution for 1 hour at room temperature.  
The  cells  were  then  washed  with  PBS  and  nuclei  were  stained  with  4',6-
diamidino-2-phenylindole (DAPI) (Sigma) 5 µg/ml in PBS for 15 minutes at room 
temperature. After the final double wash with PBS the cells were covered with a 
glass  coverslip  of  the  appropriate  size  using  fluorescent  mounting  media 
(Dako).  
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Antibody name  Specificity  Raised 
in 
Suppleir  Titre  Fixation 
Arl3-854  Arl3  rabbit  Gift  Dr 
N.Cowan 
1:250  PFA 
S974  RP2  sheep  Our own  1:50  methanol 
M2  FLAG  mouse  Sigma 
(F1804) 
1:100  methanol 
PK/35/30d/1k/1g  CCT6  rat  Gift  Dr  K. 
Willison 
1:25  PFA, 
methanol 
9E10  c-myc  mouse  Sigma 
(M4439) 
1:500  methanol 
Anti-arrestin  F4C1epitope  rabbit  Gift  Dr  V. 
Gurevich 
1:100  methanol 
Table 2.8. Primary antibodies used for immunocytochemistry 
2.3.5. Microscopy 
The staining was initially analysed using X 40 and X 60 oil immersion objectives 
of Nikon Eclipse 80i epifluorescent microscope with excitation filters used as 
recommended by the manufacturer for the fluorochrome type.  
The  cell  images  were  taken  using  a  Carl  Zeiss  LSM  510  laser  scanning 
confocal  microscope  with  the  63  X  oil  immersion  objective.  The  following 
excitation/emission conditions were used in separate channels: DAPI 364/475-
525nm,  GFP  488/505-530  nm,  Cy3  543/560  nm.  For  the  software  used  see 
section 2.6. 
2.3.6. Subcellular fractionation 
To separate cytosolic, nuclear, membrane and cytoskeletal fractions of cells a 
general subcellular fractionation was used. All the recipes for buffers used in 
this method are described in Appendix.  
Cells were cultivated as in 2.3.1 and transfected as in 2.3.2. After that cells 
were treated with trypsin as in 2.3.1, resuspended in the appropriate media and 
counted.  3  X  10
6  cells  then  were  pelleted  at  1000g  for  3  minutes  at  room 
temperature, the supernatant discarded and the cells were resuspended in 300 
 l of cold buffer C. The suspension was incubated at 4ºC with slow rotation for Chapter II 
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20 minutes, passed through a syringe with a 27 gauge needle 60 times and 
centrifuged at 15000 g for 20 minutes at 4ºC. The supernatant was collected 
and represented a cytosolic fraction.  
To remove a possible contamination of the next fraction with cytosolic proteins, 
the pellet from this fraction was washed in 700  l of buffer C and centrifuged at 
15000 g for 20 minutes at 4ºC. The supernatant was discarded. This pellet was 
resuspended in 150  l of cold buffer N. The pellet was incubated at 4ºC with 
slow rotation and centrifuged at 15000 g for 20 minutes at 4ºC. The supernatant 
was collected and represented the nuclear fraction.  
The pellet from the last fraction was recovered in 150  l of cold buffer M and 
incubated with slow rotation at 4ºC with subsequent centrifugation at 15000 g 
for 20 minutes at 4ºC to obtain the supernatant (membrane fraction). 
The fraction was collected and the pellet was resuspended in 75  l of CS buffer 
per 10 million cells and incubated for 20 minutes with slow rotation at 22ºC. 
Then the cytoskeleton proteins fraction was isolated by centrifuging at 15000 g 
for 20 minutes at 4ºC. The pellet left from the last fraction was resuspended in 
Laemmli buffer (Appendix). All the proteins in other fractions were precipitated 
as described below in 2.4.1 (Appendix), and analysed further as in section 2.4. 
2.3.7. Detergent resistant membrane fraction isolation 
The cells were cultivated as in 2.1.1 or cultivated and transfected as in 2.1.2 in 
T25 flasks (Falcon). After a confluent monolayer had formed, cells were washed 
with ice-cold 25 mM Tris pH 7.5/ 150mM NaCl/ 5mM EDTA buffer and all other 
procedures were carried out at 4ºC in a cold room with ice-cold reagents and 
equipment. The cells were scraped into 0.5 ml of the lysis buffer (25 mM Tris pH 
7.5;  150mM  NaCl;  5mM  EDTA;  0.5  %  triton  X100  (v/v),  protease  inhibitor 
cocktail, phosphatase inhibitor cocktail (all from Sigma) and left for 15 minutes 
to lyse. 
 The  lysate  was  mixed  with  80  %  (w/v)  sucrose  (Sigma)  in  MNE  buffer 
(Appendix) and transferred into 5 ml centrifuge tubes (N344057) for a MLS-50 
swinging bucket rotor (Optima™ MAX-XP Benchtop Ultracentrifuge, Beckman). Chapter II 
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Above the sucrose/lysate mixture 1 ml of 27.5 % sucrose in MNE buffer (w/v) 
was layered on top. Without mixing with any of previous layers 0.5 ml of 5 % 
sucrose  in  MNE  buffer  (w/v)  was  applied.  The  tubes  were  centrifuged  at 
average speed 200000 g for 18 hours at 4ºC. Fractions of 180 µl were collected 
from  the  top  of  the  gradient  to  the  bottom  and  the  fractionated  protein  was 
precipitated by trichlore acetic acid (TCA) as in 2.4.2 and analysed as in 2.4.1-
2.4.4 sections of this chapter. 
2.3.8. Retinal lysate preparation 
Retinae were dissected from fresh porcine eyes (Cheal Meats) and washed with 
cold PBS at 4ºC for 10 minutes three times with slow rotation. Excess buffer 
was removed and the retinae were placed in different ice-cold lysis buffers (see 
table 2.9), where they were mechanically homogenised by 10 passages in a 
cold Dounce homogeniser.  
The lysates were centrifuged at 16200 g for 15 min at 4ºC. The supernatants 
were collected and the protein concentration was measured by Bradford protein 
assay as in section 2.4.1. The lysates were stored at -80ºC. 
Buffer 
name 
Buffer composition  Lysis 
conditions 
Lysis 
buffer 1 
25 mM Tris pH 7.5, 150mM NaCl, no detergents, 
Protease  inhibitors  coclail  (PIC),  phosphatases 
inhibitors cocktail (PhIC), 1 mM EDTA 
Freeze-
thawing  
Lysis 
buffer 2 
25 mM Tris pH 7.5, 150mM NaCl, 0,1 % Triton- X100, 
PIC, PhIC. 1 mM EDTA 
15 min on ice 
Lysis 
buffer 3 
25 mM Tris pH 8.0, 150mM NaCl, 0,1 % Triton- X100, 
PIC, PhIC. 1 mM EDTA 
15 min on ice 
Lysis 
buffer 4 
25  mM  Tris  pH  7,5,  150mM  NaCl,  0.25  % 
deoxycholate, 1 % NP-40,   PIC, PhIC. 1 mM EDTA 
10 min on ice 
Lysis 
buffer 5 
25  mM  Tris  pH  7,5,  50mM  NaCl,  0.25  % 
deoxycholate, 1 % NP-40,   PIC, PhIC. 1 mM EDTA 
10 min on ice 
Lysis 
buffer 6 
PBS  (Appendix),  1  %  n-Dodecyl-beta-D-maltoside 
(DM), PIC, PhIC. 
15 min on ice 
RIPA  RIPA (Appendix), PIC  15 min on ice 
 
Table 2.9. Buffers and conditions used for cell and retinal lysis Chapter II 
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2.4. Protein based techniques 
2.4.1. Protein concentration determination 
In  order  to  determine  the  protein  concentration  of  cell  or  retinal  lysates  the 
Bradford method was applied. Bradford technique is based on the observation 
of the absorbance shifts of an acidic solution of Coomassie Brilliant Blue G-250 
from 465 nm to 595 nm when binding to protein. Both hydrophobic and ionic 
interactions stabilize the anionic form of the dye, causing a visible color change 
(Bradford, 1976). To measure the protein concentration 5 X Bradford reagent 
(Pierce) was diluted up to a final 1 X concentration and 200  l was added to 
each well of a 96 well plate (Starlab).  
Protein concentration standards bovine serum albumin (BSA, Sigma) in a range 
from 100 ng to 1 mg were prepared in buffers used for cell or retinal lysis and 
added to the reagent. The buffer used for lysis, lysates and their dilutions were 
added  to  the  reagent.  Absorbencies  were  taken  using  a  microplate  reader 
Saphire  at  595  nm  (Tecan,  Germany  GmbH).  The  calibration  curve  of 
absorbance to protein concentration was obtained using the BSA standards and 
the concentration in lysates was calculated. 
2.4.2.  Sample  preparation  and  SDS-polyacrylamide  gel 
electrophoresis (SDS-PAGE) 
Protein for analysis after cell fractionation was precipitated from each fraction 
using trichloroacetic acid (TCA). For each fraction TCA was added to a final 
concentration of 5 % w/v and the tubes were incubated on ice for 10 minutes.  
After that the samples were centrifuged at 16200 g for 15 minutes at 22ºC and 
the supernatants were discarded.  
500 µl of ice-cold ethanol was added to the pellets to remove residual TCA and 
the samples were centrifuged again as before. The ethanol was removed and 
the  tubes  left  open  for  10  minutes  to  evaporate  residual  ethanol.  The  dried 
pellet was resuspended in 30  l of 1 X Laemmli sample buffer (Appendix). Chapter II 
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All  other  samples  were  prepared  using  2  X  or  4  X  Laemmli  sample  buffer 
(Appendix) and heated at 98ºC for 3 minutes. Gels were prepared using vertical 
BIO-RAD  mini-protean  II  SDS-PAGE  equipment  or  BIO-RAD,  Protean®II  xi 
Cell. An 11 % w/v resolving gel was used for most applications with a 3 % w/v 
stacking gel.  
The  samples  were  electrophoresed  at  200  V  until  the  bromphenol  blue  dye 
reached  the  bottom  of  the  gel.  The  sizes  of  proteins,  once  detected,  were 
compared to the protein ladder containing proteins of known molecular weights 
(PageRuler Prestained Protein Ladder, Fermentas).  
2.4.3. Staining of protein gels using Coomassie Blue 
Proteins separated by SDS-PAGE were fixed with methanol and glacial acetic 
and stained with 0.25 % w/v Coomassie brilliant blue R250 (Appendix). Gels 
were immersed in stain for 4 hours and then destained with a destain solution 
(Appendix)  overnight.  After  that,  gels  were  soaked  in  water  with  20  %  v/v 
glycerol for 1 hour and air dried between two pieces of cellulose film using Gel 
Drying Kit (Promega). 
2.4.4. Silver stain of protein gels 
All the solutions and washes were made with ultra-pure MilliQ water. The gel 
slab was fixed in two changes of 50 % v/v methanol with 5 % v/v acetic acid in 
water for 15 minutes each and followed by washing in 50 % methanol for 10 
minutes.  Then  the  gel  was  washed  with  water  overnight  to  remove  the 
remaining acid and methanol.  
The gel was sensitised by a 1 min incubation in 0.02 % sodium thiosulfate (w/v), 
and rinsed with two changes of water for 1 min each. After rinsing the gel was 
submerged in chilled 0.1 % silver nitrate solution (w/v) and incubated for 20 min 
at 4ºC. Then the silver nitrate was discarded and the gel slab was washed twice 
with water for 1 min, followed by the development in 0.04 % v/v formalin in 2 % 
w/v sodium carbonate with shaking.  Chapter II 
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Once  the developer  turned  yellow, it  was  discarded  and  replaced  with  fresh 
solution since it is essential that the developing is carried out in an absolutely 
transparent solution.  
After  the  desired  intensity  of  staining  was  achieved,  the  development  was 
terminated by discarding the reagent, followed by washing the gel with 5 % v/v 
acetic acid. Then the gel was rinsed with water twice for 30 min and the gel slab 
was stored in water at room temperature until analysed. 
2.4.5. Western blotting 
Proteins  were  transferred  from  SDS-PAGE  gels  to  0.45  µm  pore  size 
nitrocellulose  membrane  (Protran
®,  Whatman)  by  semi-dry  electrophoretic 
transfer (BioRad) at 15 V and 0.8 A for 2 mini gels for 20 minutes. Non-specific 
binding sites of the membrane were blocked by incubation in 3 % (w/v) Marvel 
Skimmed milk powder (Premier Brands) for 1 hour at room temperature. 
 The  blots  were  hybridised  with  primary  antibody  (table  2.10)  in  blocking 
solution for 1 hour, washed 3 times for 5 minutes with 0.05 % Tween-20 (v/v) in 
PBS  and  subsequently  incubated  with  appropriate  horseradish  peroxidase-
conjugated  (HRP)  secondary  antibody  (table  2.11)  in  blocking  solution  and 
further washed with 0.05 % Tween-20 in PBS as before.  
Immunoreactive bands were detected using an enhanced chemiluminescence 
reagent  (ECL,  GE  Healthcare)  according  to  the  manufacturers  protocol  and 
visualised by exposing to X-ray film (Fuji Film). 
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Antibody 
name 
Specificity  Raised 
in 
Supplier  Titer for 
WB 
Titer for 
IP 
S974  RP2   sheep  our own  1:1000  1:50 
Arl3 854  Arl3  rabbit  Gift Dr 
N.Cowan 
1:2000  1:200 
Anti-
BART1 
BART1  rabbit  Gift Dr R. Kahn  1:1000  - 
PA1-725  Transducin β  rabbit  ABR  1:500  - 
(C-16):sc-
379 
Transducin β  rabbit  Santa Cruz  1:1000  1:50 
(K-20):sc-
389 
Transducin α  rabbit  Santa Cruz  1:2000  - 
PDS1  Visual arrestin  mouse  Santa Cruz  1:500  - 
F4C1  Pan arrestin  rabbit  Gift Dr V. 
Gurevich 
1:2000  - 
G8795  GAPDH  mouse  Sigma  1:40000  - 
M0725  Vimentin  mouse  Dako  1:500  - 
CNX  Calnexin  mouse  StressGen  1:10000  - 
T4026  β-tubulin  mouse  Sigma  1:2000  - 
M2  FLAG  mouse  Sigma  1:2000  1:100 
NCL  Nucleolin  rabbit  Sigma  1:5000  - 
BRM22  Hsp70/Hsc70  mouse  Sigma  1:1000  - 
9E10  Myc  mouse  Sigma  1:2000  - 
Table  2.10.  Primary  antibodies  used  for  Western  blotting  and 
immunoprecipitation. 
 
 
Specificity  Raised in  Supplier  Titre 
Mouse IgG  donkey  Pierce  1:10000 
Rabbit IgG  1:30000 
Sheep IgG  1:7000 
Table  2.11.  HRP  conjugated  secondary  antibody  used  for  Western 
blotting. 
 
 Chapter II 
98 
   
2.4.6. Production of recombinant proteins 
Prior to large scale production of GST- or His-tag fusion recombinant proteins, 
each of the constructs was checked in small-scale analytical expression studies 
and examined by SDS-PAGE. The expression studies were used to confirm that 
the bacteria efficiently expressed the recombinant proteins of the correct size 
and  to  optimise  conditions  for  the  preparation  of  each  protein.  For  optimal 
protein  expression  and  yield,  all  plasmids  were  transformed  into  OneShot 
TOP10  competent  cells  (Invitrogen)  as  described  in  2.1.2  and  two  single 
colonies from each transformation were used to inoculate an overnight starting 
culture of 10 ml of LB (Appendix) with 50 µg/ml of ampicillin.  
2.4.7. Preparation of recombinant proteins 
The  overnight  cultures  of  transformed  OneShot  TOP10  cells  were  grown  as 
described in 2.3.5. These cultures were used to inoculate 500 ml of LB with 50 
µg/ml ampicillin for GST-Arl3s and His-PFDN5 and in 700ml for GST-RP2. The 
cells  were  grown  in  an  orbital incubator  at 37ºC  with  250  rpm  shaking  until 
OD600 reached 0.6. The protein expression was induced by adding of isopropyl-
beta-D-thiogalactopyranoside (IPTG) (Sigma) to a final concentration 1 mM and 
incubated further for 2-4 hours at 37ºC or 35 ºC, depending on the levels of 
protein expression determined by a scaled-down expression studies.  
The cells were harvested by centrifugation at 6000 g for 15 minutes at 4ºC and 
the  pellet  was  resuspended  in  15  ml  of  PBS,  containing  protease  inhibitor 
cocktail for bacterial cultures (Sigma). The cells were then sonicated on ice 10 
X 10 second pulses with 30 second cooling between them, using a 9 mm probe 
sonicator  (MSE  Soniprep  150).    The  resulting  lysate  was  cleared  by 
centrifugation  at  14000  g  for  30  min  at  4ºC.  The  supernatant  was  filtered 
through 45 µm membrane (Millipore) and the pellet was discarded.  
2.4.8. Purification of GST-fused recombinant protein 
The GST-fused recombinant proteins were purified by affinity chromatography 
using glutathione sepharose (GE Healthcare). All steps were performed using 
pre-chilled buffers and plastic ware to maintain protein stability. 200 µl of the Chapter II 
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sepharose  slurry  was  loaded  onto  each  10ml  polypropylene  column  and 
washed with 2 ml of PBS once.  
The  clarified  supernatants  were  added  to  the  columns  and  allowed  to  pass 
through  by  gravity  flow,  collected  and  re-applied  three  times.  After  that  the 
columns were washed with 50 ml of PBS using a peristaltic pump with a flow 
rate approximately 5 ml/ min. Proteins were left non-eluted from the columns. 
2.4.9. GST pull-down 
All steps were carried out at 4ºC using pre-chilled buffers and plastic ware. The 
beads of glutathione-sepharose with GST-fused recombinant proteins bound to 
them were washed in 1.5 ml of the buffer which was used for cell lysis (table 
2.8). The beads were transferred from columns into Eppendorfs and centrifuged 
at 500 g for 2  minutes. The supernatant was discarded and 500 µg of total 
protein from the mammalian cell lysates or retina lysates (table 2.8) was added 
to 50 µl of the beads. The reactions were incubated overnight with slow rotation. 
The  samples  were  then  centrifuged  at  500  g  and  washed  4  times  with 
appropriate lysis buffer without PIC and the detergents. Afterwards the beads 
were  resuspended  in  50  µl  of  2  X  Laemmli  buffer  and  kept  at  -20ºC  until 
analysed. 
2.4.10. Mass spectrometry 
The samples from GST pull-down experiment were resolved by Protean®II xi 
Cell  SDS-PAGE  (as  described  in  2.4.2)  with  subsequent  mass-spectrometry 
compatible  silver  stain  (see  2.4.5).  The  unique  bands  were  excised  and 
digested in the gel, using a robotic system as described in Wait et al. (2001) by 
Dr.  Robin  Wait,  Kennedy  Institute  of  Rheumatology  Division,  Faculty  of 
Medicine, Imperial College London. Tandem mass spectra were recorded using 
a  Waters  Q-Tof  (Waters,  Manchester,  UK)  interfaced  to  a  Waters  CapLC 
capillary chromatograph.  
Samples were dissolved in 0.1 % v/v aqueous formic acid and injected onto a 
Pepmap C18 column (300 µm x 0.5 cm; LC Packings, Amsterdam, NL) and 
eluted with an acetonitrile/0.1 % formic acid gradient v/v (5 %-70 % acetonitrile Chapter II 
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over 20 minutes) at a flow rate of 1 µl per minute. The capillary voltage was 
3500  V.  A  survey  scan  over  the  m/z  range  400-1300  was  used  to  identify 
protonated peptides with charge states of 2, 3 or 4, which were automatically 
selected for data-dependent MS/MS analysis, and fragmented by collision with 
argon.  
The resulting product ion spectra were transformed onto a singly charged m/z 
axis  (MaxEnt3,  Waters)  and  proteins  were  identified  by  correlation  of 
uninterpreted  spectra  to  entries  in  the  NCBInr  database  using  MASCOT 
(www.matrixscience.com).  
2.4.11. Co-immunoprecipitaion from mammalian cell or retinal 
lysates 
Transfected cells or the retina lysate prepared with lysis buffer 4 (table 2.9) was 
pre-cleared with protein G sepharose to minimise non-specific binding. For each 
sample 50 µl of protein G sepharose slurry was washed twice with 500 µl of the 
appropriate lysis buffer (table 2.9), prepared without protease and phosphatase 
inhibitors, and centrifuged at 16200 g for 2 min at 4ºC after each wash. These 
beads were incubated with 500 µg of total protein in 500 µl for 1 hour at 4ºC 
with slow rotation.  
The pre-cleared lysates were then incubated with the antibodies (table 2.6) at 
4ºC over night with slow rotation followed by binding with prepared protein G 
beads as above for 1 hour at 4ºC with rotation. The tubes then were centrifuged 
for 2 min, the supernatants were removed and the beads were washed 5 times 
with 500 µl of ice-cold appropriate buffer.  
After the last wash the supernatants were aspirated and 50 µl of 2 X Laemmli 
buffer was added to the pellets. The samples were incubated for 15 min at room 
temperature, boiled for 3 min, centrifuged at 16200 g for 2 min, resolved by 
SDS-PAGE and analysed by standard protein blotting techniques described in 
sections 2.4.2 - 2.4.5. 
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2.5. Automated DNA sequencing 
Cycles of DNA denaturation, primer annealing and DNA synthesis with dNTPs 
and  fluorescently  labeled  ddNTPs  form  the  basis  of  automated  sequencing. 
These ddNTPs lack an -OH residue at the 3’ position of the deoxiribose, which 
prevents  the  formation  of  a  phosphodiester  bond  when  incorporated  into 
elongating DNA, leading to chain termination. Thus reaction products contain a 
set of DNA segments of different lengths, each terminating with different labeled 
ddNTPs, which is detected by fluorescence signal in sequencer.  
2.5.1. Genomic sequencing 
For  screening  of  the  PFDN5  gene,  its  exons  were  amplified  by  PCR  as 
described in 2.1.1 section. Before sequencing, PCR products were purified to 
remove unincorporated nucleotides and primers by using 1 U of ExoSAP- IT® 
(USB), which contains Exonuclease I and Shrimp Alkaline Phosphatase in a 
specially formulated buffer. A 2 µl aliquot of each PCR product was diluted in 23 
µl of water and treated with 1 U of ExoSAP- IT for 15 min at 37ºC, followed by 
80 ºC for 15 min to inactivate the enzyme. The purified DNA was then used for 
sequencing: 13 µl of DNA, 5 µl of TM buffer (200 mM Tris pH 9.0, 5 mM MgCl2), 
1  µl  of  Big  Dye® Terminator  Version  3.1 and  1  nM  of  a  specific  forward or 
reverse primer (table 2.2).  
The sequencing reaction consisted of 30 cycles of 96ºC for 30 sec, 50 ºC for 15 
sec  and  60  ºC  for  4  min  and  was  carried  out  in  Techne  Genius  PCR 
thermocycler. Sequencing reaction products were precipitated by adding 26 µl 
of precipitation solution (120 mM NaOAc in 95 % (v/v) ethanol) at -20ºC for 10 
min, centrifuged at 16000 g for 30 min and the supernatant was discarded, then 
the pellet was washed with 200 µl of 70 % (v/v) ethanol and centrifuged for 10 
min at 16000 g. The supernatant was carefully removed and the pellets were 
dried at 65 ºC for 5 min. The pellets were resuspended in 11 µl of formamide 
and loaded onto an ABI 3100 automated sequencer. 
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2.5.2. Plasmid sequencing 
To identify putative interacting partners of RP2 identified during the yeast-two 
hybrid screen, 2µl aliquots of each pMyr plasmid miniprep DNA with an insert 
containing a potential interactor was sequenced. This was combined with 1.5 µl 
of TM buffer (200 mM Tris pH 9.0, 5 mM MgCl2), 4 µl of Big Dye
® Terminator 
Version  3.1  (Applied  Biosystems)  and 1  nM  of  a  specific  forward  or  reverse 
primer (table 2.12). The sequencing reaction consisted of 30 cycles of 96ºC for 
30 sec, 50 ºC for 15 sec and 60 ºC for 4 min and was carried out in Techne 
Genius PCR thermocycler.  
Sequencing reaction products were added to 26  l precipitation solution (120 
mM NaOAc in 95 % (v/v) ethanol) and incubated at room temperature for 10 
min, centrifuged at 16000 g for 10 min and the supernatant was discarded. The 
pellets were washed with 100 µl of 70 % (v/v) ethanol and centrifuged for 10 
min at 16000 g. The supernatant was carefully removed and the pellets were 
dried at 65 ºC for 1-5 min. The pellets were resuspended in 12 µl of formamide 
and loaded onto an ABI 3100 automated sequencer. 
Primer name  Primer sequence 5’-3’ 
pMyr F  ACTACTAGCAGCTGTAATAC 
pMyr R  CGTGAATGTAAGCGTGACAT 
Bovine Arl3 F  ATGGGCTTACTCTCAATTC  
Bovine Arl3 R  TTATTTCTTCTTTGCGCTGAC 
Bovine Arl2 F  ATGGGGCTTCTGACCATACT 
Bovine Arl2 R  TCAGTCGGCCATGAAGATGC 
Clone 46 fragment 2 F  GCCAAACAGCTCGCTGACCAA 
Nucleolin fragment 2 F  GCTCCTGAAGCCAAGAAAC 
Nucleolin fragment 2 R  CTATCCCTTCTCTCCCTCTTC 
Nucleolin fragment 3 F  GCAGCTCCTGAAGCCAAG 
Nucleolin fragment 3 R  CCATGTACAAAACCATTTTTTTCC 
Nucleolin fragment 4 F  CCATTTCTCTGTACTACACCG 
Table 2.12.  Primers used for sequencing of pMyr clones Chapter II 
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2.6. Bioinformatics and software 
For analysing of DNA sequences for the presence of internal restriction sites 
which  could  interfere  with  subcloning  into  vectors  EditSeq  and  MapDraw 
applications of  DNA star program® (DNA Star Inc) were used.  
Carl  Zeiss  AIM  software  was  used  to  analyse  confocal  microscopy  images 
(2.3.5).  Images  were  studied  and  exported  using  LSM  Image  browser  (Carl 
Zeiss). 
For the analysis of the data obtained from the mass spectrometry procedure the 
MASCOT  program  (www.matrixscience.com)  was  used  in  conjunction  with 
NCBInr database for peptide sequence identification.  
To identify the sequences obtained from yeast two-hybrid screens the UCSC 
(University  California  Santa  Cruz)  genome  bioinformatics  site 
http://genome.ucsc.edu and the NCBI site (National Center for Biotechnology 
Information)  http://www.ncbi.nlm.nih.gov  were  used  for  BLAST  analysis  of 
nucleotide and predicted protein sequence. Genomic alignments with the cDNA 
sequences were also compared.  
For protein sequence prediction, computation of the theoretical pI (isoelectric 
point) and Mr the ExPASy Proteomics Server was used http://www.expasy.org. 
For the protein structure analysis Protein Data Bank with RasWin software was 
used (http:/www.rcsb.org/pdb   www.rasmol.org).  
The SeqMan 4.03 tool of DNA star program
® (DNA Star Inc) was employed for 
analysis of DNA sequencing reaction products since it allows the display of an 
ABI chromatogram and aligns sequences obtained using ABI sequencer. Other 
tools  for  DNA  chromatogram  reading  such  as  BioLign  4.0.6  (Biosoft  Net, 
http://en.bio-soft.net) were also used mainly for plasmid sequence analysis. For 
single nucleotide polymorphism identification the SNP database of NCBI was 
searched (http://www.ncbi.nlm.nih.gov/projects/SNP).  
Figures were cropped, adjusted and annotated using Adobe Illustrator CS2 and 
Adobe Photoshop CS2.   Chapter III 
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Chapter III. Novel putative interacting 
partners of RP2 identified by yeast two-
hybrid screening 
3.1. Introduction 
In order to find novel interacting partners of RP2, a yeast two-hybrid system 
was used. The system was developed almost 20 years ago by Fields and Song 
(1989). It was based on the principle that when two functional domains of a 
transcription factor (DNA binding domain and transcriptional activation domain) 
and separated and are able to exist independently. For the transcription factor 
to activate a reporter gene its two domains must be physically brought together. 
For this purpose the cDNA of a protein of interest, the “bait”, was fused with the 
DNA binding domain and putative interacting protein cDNA, the “prey”, with the 
transcriptional activation domain. When a “bait” protein interacts with a “prey” 
protein, two domains of the transcription factor are joined and the reporter gene 
is activated (β-galactosidase), which can then be detected by an appropriate 
assay.  
Variations  on  this  methodology  have  been  developed  since  it  was  first 
published. In this study the Son of Sevenless (Sos) recruitment system  was 
used. It is based on using a strain of yeast, cdc25-H, which contains a point 
mutation  at  position  1328  of  Cdc25  gene.  The  cdc25  yeast  protein  is 
functionally homologous to human Sos (hSos). Cdc25 and hSos proteins act as 
guanyl nucleotide exchange factors for Ras, which is required for yeast growth, 
and hSos is able to substitute this function of cdc25 in mutant yeast (Broder et 
al., 1998). The mutant strain is temperature sensitive and the yeast are able to 
grow  only  at  22-25ºC  (permissive  temperature)  but  not  at  37ºC  (restrictive 
temperature) (Aronheim et al., 1994).  
The protein of interest is fused with hSos and is used as a “bait”. The fusion 
protein  hSos-“bait”  can  activate  Ras,  compensating  the  mutant  cdc25,  only 
when it is targeted to the membrane. For this study a bovine retina cDNA library Chapter III 
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was used in the pMyr vector which attaches a myristoylation signal to the N-
terminus of target proteins (Stratagene, CytoTrap®). When the “bait” physically 
interacts with the target protein expressed from the library, it recruits hSos to 
the plasma membrane. The Ras pathway becomes activated by hSos and the 
mutant yeast strain can grow at the restrictive temperature (Figure 3.1).  
This system has several advantages compared to the one developed by Fields 
and Song in 1989. First, the proteins do not have to be transported into the 
nucleus, so it may be used for proteins which do not translocate easily. Second, 
it allows limited post-translational modifications that may occur in the cytoplasm 
and might be important for the interaction. A further advantage of CytoTrap® is 
the signal amplification by the cascade nature of the Ras activating pathway, 
which helps to reveal even weak interactions.This system was the most suitable 
one for detecting of potential RP2 interactors since RP2 is dually acylated and 
targeted to the cytosolic surface of the plasma membrane (see 1.5.3).  As such, 
the  localisation  of  a  “prey”  to  the  plasma  membrane  was  considered  to  be 
closer to the normal physiological environment for RP2 than the nucleus.  
However, this system also has problems that are typical for all yeast two hybrid 
strategies. One of them is false positive interacting partners, which are either 
able  to  activate  the  Ras  pathway  without  recruiting  hSos  or  are  able  to 
substitute  yeast  Ras  and  cause  growth  at  37ºC.  Another  problem  is  that 
CytoTrap® uses a temperature sensitive strain which is prone to a phenomenon 
of  reversion  to  the  non-temperature  sensitive  phenotype.  This  phenomenon 
occurs  when  yeast  start  to  compensate  for  the  impaired  Ras  pathway  by 
alternative pathways and become able to grow at 37ºC (Huang et al., 2001).   
Despite these difficulties, the yeast two-hybrid system is suitable as a method 
for  identifying  protein-protein  interactions.  It  has  been  used  to  successfully 
identify  many  protein-protein  interactions  including  an  interaction  between 
GABAp1 and cellular retinoic acid binding protein (CRABP) (Song et al., 2005). 
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Figure  3.1.  Schematic  of  yeast  two-hybrid  hSos  recruitment  system 
(CytoTrap®) 
a. At a permissive temperature (24ºC) the yeast are able to grow due to the 
cdc25 mutation having no effect. b. At the restrictive temperature (37ºC) when 
there is no interaction between the “bait” and the “target” yeast are not able to 
grow. This is due to the mutant strain being unable to convert Ras-GDP into 
Ras-GTP  and  thus  growth  at  37ºC  does  not  occur.  c.  At  the  permissive 
temperature the yeast grow whether there is an interaction or not. d. If there is 
an interaction, the loss of function of cdc25 is compensated by the recruitment 
of hSos to the plasma membrane. This causes the conversion of Ras-GDP to a 
GTP  bound  form  and  the  yeast  cells  are  able  to  grow  at  the  restrictive 
temperature (Evans et al., 2005). 
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The interaction of RP2 and Arl3 was studied using the CytoTrap® method as an 
in vivo system (Evans et al., 2005). During screening for RP2 interactors with a 
bovine  retina  cDNA  library,  91  %  of  putative  positive  interactors  were 
represented by Arl3 (Evans, 2007), indicating that this interaction in vivo is very 
abundant. Using CytoTrap® it was also revealed that RP2 was able to bind 
Arl2,  although  with  a  much  lower  affinity  compared  to  Arl3.  This  interaction 
required full length RP2 and did not show any binding to the N-terminus of RP2 
(1-200 AA) unlike Arl3 (Evans, 2007). RP2 and Arl2 have not been described as 
interactors (Bartolini et al., 2002; Kuhnel et al., 2006). However, in biochemical 
studies  of  GAP  activity,  Arl2  demonstrated  a  weak  GTP  hydrolysis  upon 
incubation  with  RP2  at  stoichiometric  concentration  (Veltel  et  al.,  2008a), 
indicating that the CytoTrap® system is highly sensitive to weak interactions. 
Moreover, several novel potential interacting partners binding to the C-terminus 
of RP2 (190-350 AA) were identified by this method during screening of RP2 
with a bovine retina cDNA library (Evans, 2007). 
One of the novel interactors was a small GTPase RAN (Evans, 2007). RAN 
protein  (CAG  29343)  is  a  small  GTPase  of  Ras  superfamily  that  localises 
predominantly in the nucleus (Macara, 2001; Kornbluth et al., 1994). Studies 
into RAN function suggested involvement in the nucleo-cytoplasmic transport of 
proteins  (Ribbeck  et  al.,  1998;  Yoneda  et  al.,  1999)  and  mitotic  spindle 
formation (Kalab and Heald, 2008). The role of the interaction of RP2 with RAN 
is unclear. The L253R mutant of RP2, along with misfolding mutants (C67T and 
C86T) disrupted the interaction. Interestingly, the interaction of RP2 and RAN 
was stronger when RAN was in a GDP-locked conformation.  
Another of the identified interacting partners was p27 (cyclin dependent kinase 
inhibitor 1, BAA25263). High levels of p27 are associated with different types of 
cancer (Curry et al., 2008; Caldon et al., 2006). This protein is involved in cell 
cycle  control  progression  from  G1  to  S  phase  (Caldon  et  al.,  2006).  It  was 
demonstrated that RAN is involved in p27 nuclear export (Connor et al., 2003). 
Transportin  3  from  importin-β  family  (TNPO3,  NP036602),  which  was  also 
identified in the CytoTrap® screen along with RAN and p27, is mainly involved 
in  the  transport  of  proteins into  the  nucleus.  It  takes part in  transport of  SR Chapter III 
108 
   
proteins and splicing regulators to the nucleus in conjunction with RAN (Lai et 
al.,  2001).  Thus,  these  three  putative  interacting  proteins  found  during 
CytoTrap® screening by Dr. R.J. Evans (2007) belong to one nuclear transport 
pathway,  possibly  involving  RP2.  The  mechanism  of  nuclear  transport  could 
potentially  be  involved  in  RP2  retina  degeneration  pathogenesis.  There  are 
numerous  mutations  in  genes  encoding  splicing  factors  which  cause  retinal 
degeneration,  such  as  PRPF31  (Chakarova  et  al.,  2002),  PRPF8  and  3 
(Gamundi et al., 2008). Potentially their impaired transport to the nucleus could 
cause retinal degeneration. 
To date, the putative novel interacting partners of RP2 found during CytoTrap® 
screening were proteins with a ubiquitous expression pattern which bound to 
the  C-terminal  region  of  RP2  (amino  acids 190  to  350)  (Evans,  2007).  This 
region includes the NDK homology domain and a short linker region between 
this  domain  and  the  N-terminus  (see  1.5.2).  However,  most  of  pathogenic 
mutations  in  RP2  are  found  in  the  N-terminal  region  and  the  only  known 
interacting partner for the N-terminus of RP2 is Arl3. Therefore, it was important 
to identify and confirm novel interacting partners of RP2 that would shed light on 
RP2 function in the retina.  
Yeast  two-hybrid  screening  has  been  successfully  used  to  identify  retina 
specific interacting partners for other retinal degeneration related proteins. For 
example,  the  screening  of  a ubiquitously  expressed  protein  causing  X-linked 
retinitis pigmentosa, RPGR, was performed by Boylan and Wright (2000) and 
Roepman et al. (2000). The RCC1 domain of this protein was used as “bait” for 
screening  a  retinal  cDNA  library,  which  resulted  in  identification  of  a  retina-
specific  protein,  RPGRIP1.  This  protein  was  subsequently  found  to  be  a 
causative gene for Leber congenital amaurosis (Dryja et al., 2001; Gerber et al., 
2001).  
Therefore,  CytoTrap®  was  chosen  for  further  screening  for  new  interactions 
using the full-length RP2 and its domains as“bait”. A schematic of the fragments 
of RP2 used for screening, domain mapping and the RP2 mutants tested for 
interaction are shown in figure 3.2.   Chapter III 
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Figure  3.2.  Schematic  of  fragments  and  mutants  of  RP2  used  in 
CytoTrap® 
The  top  panel  represents  a  schematic  of  the  domain  structure  of  the  RP2 
protein. The N-terminal acylation motif is shown by two tags representing the 
myristoylation and palmitoylation posttranslational modifications. The position of 
introduced  pathogenic  amino  acid  substitution  mutations  is indicated.  Panels 
below show the fragments used in CytoTrap®. Yellow boxes illustrate the very 
N-terminal region, red boxes highlight the cofactor C homology domain, pink 
boxes correspond to the NDPK homology domain.  
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3.2. CytoTrap® system characterisation  
The  CytoTrap®  system  was  first  tested  with  positive  and  negative  control 
plasmids, provided by the manufacturer (Stratagene). The yeast strain cdc25-H 
was maintained as described in 2.2.1. The yeast cells were co-transformed with 
pSos RP2 or its fragments and mutants (figure 3.2, described in section 2.1.8) 
and pMyrSB as a positive control (hSos-binding). This plasmid contains Sos 
binding protein as a “prey” and therefore when it is targeted to the membrane by 
the myristoylation signal it binds to hSos, activating the Ras pathway and thus, 
yeast are able to grow at 37ºC. For the negative control all RP2 constructs were 
co-transformed with pMyr LaminC since Lamin C protein does not interact with 
hSos or RP2. 
Upon  co-transfection  with  RP2  constructs  and  the  positive  control  plasmid, 
yeast  exhibited  growth  at  24ºC  on  the  selective  media  after  72  hours  of 
incubation. After replating several yeast colonies from each transformation (as 
in 2.2.6) it was found that yeast cells were able to grow at 37ºC on selective 
media.  The  intensity  of  yeast  growth  when  using  the  same  positive  control 
plasmid as a “prey” directly corresponds to the expression level of the hSos 
fusion construct (Evans, 2007).  
It was revealed that the positive control (pMyr SB) with wild type pSos and 1-
200 RP2, 190-350 RP2 fragment fusions with hSos co-transfected grew on the 
first day of incubation at the restrictive temperature (37ºC) on selective media, 
indicating a high expression level of RP2 and these fragments (figure 3.3a). The 
intensity of yeast growth was higher in yeast transformed with the wild type RP2 
than any of the domain deletions. Yeast expressing RP2 fragments 42-200 and 
238-350  and  hSos  binding  protein  exhibited  growth  only  after  72  hours  of 
incubation at 37ºC, suggesting low expression level of these RP2 fragments 
(figure 3.3a). 
The hSos-RP2 constructs were tested in the system with the negative control 
plasmid  pMyr  LaminC  (Figure  3.3b).  It  was  found  that  after  144  hours  of 
incubation  at  37ºC  on  the  selective  media,  none  of  the  constructs  exhibited 
visible growth. However, after incubation longer than 144 hours weak growth  Chapter III 
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Figure 3.3. Interaction of hSos-RP2 constructs with positive and negative 
controls 
Three  different  colonies  for  each  transformation  were  spotted  onto  selective 
media as described in 2.2.6. The growth observed after incubation at the non-
restrictive temperature (24ºC) for 96 hours and at the restrictive temperature 
(37ºC)  for  144  hours  is  shown.  Each  saturated  spot  contains  approximately 
1x10
8 yeast cells. a. Growth of yeast co-transformed with pSos RP2 constructs 
and a positive control plasmid pMyr SB. b. Co-transformation of yeast with pSos 
RP2  constructs  and  the  negative  control  plasmid  pMyr  LaminC  resulted  in 
growth only at 24ºC and not at 37ºC. Chapter III 
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was observed in yeast co-transformed with pMyr Lamin C and full-length pSos 
RP2 or pSos 190-350 RP2 fragment. The yeast growth was more pronounced 
after 168 hours of incubation (data not shown) therefore indicating a low level of 
transactivation. Results for the full length RP2 and its 190-350 fragment were 
therefore evaluated after a maximum 144 hours of incubation at the restrictive 
temperature on the selective media.  
3.3. Screening of the bovine retinal cDNA library with 
the full length human RP2 
Cdc25-H yeast cells were co-transformed with the pSos RP2 construct and a 
bovine  retinal  cDNA  library  as  described  in  2.2.2.  The  co-transformed  yeast 
cells were incubated on the selective media at 24ºC. The colonies from each 
transformation  were  counted  for  analysis  of  the  number  of  “prey”  plasmids 
screened  and  yeast  transformation  efficiency.  The  plates  were  then  replica-
plated and incubated at 37ºC restrictive temperature on the selective media with 
galactose to activate the library vector promoter and induce expression (as in 
2.2.3).  
Single colonies which exhibited growth under such conditions after 144 hours 
were picked and cultivated (2.2.4). Total yeast DNA from selected colonies was 
isolated  as  described  in  2.2.4.  Bacterial  cells  were  then  transformed  with 
isolated total yeast DNA to derive pMyr plasmids of putative interacting partners 
as described in section 2.2.5.  
The cdc-25H yeast strain is prone to produce temperature resistant revertants 
(described  in  3.1),  causing  yeast  cells  to  grow  at  37ºC.  Such  yeast,  being 
transformed with empty pMyr or pMyr containing “prey”, would exhibit growth on 
the selective media at 37ºC, giving a false positive result.  
This  problem  was  overcome  two  ways.  First,  the  number  of  revertants  from 
each  transformation  was  monitored  at  37ºC  on  non-selective  media  (as  in 
2.2.5).  When  this  number  was  more  than  30  revertants  per  plate,  the 
transformation was considered not successful and was not analysed further.  Chapter III 
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Secondly,  verification  of  a  putative  interaction  was  performed  by  re-
transformation from another batch of cdc25-H yeast with newly isolated pMyr 
clone and pSos RP2 or pSos. This would eliminate false positive interacting 
partners binding to Sos or Ras pathway activators. At least three colonies for 
each pMyr clone were then tested for growth on the selective media at 37ºC to 
ensure  that  the  isolated  pMyr  clones  caused  yeast  growth  at  37ºC  on  the 
selective media in the presence of pSos RP2(2.2.6).  
Approximately 250,000 colonies of yeast transformants were obtained during 
the screening of pSos RP2 with the retinal library, which were able to grow on 
selective media at 24ºC permissive temperature. After screening for the ability 
to  grow  at 37ºC  (as  described  in  2.2.3),  135  putative  positive  colonies  were 
isolated and checked for the presence of pMyr clone inserts by restriction with 
EcoRI and SalI (figure 3.4).  
Upon analysis of clones which grew in the first 48 hours of library screening, it 
was  revealed  that  most  of  them  (124)  did  not  demonstrate  any  growth, 
suggesting  they  were  revertants.    9  colonies  exhibited  growth  upon  re-
transformation with pSos RP2 at 37ºC on the selective media. The pMyr cDNA 
inserts were sequenced as in 2.5.2 and bioinformatic analysis revealed that the 
open reading frames of these nine pMyr plasmids corresponded to in frame Arl3 
coding sequence (data not shown).  
The other three clones that exhibited growth in the re-transformation test (as in 
2.2.5) grew at a slower rate with colonies visible between 48 and 144 hours of 
incubation at 37ºC.  The inserts of these cDNA were sequenced as in 2.5.2 and 
clone 28 contained an open reading frame encoding TNPO3 (data not shown). 
This interacting partner has been reported previously (Evans, 2007). 
The  other  two  clones  that  exhibited  growth  at  37ºC  on  the  selective  media 
during interaction verification were sequenced and it was identified that open 
reading frames of these clone contained coding sequences of novel  putative 
interacting  partners  of  RP2.  The  screen  summary  is  shown  in  figure  3.4b.Chapter III 
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a. 
 
b. 
  Full length RP2 
as “bait”  
1-200 RP2 
fragment as 
“bait” 
No. Colonies screened 
 
~224,000  ~60,000 
No. potential interactors 
 
135  86 
No. interactors analysed  135  69 
(first 17 excluded) 
No. revertants/ False positives (%)  124 (91.8 %)  62 (89 %) 
 
No. Interactors 
 
12  7 
No. Arl3 clones   9  2 
 
No. of TNPO3 clones 
 
1  0 
Novel putative interactors   2  5  
 
 
Figure 3.4. Summary of CytoTrap® screening performed in this study 
a. Examples of analytical restriction digest with EcoRI and SalI of isolated pMyr 
plasmids of putative interacting partners. The lane on the left represents a 1kb 
DNA  ladder.  Clone  numbers  are  as  indicated.  b.  Tabulated  summary  of 
CytoTrap® screening of pSos RP2 and pSos 1-200 RP2 fragment with a bovine 
retinal cDNA library. Chapter III 
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3.3.1. Nucleolin 
Clone 30  was  verified  for interaction  upon re-transformation  with  pSos  RP2. 
This pMyr clone proved negative for the interaction with an empty pSos vector 
(figure 3.5). Clone 30, when co-transformed with full-length RP2, demonstrated 
visible growth after 48 hours of incubation at 37ºC on the selective media (figure 
3.5).  
The  plasmid  was  sequenced  and  the  electropherogram  was  interpreted  as 
described in 2.5.2 and 2.6. The open reading frame of pMyr clone 30 had 100 
% identity to cDNA of nucleolin (NCL) (figure 3.6a).  
The  protein  sequence  was  predicted  by  bioinformatics  tools  (2.6)  using  the 
insert in frame DNA sequence and it was revealed that the protein contained 
573 amino acids with a molecular weight 62.6 kDa and calculated pI 4.57. The 
protein sequence was used to search for matches against the NCBI database 
(2.6) and it was found that the protein sequence of clone 30 had 100 % identity 
to bovine NCL isoform 1 (XP 614626) (figure 3.6c).  
The  identity  between  clone  30  and  NCL  began  at  clone  30  residue  67  and 
extended  to  the  C-terminus  (amino  acid  720)  including  predicted  RNA 
recognition motif (RRM) domains of the NCL protein (figure 3.6). The first 66 
amino acids did not match any proteins in the databases searched (2.6), but the 
DNA showed 100 % identity to an in frame region of the intron 4 of the bovine 
NCL gene suggesting either alternate or incomplete splicing (figure 3.6a).  
3.3.1.1. Characterisation of NCL interaction with RP2 in CytoTrap® 
Clone 30 was tested further by CytoTrap® to determine which domain of RP2 
takes part in binding to NCL and whether RP2 mutants were able to affect this 
interaction.  
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Figure 3.5. Interaction of clone 30 with RP2 in CytoTrap® 
a. Growth of yeast co-transformed with pMyr clone 30 and wild type (wt) pSos 
RP2 and RP2 fragments as indicated. Three different colonies were used for 
each transformation and were tested at the permissive (24ºC) after 96 hours of 
incubation  on  the  selective  media,  and  at  the  restrictive  temperature  (37ºC) 
after 144 hours. b. Yeast growth when co-transformed with pMyr clone 30 and 
pSos RP2 mutants as indicated. Yeast tested for growth at two temperatures on 
the selective media with pSos empty vector negative control. 
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Figure 3.6. Characterisation of clone 30 
a. Alignment of clone 30 to the bovine NCL gene. The exons of bovine NCL are 
in  green  and  numbered  as  indicated,  black  horizontal  lines  correspond  to 
introns. Regions of clone 30 corresponding to exons of NCL are in grey with 
vertical lines highlighting these regions. b. Comparison of the protein domain 
structure of bovine NCL (green) with a predicted domain structure of clone 30 
protein (grey). Black boxes with numbers above indicate the position of RNA-
binding RRM domains. c. Alignment of the predicted protein sequence from the 
open reading frame of pMyr clone 30 (Query) to the protein sequence of bovine 
NCL (Sbjct) performed using BLAST at NCBI (2.6).     Chapter III 
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Upon  co-transformation  of  the  pMyr  NCL  plasmid  with  RP2  fragments  yeast 
growth was mainly observed with RP2 fragment amino acids 190-350 but not 
other fragments, including a smaller C-terminal RP2 fragment of amino acids 
238-350 (figure 3.5a). RP2 fragment 1-200 resulted in weak yeast growth after 
120  hours  of  incubation  at  37ºC  upon  co-transformation  with  pMyr  NCL 
fragment, but not with RP2 41-200 fragment. However, yeast co-transformed 
with RP2 41-200 plasmid and the positive control pMyr SB had exhibited poor 
growth before (figure 3.3), suggesting a lower expression level of this fragment 
of  RP2  protein.  Therefore,  in  this  case  the  absence  of  growth  cannot  be 
interpreted. These data  suggest  that  the  NCL  protein  fragment  binds  the  C-
terminal region of RP2 with the region essential for binding defined as amino 
acid 190 to 350.  
The NCL fragment was also tested for its ability to bind mutants of RP2. It was 
revealed  that  NCL,  when  co-transformed  with  pSos  RP2  misfolding  mutants 
such as C67Y and C86Y, significantly slowed yeast growth (figure 3.5b). C67Y 
co-transformed yeast were able to grow only after 120 hours of incubation at 
37ºC and cells co-expressing C86Y mutant with pMyr clone 30 did not exhibit 
growth  after  144  hours.  However,  this  mutant  has  a  lower  expression  level 
compared to other constructs (described in section 3.2).  The pathogenic C-
terminal mutation L253R caused slower growth of yeast compared to the full 
length  wild  type  pSos  RP2.  The  “arginine  finger”  mutation  (R188H)  did  not 
noticeably affect yeast growth, which was observed after 48 hours of incubation 
at 37ºC as was growth for the full length wild type RP2 (figure 3.5b). 
Thus, it was shown that in CytoTrap® the NCL fragment preferably interacts 
with the C-terminus of RP2 and that misfolding mutations in the N-terminus and 
the C-terminal mutation L253R could affect this interaction. As the cDNA does 
not represent the full length NCL, it is possible to suggest that the potential 
interaction  of  the  full length  NCL  with  RP2 is not  mediated  by  the  1-214  N-
terminal region of NCL. 
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3.3.2. Drebrin-like protein 
Re-transformation of clone 20 resulted in yeast growth with pSos RP2 and not 
with the empty pSos vector at the restrictive temperature on selective media 
(figure 3.7d). The insert sequence was obtained and interpreted as described in 
2.5.2 and 2.6. The insert sequence of pMyr clone 20 had 95 % identity to 7 
exons  of  the  drebrin-like  protein  (DBNL)  gene  positioned  at  chr22:62,002-
80,241 of bovine genome (figure 3.7a).  
The in frame open reading frame (ORF) of pMyr clone 20 was translated into a 
protein sequence using bioinformatic tools (2.6) and used for BLAST analysis. 
The predicted clone 20 protein sequence had 95 % identity to bovine DBNL 
protein isoform 2 (XP 001092440) (figure 3.7b and c). Clone 20 protein aligned 
to DBNL starting from amino acid 171 to the C-terminus but did not include a 
region between amino acids 240 to 250 of DBNL. This region of 10 amino acids 
corresponds to the sequence of exon 8 of the bovine DBNL gene (figure 3.7b). 
These data suggest that this exon was spliced out producing a DBNL isoform 
different to isoform 2. This region does not include known functional domains of 
DBNL or disrupts the reading frame. Clone 20 is predicted to contain the SH3 
conserved domain but lack the actin depolymerisation factor/cofilin-like domain 
(ADF) of DBNL (figure 3.7b).  
3.3.2.1. RP2 domain mapping of the interaction with clone 20 
To  investigate  further  which  part  of  RP2  binds  to  the  DBNL  fragment,  the 
CytoTrap® assay was performed with RP2 fragments. It was revealed that pMyr 
clone 20 when co-transformed with full-length RP2 exhibited growth only after 
96 hours of incubation at 37ºC on the selective media. Upon co-transformation 
of pMyr clone 20 with pSos RP2  fragments (figure 3.2) the yeast growth was 
observed only for the C-terminal 190-350 pSos RP2 fragment after 120 hours of 
incubation at 37ºC on the selective media (figure 3.7d). These data suggest that 
clone 20 protein binds the C-terminus of RP2.  
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Figure 3.7. Clone 20 characterisation and its interaction with RP2 
a. Comparison of clone 20 (grey boxes) sequence to the exon organisation of 
the  bovine  DBNL  gene  (green  boxes  are  exons,  black  horizontal  lines  as 
introns).  Exon  8  of  DBNL  was  not  present  in  the  clone  20  sequence.  b. 
Comparison  of  the  domain  structure  of  bovine  DBNL  protein  (green)  to  the 
predicted  domains  of  clone  20  (grey).  White  box  represents  the  actin 
depolymerisation factor (ADF) domain and the black box is the SH3 domain. c. 
Alignment  of  clone  20  protein  sequence  to  bovine  DBNL  performed  using 
BLAST at NCBI (2.6). d. Three different colonies of yeast co-transformed with 
pMyr clone 20 pSos RP2 or RP2 fragments after incubation on the selective 
media at permissive (24ºC) and restrictive temperature (37ºC) after 144 hours.Chapter III 
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3.3.3. Unc119 
Clone 58 only resulted in a low level of yeast growth upon re-transformation 
with pSos RP2. The yeast did not exhibit growth compared to the pMyr Lamin C 
negative  control  after  144  hours  of  incubation  at  37ºC.  However,  after 
incubation for 156 hours at 37ºC yeast co-transfected with pMyr clone 58 and 
pSos RP2 exhibited growth slightly above the level of pSos RP2 transactivation 
(data not shown). This growth indicated a possibility of a low affinity interaction 
and therefore, the pMyr clone 58 insert was sequenced and analysed by BLAST 
searching as described in 2.5.2 and 2.6. pMyr clone 58 cDNA sequence had 
100  %  identity  to  all  5  exons  of  the  bovine  Unc119  gene  positioned  at 
chr19:19,894,298-19,909,204 of the bovine genome (figure 3.8a). The in frame 
sequence of clone 58 was translated into protein sequence and it was revealed 
that  the  protein  contained  222  amino  acids  and  was  predicted  to  have  a 
molecular  weight  25.3  kDa  with  pI  5.33.  Clone  58  protein  aligned  to  bovine 
Unc119 (NP 001029817.1) from amino acid 19 to the C-terminus and contained 
GMP PDE δ domain of Unc119 (figure 3.8b, c).  
Further study of this putative interacting partner was attempted due to the fact 
that Unc119 is a retinal specific protein involved in pathogenesis of cone-rod 
dystrophy and has been reported to form a ternary complex with Arl3 and RP2 
(Kobayashi et al., 2000; Veltel et al., 2008b). However, the clone 58 - pSos RP2 
interaction  was  not  reproducible  in  CytoTrap®  and  no  yeast  growth  was 
observed when pMyr 58 was co-transformed with pSos RP2 fragments (data 
not shown).  
The DNA insert of clone 58 was directly subcloned from the pMyr vector into the 
mammalian expression vector pCMV Tag 3(b) as described in sections 2.1.5-
2.1.8 and table 2.3. SK-N-SH cells were transfected (as in 2.3.2) with pCMV 
Tag  3(b)  Unc119  construct  and  co-transfected  with  RP2-GFP  to  test  for  an 
overlap in their subcellular localisation. After visualising expressed myc-Unc119 
with  anti  tag  antibody,  no  overlap  with  RP2-GFP  localisation  was  observed 
(figure  3.9).  Thus,  it  is  unclear  whether  the  potential  interaction  between 
Unc119 and RP2 occurs.  Chapter III 
122 
   
 
Figure 3.8. Characterisation of clone 58 
a. Schematic of exon structure of the bovine Unc 119 gene (green boxes) and 
corresponding  DNA  sequence  of  clone  58  (grey  boxes).  The  corresponding 
regions are indicated by black vertical lines. b. Domain structure of bovine Unc 
119 protein (green) and the predicted protein translated from the open reading 
frame of pMyr 58 (grey) with a white box indicating the GMP PDE δ domain. c. 
Alignment of predicted protein sequence of the open reading frame of clone 58 
to bovine Unc119 performed using BLAST (NCBI) as described in 2.6. Chapter III 
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Figure 3.9. Subcellular localisation of Unc119 
Confocal  microscopy  images  of  representative  SK-N-SH  cells  co-transfected 
with  RP2-GFP  (green)  and  myc-Unc119,  visualised  with  anti-myc  antibody 
(red). Scale bars are 10  m. 
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3.4.  Screening  of  the  N-terminus  of  RP2  using 
CytoTrap® 
Novel interacting partners identified during the screening of full-length RP2 with 
a retinal cDNA library exhibited binding to the C-terminus of RP2. Moreover, the 
difficulty of the screening protocol was enhanced by the transactivation of the 
pSos RP2 construct after incubation for longer than 144 hours at 37ºC, which 
probably resulted in losing low affinity interacting proteins.  
Therefore, the retinal cDNA library was further screened using an N-terminal 
fragment of RP2. The 1-200 fragment was chosen since it was demonstrated to 
have a good expression level compared to 41-200 fragment (figure 3.3a). The 
pSos  1-200  RP2  construct  did  not  transactivate  the  CytoTrap®  system  after 
incubation for longer than 240 hours (data not shown) and thus, allowed longer 
incubation times and potentiated detection of low affinity interactions. 
After  yeast  transformation  (performed  as  described  in  2.2.1-2.2.2) 
approximately 60,000 colonies were obtained, which were able to grow on the 
selective  media  at  24ºC  permissive  temperature.  These  colonies  were  then 
replica-plated (as in 2.2.3) and tested for ability to grow at 37ºC on selective 
media. As a result, 86 putative positive colonies were selected and plasmids 
were isolated (summary of the screening is shown in figure 3.4b).  
Based  on  the  previous  experience  of  the  screening  of  the  full-length  RP2 
(described in section 3.2.3), colonies which appeared to grow on the second 
day (starting at colony number 17) and until 192 hours of incubation at 37ºC 
were selected. This was done to avoid revertants or clones containing the high 
affinity interacting partner Arl3. 
The remaining 67 clones were analysed by restriction digest to determine the 
presence  and  size  of  the  insert.  Two  pMyr  clones  (clone  8  and  clone  10) 
released a fragment of about 550 bp. After re-transformation with pSos 1-200 
RP2 for interaction verification clones 8 and 10 exhibited growth on the first day 
of incubation at 37ºC on selective media. The pMyr inserts of clones 8 and 10 
were sequenced (as in 2.5.2) and it was revealed that these clones contained Chapter III 
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the full coding sequence of bovine Arl3 as the open reading frame (data not 
shown). Other plasmids released inserts of different sizes and were therefore 
re-transformed with pSos 1-200 RP2 for verification. It was found that only 5 out 
of 65 pMyr clones exhibited growth at 37ºC on the selective media. These pMyr 
clones inserts were sequenced and it was found that they represented novel 
putative interacting partners of RP2. The summary of the screening is shown in 
figure 3.4b. 
3.4.1. Rod arrestin 
pMyr clone 46 was verified by re-transformation with pSos 1-200 RP2 fragment. 
This “prey” demonstrated yeast growth after 120 hours of incubation at 37ºC 
(figure 3.9). It was also tested for yeast growth when co-transformed with an 
empty pSos vector to ensure that clone 46 did not bind hSos (figure 3.10).  
pMyr clone 46 insert was sequenced (as in 2.5.2) and the electrophoregram 
was interpreted using bioinformatic tools described in 2.6. The DNA sequence 
of the open reading frame of clone 46 had 100 % identity to 11 exons of a gene 
positioned  at  chr3:120,315,637-120,373,305  of  bovine  genome  that 
corresponds to the bovine s-antigen SAG gene (figure 3.11a). 
Bioinformatic  tools (section  2.6)  were used to  translate  the  in  frame  DNA  of 
pMyr clone 46 insert into protein sequence which was predicted to contain 282 
amino  acids  with  a  molecular  weight  of  approximately  31.5  kDa  and  a 
calculated  pI  5.26.  This  protein  sequence  was  searched  against  the  NCBI 
database (2.6) and it was found that clone 46 protein had 100 % identity to the 
bovine rod arrestin protein isoform p48 (1CF1) starting from amino acid 123 to 
amino acid 404 (figure 3.11c). Clone 46 protein contained a part of the “Arrestin 
N”  conserved  domain  at  the  N-terminus  and  the  full  C-terminal  “Arrestin  N” 
domain (figure 3.11b).  
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Figure 3.10. Interaction of clone 46 with RP2 in CytoTrap® 
Yeast growth when co-transformed with pMyr clone 46 and wild type pSos RP2, 
RP2 fragments “a.” and RP2 mutants “b.” as shown. pSos empty panel shows 
the  negative  control  for  pMyr 46  clone  with  the  pSos  vector.  Three different 
colonies  were  used  for  each  transformation  and  were  tested  at  the  non-
restrictive temperature (24ºC) for 96 hours and at the restrictive temperature 
(37ºC) for 168 hours. Chapter III 
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Figure 3.11. Comparison of clone 46 to bovine rod arrestin 
a.  Alignment  of  the  DNA  insert  of  clone  46  to  the  bovine  rod  arrestin  gene 
(SAG). Exon 1 is a non-coding exon and is in light green. Other SAG exons are 
shown as green boxes and regions of clone 46 corresponding to SAG exons 
are in grey. b. The domain structure of the bovine rod arrestin protein (green) 
and a predicted domain structure of clone 46 protein (grey) with black boxes 
showing position of two Arrestin_N domains. c. The protein sequence predicted 
by  translation  of  the  in  frame  sequence  of  pMyr  clone  46  insert  DNA  using 
bioinformatic tools (2.6). Alignment of the predicted protein sequence of clone 
46 (Query) and the protein sequence of bovine rod arrestin (Sbjct) performed 
using BLAST analysis at NCBI (2.6). Chapter III 
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3.4.1.1. Characterisation of RP2-rod arrestin interaction by CytoTrap® 
pMyr clone 46 was investigated further with the yeast two-hybrid system. The 
ability to interact with the full-length RP2 and RP2 fragments  was examined 
(figure 3.10a). It was revealed that yeast growth was slower with the full-length 
protein rather than with 1-200 fragment. The two other fragments of pSos RP2 
did not exhibit growth and the small single colonies which appeared after 168 
hours  of  incubation  at  the  restrictive  temperature  are  more  likely  to  be 
temperature resistant revertants (3.1). The co-transformation of pMyr clone 46 
with RP2 mutants did not result in detectable yeast growth after 120 hours of 
incubation at 37ºC suggesting no interaction occurred (figure 3.10b). Therefore, 
the  putative  interaction  of  rod  arrestin  fragment  with  RP2  required  further 
investigation.  
3.4.1.2. Expression of rod arrestin fragment in SK-N-SH cells 
The open reading frame of clone 46 was subcloned from the pMyr vector into a 
pCMV-Tag3b  vector  to  facilitate  mammalian  expression  of  N-terminally  myc-
tagged rod arrestin fragment (as in 2.1.1-2.1.8). It was also subcloned into the 
pEGFPC1  vector  to  produce  N-terminally  tagged  GFP  fusion  protein.  The 
primers used for subcloning into the vectors are shown in table 2.3. However, 
the internal SalI and EcoRI sites of TA-cloned pGEM-T Easy® clone 46 were 
used to construct pCMV-Tag3b-clone 46. To produce a GFP fused clone 46 
protein,  two  EcoRI  restriction  sites  of  pGEM-T  Easy®  were  used  with 
subsequent check for correct orientation in pEGFPC1 frame by restriction digest 
using HindIII and SalI.  
SK-N-SH human neuroblastoma cells were transfected as described in 2.3.2 
with the rod arrestin fragment expression plasmids. The cells were incubated for 
24  hours  and  fixed  using  different  protocols  (2.3.4).  The  expression  of 
pEGFPC1 clone 46 construct was not detectable with fluorescent microscopy of 
live  cells  or  of  either  paraformaldehyde  or  methanol  fixed  cells.  It  was  not 
detected in cell lysates by Western blotting with an anti GFP antibody (data not 
shown). Transfection of SK-N-SH cells with pCMV-Tag3b clone 46 followed by 
immunostaining  with  anti-myc  antibody  revealed  that  the  myc-tagged  protein 
formed intracellular inclusions (figure 3.12a). The inclusions varied in size and Chapter III 
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number per cell. The subcellular localisation of the myc-rod arrestin fragment 
did not change when it was co-transfected with human RP2-GFP (figure 3.12a, 
b). Also transfection with myc-rod arrestin fragment did not change RP2-GFP 
localisation compared to the previously reported subcellular localisation of RP2 
(described in 1.5.3) (figure 3.12c). Chapter III 
130 
   
 
 
 
Figure  3.12.  Subcellular  localisation  of  myc-rod  arrestin  fragment  and 
RP2-GFP 
Confocal  microscopy  images  of  SK-N-SH  cells  immunostained  with  anti-myc 
antibody (red). Nuclei were visualised with DAPI (blue). a. Cells transfected with 
myc-rod arrestin fragment (red) exhibit formation of large and small intracellular 
inclusions (indicated with arrows). b. Representative image of cells transfected 
with RP2-GFP exhibit the previously observed RP2 localisation predominantly 
on the plasma membrane. c. Cells expressing both myc-rod arrestin fragment 
and RP2-GFP proteins demonstrate no overlap of RP2-GFP localisation, with 
inclusions formed by myc-rod arrestin fragment (indicated by arrows). The scale 
bars are 10 µm. Chapter III 
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3.4.1.3. Specific binding of rod arrestin to RP2 
For further investigation of the RP2-rod arrestin interaction, a complementary 
immunoprecipitation (IP) method was applied. SK-N-SH human neuroblastoma 
cells were chosen for the IP experiment. These cells were considered to be 
most  suitable  for  transfection  with  RP2  constructs  since  they  had  been 
previously shown to have an undetectable level of endogenous RP2 (data not 
shown). Cells were treated and co-transfected as described in 2.3.2 with human 
RP2-GFP and full length both bovine rod arrestin-FLAG plasmid or β-arrestin-2-
FLAG constructs (Dr S. Gurevich, section 2.1.8, table 2.4).  
β-arrestin-2 was used to test whether RP2 was able to discriminate between rod 
arrestin and a ubiquitous arrestin. β-arrestin-2 is expressed ubiquitously with a 
higher  expression  level  in  the  central  nervous  system  and  is  involved  in 
quenching of β-adrenoreceptor-2 (Attramadal et al., 1992).  
An alignment of protein sequences that compares rod arrestin with β-arrestin-2 
is shown in figure 3.13. The proteins share 55 % identity in their amino acid 
sequences  and  have  similar  functions.  Therefore,  the  efficiency  of  co-IP 
between human RP2-GFP co-transfected with bovine rod arrestin and human 
RP2-GFP co-expressed with bovine β-arrestin-2 was tested. 
The transfected cells were lysed with RIPA buffer (table 2.8), incubated with 
anti-FLAG antibody (table 2.9) and all subsequent procedures were performed 
as  described in  2.4.11.  To  control  for  non-specific  binding,  the  lysates  were 
incubated with mouse IgG and treated the same way as the samples with anti-
FLAG antibody. The protein G sepharose eluates were resolved by SDS-PAGE 
and analysed by Western blotting (as in sections 2.4.2 and 2.4.5). The results 
are shown in figure 3.14. 
The  F4C1  anti  pan-arrestin  antibody  (table  2.9)  detected  bands  of 
approximately 45 kDa, corresponding to both FLAG tagged rod arrestin and β-
arrestin-2 in the input lanes. The β-arrestin-2 immunoreactive band appeared to 
be less intense (figure 3.14).  
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Figure 3.13. The alignment of bovine rod arrestin to bovine β-arrestin-2 
protein sequences 
The  protein  sequences  of  bovine  β-arrestin-2  and  bovine  rod  arrestin  are 
aligned using Clustal W. The red shaded residues indicate identities between 
rod arrestin and β-arrestin-2. 
   Chapter III 
133 
   
 
 
 
Figure 3.14. Co-immunoprecipitation of rod arrestin-FLAG with RP2-GFP 
Western  blots  of  the  immunoprecipitation  (IP)  of  rod  arrestin-FLAG  and  β-
arrestin-2-FLAG using anti-FLAG antibody are shown. The first panel shows the 
blot  immunostained  with  anti-pan  arrestin  antibody  detecting  bands  of 
approximately 45 kDa, the second blot is immunostained with anti-RP2 antibody 
and  shows  the  RP2-GFP  bands  at  the  predicted  molecular  weight  66  kDa. 
Western  blot  immunostained  with  anti-GAPDH  antibody  shows  endogenous 
GAPDH of approximately 36 kDa in the cell lysates and no detectable signal in 
the IP lanes. The bottom Western blot shows endogenous Arl3 of approximately 
20 kDa in the input lanes, but not in the lanes with IP. 
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The anti-FLAG antibody immunoprecipitated both FLAG conjugated arrestins, 
showing the bands of appropriate size (45kDa) on the Western blot. In samples 
where  the  lysates  were  incubated  with  mouse  IgG  no  arrestin  bands  were 
detected. Upon immunostaining with an anti-RP2 antibody (table 2.10) it was 
found that RP2-GFP was detected as a band of 66kDa in the input lanes of both 
types of lysates.  
Importantly, in the lanes from the FLAG immunoprecipitation samples, the RP2-
GFP band was detected only in the presence of rod arrestin-FLAG. There were 
no bands detected in IgG negative control samples for both types of lysates. 
This suggested that the binding of RP2-GFP to rod arrestin was specific.  
No  band  corresponding  to  RP2-GFP  was  detected  with  anti-FLAG  antibody 
incubated with the lysate in which cells co-expressed β-arrestin-2-FLAG with 
RP2-GFP, suggesting no interaction occurred. The RP2-GFP band in the lane 
with rod arrestin co-IP appeared to have a slightly slower mobility (about 68 
kDa) compared to the RP2-GFP band in the input lane, suggesting potential 
protein modifications.  
The Western blot was also probed with anti GAPDH antibody (table 2.10) to 
control equal loading of inputs, and the specificity of IP experiment. GAPDH 
analysis  showed  that  this  was  achieved.  Thus,  IP  demonstrated  that  RP2 
specifically bound to rod arrestin and not to β-arrestin-2. 
3.4.1.4. Arrestins and endogenous Arl3 
An anti Arl3 antibody (table 2.9) was used to test if endogenous Arl3 was co-
precipitated with arrestin proteins. Arl3 bands were detected only in the inputs 
but  not  in  any  of  the  IPs  suggesting  that  no  co-IP  occurred  (figure  3.14). 
However, the band in the lane of the input containing rod arrestin-FLAG was 
less  intense  compared  to  the  one  in  the  input  with  β-arrestin-2-FLAG.  The 
significance of difference in the Arl3 band intensity is not clear. 
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3.4.1.5. Co-Immunoprecipitation of rod arrestin with RP2 mutants 
Co-IP  it  was  then  used  to  confirm  the  previous  yeast  two-hybrid  results  of 
disruption of the interaction by RP2 mutations. For this purpose SK-N-SH cells 
were transfected (described in 2.3.2) with bovine rod arrestin-FLAG and RP2-
GFP mutants: C67T, C86T, R118H and L253R (section 2.1.8, table 2.4). The 
experiment was performed as described before, but in this case only bovine rod 
arrestin-FLAG was used for IP for all lysates and RP2-GFP constructs were 
varied as described above.  
Western blotting confirmed that the anti-FLAG antibody immunoprecipitated rod 
arrestin-FLAG from the lysates (figure 3.15). The expression level in the inputs 
of cell lysates was inconsistent. However, the bands of precipitated rod arrestin-
FLAG demonstrated a similar intensity in all the IPs (figure 3.15).  
Western blotting with anti-RP2 antibody demonstrated that the expression level 
of the RP2 constructs differed. The lowest expression level was observed for 
C67Y and L253R mutants. The highest expression level was exhibited with wild 
type  RP2,  with  moderate  expression  level  for  the  R118H  mutant.  Co-
immunoprecipitated  RP2-GFP  variants  were  detected  at  a  similar level in  all 
lanes (figure 3.15). Importantly, the bands of co-precipitated RP2-GFP and the 
mutants appeared to run slower on SDS-PAGE compared to RP2-GFP in the 
input lanes.  
Thus,  the  co-IP  experiment  did  not  show  any  disruption  of  rod  arrestin 
interaction with tested RP2 mutants. However, an SDS-PAGE mobility shift of 
RP2-GFP precipitated by rod arrestin was observed once more, suggesting that 
RP2 undergoes changes upon binding to rod arrestin. 
3.4.1.6. RP2 is a putative calcium binding protein 
To test whether the shift in RP2-GFP SDS-PAGE mobility was caused by its 
binding to calcium, a calcium  mobility shift assay was performed (Maruyama 
and Nonamura, 1984). This method is based on the ability of proteins bound to 
calcium  to  resolve  faster  on  SDS-PAGE  due  to  becoming  more  positively 
charged.  
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Figure 3.15. Co-IP of rod arrestin-FLAG with wild type RP2-GFP and RP2 
mutants 
Westen blot showing IP of rod arrestin-FLAG with different RP2-GFP mutants 
as indicated. The first panel shows bands of 45 kDa size which correspond to 
rod  arrestin-FLAG  protein  in  the  inputs  and  IP  lanes.  The  bands  of  co-
precipitated  RP2-GFP  are  shown  on  IP  lanes.  Their  mobility  was  slower 
compared to expected and corresponded to approximately 68 kDa. The bands 
in  inputs  of  different  RP2-GFP  demonstrated  the  expected  mobility  for  this 
protein of approximately 66 kDa. The expression level of RP2-GFP constructs 
was reflected by their band intensity in input lanes in comparison to GAPDH 
control for a house keeping protein (bottom panel).  
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Figure 3.16. RP2 is a putative calcium binding protein 
Coomassie stained SDS-PAGE of 6xHis-RP2 in the presence of 2mM CaCl2 or 
2mM EGTA as indicated. Arrow shows the mobility of 6xHis-RP2 and arrow with 
asterisk indicates a band with a lower mobility which corresponds to potential 
calcium free 6xHis-RP2.  Chapter III 
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Purified 6xHis-RP2 protein (provided by Dr N. Schwarz) was resolved by SDS-
PAGE (as described in 2.4.2) under two conditions: 2 mM CaCl2 or 2 mM EGTA 
was added to Laemmli sample buffer and SDS-PAGE running buffer. 500 ng of 
6xHis-RP2 for each SDS-PAGE condition was resolved and the protein was 
visualised with Coomassie blue stain. 
It was observed that in the presence of 2 mM EGTA 6xHis-RP2 appeared to 
separate into two bands, whereas in the presence of 2 mM CaCl2 only one band 
was observed (figure 3.16). The size of the single band on the gel resolved in 
the presence of 2 mM CaCl2 corresponded to the lower band of 6xHis-RP2 in 
the presence of 2 mM EGTA, suggesting enhanced mobility of calcium bound 
6xHis-RP2. The upper band on the gel resolved in the presence of 2 mM EGTA 
exhibited  slower  electrophoretic  mobility  compared  to  the  lower  band, 
suggesting the presence of calcium free protein. As a slower mobility 6xHis-
RP2  band  was  observed  in  the  previous  immunoprecipitation  experiments, 
these data suggest that RP2 might release calcium upon binding to rod arrestin.  
3.4.1.7. Subcellular localisation of rod arrestin and RP2 
To investigate the nature of the putative interaction of RP2 with rod arrestin 
further, immunocytochemistry was employed. SK-N-SH cells were transfected 
with full length rod arrestin alone or co-transfected with rod arrestin and RP2 
constructs.  Rod  arrestin  constructs  were  designed  to  express  this  protein 
without a tag, with FLAG tag and GFP fused (Dr S. Gurevich, section 2.1.8 and 
table 2.4). 
After  24  hours  the  cells  were  methanol  fixed  and  immunostained  using  anti 
RP2, anti pan-arrestin and anti FLAG antibody as in table 2.7 (as described in 
2.3.4). Rod arrestin exhibited predominantly cytoplasmic localisation with a less 
intense staining in the nucleus. In most of the cells, rod arrestin did not decorate 
any particular cellular structures (figure 3.17). Upon co-transfection with RP2-
GFP  it  was  observed  that  the  rod  arrestin  staining  pattern  did  not  change 
compared with rod arrestin alone and did not overlap with RP2 localisation. RP2 
localisation did not show any changes from previously reported (figure 3.18).  Chapter III 
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Figure  3.17.  Subcellular  localisation  of  bovine  rod  arrestin  in  SK-N-SH 
cells 
Immunofluorescence of cells transfected with different constructs of bovine rod 
arrestin  expression.  C-terminal  GFP  tagged  rod  arrestin  demonstrated  some 
nuclear staining and diffuse cytoplasmic, as did the untagged construct when 
visualised  with  anti  pan-arrestin  (F4C1)  antibody.  The  cell  nuclei  were 
visualised  with  DAPI  staining  on  the right  panels (blue).  The  scale  bars  are 
10µm. Chapter III 
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Figure 3.18. Subcellular localisation of bovine rod arrestin and human RP2 
in SK-N-SH cells 
Immunofluorescence of cells co-transfected with various constructs as follows:  
a.  Cells  co-transfected  with  arrestin-FLAG  (A1-FLAG,  red)  and  RP2-GFP 
(green). b. untagged rod arrestin (A1) visualised with anti pan-arrestin antibody 
(F4C1) (red) and RP2-GFP (green). The scale bars are 10µm. 
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3.4.2. Other novel interacting partners identified in CytoTrap® 
screening of the N-terminal fragment of RP2 
Several  other  potential  interacting  partners  for  the  N-terminus  of  RP2  were 
found  during  the  screening  (section  3.4).  Isolated  pMyr  clones  from  yeast 
colonies number 43, 44, 48, 55 were verified by re-transformation with the N-
terminal  fragment  of  RP2.  All  four  clones  grew  at  the  37ºC  restrictive 
temperature. The clones were also checked for growth when co-transformed 
with an empty pSos vector to test for false positives binding to hSos without 
RP2 “bait”. These interactors corresponded to chaperones and components of 
the ubiquitin – proteasome system (UPS).  
3.4.2.1. Chaperones as putative interacting partners of RP2 
3.4.2.1.1. Hsc70 
pMyr clone 44 exhibited growth after 96 hours of incubation at 37ºC with pSos 
1-200  RP2,  and  no growth  upon  co-transfection  with  the  empty  pSos  vector 
negative control (figure 3.19e). The plasmid was sequenced (as in 2.5.2) and 
analysed using bioinformatic tools (2.6). The DNA sequence had identity with 
three exons of a gene at position chr15:32,343,661-32,354,150, which was a 
part of the bovine HSPA8 gene (figure 3.19a). 
The in frame translation of pMyr clone 44 insert sequence to a predicted amino 
acid sequence and BLAST analysis revealed that it was 100 % identical to the 
bovine Hsc70 protein (AAI54390) spanning the region from amino acid 463 to 
the  C-terminal  amino  acid  650  (figure  3.19d).  The  predicted  protein  was 
calculated to have a molecular weight of 20.4kDa and a pI 4.85.  
To confirm Hsc70 protein expression the yeast cells of clone 44 were grown 
(section 2.2.5) and the total protein from the culture was extracted (2.2.7). The 
protein  was  analysed  by Western  blotting  using  an  anti-Hsp/Hsc70  antibody 
(table 2.10). The yeast culture expressing Arl3 in pMyr vector was used as a 
control for non-specific antibody reactivity.  Chapter III 
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Figure 3.19. Characterisation of clone 44 
a. Schematic of bovine HSPA8 gene. Exons are indicated with green boxes. 
Exon 1 is a non-coding exon and is in light green. Clone 44 DNA is grey with 
lines showing corresponding regions of HSPA8. b. Domain structure of bovine 
Hsc70 protein and predicted domains of protein translated from clone 44 open 
reading  frame.  ATPase  domain  of  Hsc70  is  shown  by  a  black  box  and  the 
substrate binding domain by a white box. c. Western blot of yeast cell lysates, 
expressing pMyr plasmids as indicated, immunostained with anti Hsp70/Hsc70 
antibody  shows  the  presence  of  bands  corresponding  to  the  endogenous 
Hsp70/Hsc70 (70 kDa) in both lanes and a 20 kDa protein expressed by pMyr 
clone 44. d. Alignment of protein sequence of the open reading frame of clone 
44 (Query) to bovine Hsc70 (Sbjct) (section 2.6). e. Yeast growth of cells co-
transformed with pMyr clone 44 and pSos RP2 constructs as indicated. Three 
different colonies for each transformation were incubated at 24ºC for 96 hours 
and 37ºC for 144 hours on the selective media. Chapter III 
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It  was  found  that  clone  44  expressed  a  protein  of  the  expected  size 
(approximately 20 kDa) corresponding to a part of the substrate binding domain 
at the C-terminus of Hsc70 (figures 3.19b, c). Weak cross-reactive bands of 
endogenous yeast Hsc70 exhibited gel mobility of approximately 70 kDa (figure 
3.19c).  
Clone 44 was tested for interaction with full-length RP2, 41-200 and 190-350 
RP2 fragments and the N-terminal mutants (figure 3.2). It was found that co-
transformation  of  clone  44  with  the  full  length  RP2  resulted  in  much  slower 
growth  of  the  cdc25-H  strain  at  37ºC  compared  to  the  1-200  RP2  fragment 
(figure 3.19e).  
When  the  cells  were  co-transformed  with  the  41-200  fragment,  almost  no 
growth was observed. The missense mutations in the N-terminus of RP2 were 
tested  for  interaction  with  pMyr  clone  44.  No  growth  was  observed  in  this 
experiment with any of the mutants tested, suggesting that they might weaken 
or disrupt the interaction (figure 3.19e). 
3.4.2.1.2. Cytosolic chaperonin subunit 6A (CCT6A) 
pMyr  clone  55  resulted  in  yeast  growth  upon  co-transformation  of  cdc25-H 
strain with the RP2 “bait” (as in 2.4.6) after 120 hours of incubation at 37ºC and 
no growth upon co-transfection with the empty pSos vector (figure 3.20). The 
insert was sequenced as in 2.5.2 and analysed using bioinformatic tools (2.6). 
The insert DNA sequence aligned to a position on chr25:29,531,890-29,577,699 
of the bovine genome where the CCT6A gene mapped (figure 3.20a).   
Analysis of the translated protein sequence of pMyr clone 55 revealed that the 
first  methionine  in  clone  55  protein  was  at  amino  acid  position  33,  which 
corresponds to the methionine start codon of CCT6A (NP 001029714) (figure 
3.20b). The insert DNA encoding the first 32 amino acids showed 100 % to the 
DNA  sequence  of  5’UTR  of  bovine  CCT6A  gene,  and  allowed  in  frame 
translation of CCT6A with the pMyr tag. Chapter III 
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Figure 3.20. Characterisation of clone 55 
a. Schematic of the bovine CCT6A gene. Exons are indicated with green boxes. 
The  DNA  sequence  of  clone  55  is  grey  with  lines  indicating  corresponding 
regions of CCT6A. b. Alignment of protein sequence of the open reading frame 
of clone 55 (Query) to bovine CCT6A (Sbjct) using BLAST at NCBI (section 
2.6). c. Yeast growth of cells co-transformed with pMyr clone 55 and pSos RP2 
constructs  as  indicated.  Three  different  colonies  are  shown  for  each 
transformation incubated at 24ºC for 96 hours and 37ºC for 156 hours on the 
selective media. Chapter III 
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The clone containing bovine CCT6A subunit was tested for its ability to interact 
with  the  full-length  RP2  by  yeast  two-hybrid.  Surprisingly,  no  growth  was 
observed  when  this  clone  was  tested  with  the  full-length  pSos  RP2  (figure 
3.20c). However, the yeast co-transformed with a 1-200 RP2 fragment as “bait” 
exhibited  growth  after  144  hours  of  incubation.  None  of  the  other  RP2 
fragments demonstrated growth (figure 3.20c). The missense mutations in the 
N-terminus  of  RP2  were  also  tested  for  the  interaction  with  CCT6A.  Similar 
growth was observed with all of the RP2 mutants with the highest intensity of 
growth for the C86Y mutant which is predicted to be misfolded (figure 3.20c).  
3.4.2.2. 26S proteasome non-ATPase subunit 4 (PSMD4) 
Co-transformation of “bait” (pSos 1-200 RP2) with the isolated pMyr clone 43 
resulted in yeast growth after 48 hours of incubation at 37ºC (figure 3.21). No 
growth was observed when clone 43 was co-transfected with the empty pSos 
vector. The insert was sequenced (as in 2.5.2) and analysed using bioinformatic 
tools (2.6). The insert DNA sequence had 98 % identity to 8 exons of the 26S 
proteasome non-ATPase subunit 4 PSMD4 gene at position chr3:21,068,954-
21,072,236 (figure 3.21a) of the bovine genome.  
The open reading frame of pMyr clone 43 was translated into a protein (2.6) and 
BLAST  analysis  revealed  98  %  identity  to  the  bovine  PSMD4  isoform  1 
(AAI19965) from amino acid 57 to the C-terminus (figure 3.21b, c). Clone 43 
protein compared to PSMD4 had an amino acid substitution (L61P) and three 
extra amino acids insertied at residue 252 of PSMD4 (figure 3.21c). The protein 
expressed  in  the  open  reading  frame  of  clone  43  was  predicted  to  have 
molecular weight 35.1 kDa with pI 4.72 and to contain a partial von Willebrand A 
(VWA) 26S proteasome conserved domain (figure 3.21b).  
Clone 43 was tested for interaction with the full-length RP2, RP2 fragments and 
RP2 mutants. Yeast co-transformed with full-length RP2 exhibited growth after 
36 hours of incubation at 37ºC. Growth was observed with fragment 1-200 RP2 
after  48  hours.  Much  slower  growth  was  demonstrated  with  the  other  RP2 
fragments after 120 hours of incubation at 37ºC (figure 3.21d).  Chapter III 
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Figure 3.21. Characterisation of clone 43 and its interaction with RP2  
a. Schematic of the bovine PSMD4 gene. Exons are indicated with green boxes 
with a non-coding exon 10 in light green. Clone 43 is shown in grey boxes with 
lines indicating corresponding regions of PSMD4. b. Domain structure of bovine 
PSMD4 protein (green) and the predicted domains of the protein translated from 
clone 43 open reading frame. VWA 26S proteasome subunit domain is shown 
by a black box. c. Alignment the predicted protein sequence of clone 43 (Query) 
to  bovine  PSMD4  (Sbjct)  using  BLAST  at  NCBI  (section  2.6).  Regions  of 
mismatch are boxed. d. Yeast growth of cells co-transformed with pMyr clone 
43 and pSos RP2 constructs as indicated. Three different colonies shown for 
each  transformation  were  incubated  at  24ºC  for  96  hours  and  37ºC  for  144 
hours on the selective media. Chapter III 
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Missense mutations in the N-terminus of RP2 were tested for interaction with 
pMyr clone 43. Slower growth was observed with all of the mutants tested after 
144 hours of incubation at 37ºC on the selective media (figure 3.21d) compared 
to the wild type, suggesting a weaker interaction. 
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3.5. Discussion 
3.5.1. Screening a retinal cDNA library with RP2 
Despite  the  large  number  of  false  positive  putative  interactors  (~91  %), 
CytoTrap
®  yeast  two-hybrid  technique  has  proven  to  be  a  relatively  efficient 
method  for  detecting  potential  novel  interactions  of  RP2.  As  a  result  one 
previously  reported  interacting  partner,  Arl3,  and  one  as  yet  unpublished 
interactor,  TNPO3,  were  confirmed.  Seven  novel  potential  interactors  were 
identified. However, when comparing the two strategies of screening with the 
full length RP2 or the 1-200 RP2 fragment it was found that screening with the 
fragment was more efficient for finding novel interactors. This higher efficiency 
could  be  due  to  the  1-200  RP2  fragment  not  transactivating  the  CytoTrap
® 
system after incubation for longer than 144 hours at the restrictive temperature. 
Incubation  of  yeast  with  “bait”  and  “prey”  for  long  time  periods  provided  the 
opportunity to detect comparably low affinity interactions such as binding of RP2 
to rod arrestin. 
On  the  other  hand,  using  full-length  RP2  to  screen  a  retinal  cDNA  library 
allowed  identification  of  two  novel  interacting  partners  that  bind  to  the  C-
terminus of RP2. One of them, nucleolin, exhibited a high affinity interaction in 
CytoTrap
®. 
3.5.2. Nucleolin 
Clone 30 contained nearly full length nucleolin (NCL) which is one of the major 
and most extensively studied nucleolar proteins. NCL is highly conserved. The 
N-terminus is composed of highly acidic regions, the central region has multiple 
phosphorylation  sites  and  the  C-terminus  is  known  to  have  four  RNA 
recognition motif (RRM) domains. The NCL protein fragment identified in this 
study  represents  part  of  the  acidic  region in  the  N  terminus,  with  all  the  C-
terminal  containing  RRM  domains.  A  bioinformatic  search  for  NCL  isoforms 
similar to the fragment did not result in any  matches, suggesting it is partial 
clone and not a result of alternative splicing. Chapter III 
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NCL is a multifunctional protein that is highly phosphorylated (Lapeyre et al., 
1986),  and  this  modification  varies  during  the  cell  cycle  and  regulates 
kinetochore formation (Morimoto et al., 2007; Ma et al., 2007). Thus, there is a 
functional overlap between NCL and other newly identified interactors of RP2 
such as RAN and p27 (Evans, 2007) which have a role in cell cycle regulation 
and spindle formation (Kalab et al, 2006).  
Interestingly, NCL was recently shown to interact with lebercilin (LCA5) protein. 
Mutations  in  LCA5  gene  encoding  this  protein  lead  to  Leber  congenital 
amaurosis  (LCA)  (described  in  section  1.3.6),  which  is  a  severe  form  of 
congenital  blindness.  Lebercilin  is  widely  expressed  throughout  development 
and  is  localised  to  the  connecting  cilia  of  photoreceptors,  microtubules  and 
primary cilia (den Hollander et al., 2007, Gerber et al., 2007).  
Another protein which causes X-linked retinitis pigmentosa, RPGR, (described 
in 1.3.2.1.1) is tethered to the cilia via its interacting partner RPGRIP (Hong et 
al., 2000, Shu et al., 2005) and they interact with  nucleophosmin, which is a 
nucleolar protein similar to NCL (Shu et al., 2005). NCL and nucleophosmin 
were also shown to interact by yeast two-hybrid (Li et al., 1996).  
Thus,  the  interaction  of  RP2  with  NCL  places  RP2  in  a  pathway  with  other 
retinal  degeneration  related  proteins,  such  as  RPGR  and  lebercilin  not  only 
because of cilia localisation, but also by the protein interaction network.   
Thus, the putative interaction of NCL with RP2 could potentially be significant 
for its retinal function. The pathogenic misfolding mutants of RP2 and the C-
terminal L253R mutation decreased the interaction affinity which highlights its 
importance.  However,  attempts  to  confirm  this  interaction  by  methods  other 
than  CytoTrap
®,
  such  as  GST  pull-down  with  the  retinal  lysate  and 
immunoprecipitation,  which  involved  mammalian  endogenous  NCL  were  not 
successful (data not shown). This could be due to RP2 binding shorter isoforms 
of NCL rather than full length NCL since the clone identified in this study is only 
partial NCL.  Chapter III 
150 
   
Therefore, subcloning NCL fragments and of the full length NCL in mammalian 
expression  vectors  with  subsequent  biochemical  experiments,  such  as  IP  is 
essential to confirm the interaction. 
3.5.3. Drebrin-like protein  
Clone 20 exhibited a low affinity interaction with RP2 in CytoTrap® specifically 
binding to the C-terminus of RP2. Clone 20 represents part of bovine drebrin-
like gene (DBNL) but with exon 8 spliced out. This exon is present in all bovine 
DBNL  sequences  on  the  UCSC  database.  Analysis  of  the  predicted  protein 
sequence encoded by clone 20 showed that the protein contained the central 
region  of  DBNL and  the  C-terminus  with  a SH3-domain  but lacked  the  ADF 
domain,  which  is  responsible  for  binding  to  F-actin  (Larbolette  et  al.,  1999). 
Thus, the protein expressed in clone 20 is unlikely to have the actin-binding 
function of DBNL. 
DBNL  was  demonstrated  to  bind  dynamin,  a  GTPase  responsible  for 
endocytosis regulation via its SH3 domain (Kessels et al., 2001). The deficiency 
of DBNL in mice leads to impaired synaptic endocytosis and failure of recycling 
of the synaptic vesicles (Connert 2006). DBNL was identified in the mouse cilia 
proteome  (Liu  et  al,  2007a),  suggesting a  potential  overlap in localisation  of 
DBNL and RP2. The role of the potential interaction of DBNL and RP2 has yet 
to be elucidated. The region where DBNL binds to RP2 lies within the RP2 C-
terminus. However, whether the mutations of RP2 could affect this interaction 
needs to be investigated further using CytoTrap®
 and biochemical methods.  
Thus, two novel putative interacting partners identified by screening a retinal 
library  with  the  full  length  RP2  were  not  retina  specific.  However,  their 
ubiquitous expression pattern does not indicate that they are not important for 
retinal  function.  Further  investigation  into  whether  these  interactions  are 
biologically significant in vivo would be important to reveal the pathways RP2 
could be implicated in.  
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3.5.4. Unc119 
Clone 58 encoded Unc119, missing the first 19 amino acids. Unfortunately, this 
interaction  required  longer  than  144  hours  incubation  time  at  the  restrictive 
temperature and therefore was difficult to verify using CytoTrap
®. However, this 
potential interaction is worth further investigation because Unc119 is a retina 
specific protein associated with cone-rod dystrophy (described in 1.3.5.1). 
Despite  CytoTrap®
  being  designed  as  a  system  for  binary  complex 
identification, there is the possibility that a ternary complex formation between 
“bait”,  “prey”  and  a  yeast  endogenous  protein  could  result  in  growth  at  the 
restrictive temperature. It has been reported that Arl3 can bind Unc119 (Van 
Valkenburgh et al., 2001). Recently a crystal structure of the ternary complex 
formed by Arl3, RP2 and Unc119 was described. However, RP2 and Unc119 
were not found to have residues that interacted directly, as they were brought 
together by Arl3 (Veltel et al., 2008b).  
Yeast homologue of Arl3, Cin4 (YMR138W), has 42.5 % identity with human 
Arl3  and  6 residues  are  conserved  between  yeast  and  human  Arl3  that  are 
responsible  for  binding  to  RP2  (figure  3.22).  Thus,  it  is  possible  that 
endogenous  yeast  Arl3  homologue  could  mediate  interaction  of  RP2  with 
Unc119 in yeast cells during CytoTrap
® screening. This mediation by Cin4 could 
result in low level yeast growth observed upon co-transformation of clone 58 
with  RP2,  indicating  the  high  sensitivity  of  the  CytoTrap
®  system.  This 
hypothesis  could be  tested  further  by  CytoTrap
®  using  Cin4  knock-out  yeast 
strain. The growth of Cin4 knock out temperature sensitive cdc25-H strain co-
transformed  with  pMyr  Unc119  and  pSos  RP2  would  indicate  that  the 
interaction is direct and not mediated by Cin4. 
3.5.5. Rod arrestin 
It was shown in this study that RP2 binds rod arrestin in CytoTrap
® with low 
affinity. The interaction was then confirmed by IP, where it was demonstrated 
that  RP2  specifically  bound  rod  arrestin  and  not  β-arrestin-2.  Thus,  the 
interaction  detected  in  this  study  potentially  provides  a  link  between  the 
phototransduction cascade and RP2 function.  Chapter III 
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Figure 3.22. Alignment of yeast Cin4 protein sequence to human Arl3 
Comparison  was  performed  using  Clustal  W  alignment.  Residues  conserved 
between human Arl3 and Cin4 are highlighted by red shadow. The residues 
responsible for the interaction with RP2, conserved between these two proteins 
are highlighted with green lines.  Chapter III 
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Mutations in rod arrestin have been shown to cause retinitis pigmentosa (see 
section 1.3.2) and therefore, the interaction identified in this study places RP2 in 
a pathway with other retinal disease causing proteins. 
The  importance  of  the  rod  arrestin  interaction  with  RP2  in  the  retina  is 
supported by the finding that RP2 does not bind β-arrestin-2. Rod arrestin and 
β-arrestin-2 proteins have 55 % identity and are considered to be highly similar 
(figure 3.12). As seen from the alignment the proteins have regions of high and 
low similarity in both N-terminal and C-terminal regions.  
The protein expressed in clone 46 is not the full length rod arrestin as it lacks a 
part of the N-terminal Arrestin_N domain. The region of significant dissimilarity 
between proteins of clone 46 and β-arrestin-2 spans amino acids 244-282. This 
is a potential binding site of rod arrestin for binding to RP2. Construction of rod 
arrestin fragments and testing the fragments for their ability to bind RP2 in IP 
and  CytoTrap®  would  identify  the  region  of  rod  arrestin  responsible  for  the 
interaction.  
The retinal cDNA library screening was performed using the N-terminus (AA 1-
200) of RP2 as “bait”, delineating this conserved RP2 domain as mediating rod 
arrestin  binding.  This  region  of  RP2 has  been  described  to  contain  the  vast 
majority of pathogenic RP2 mutations (see section 1.5.1). It was shown in this 
study  that  misfolding  mutants,  C67Y  and  C86Y,  did  not  interact  with  rod 
arrestin. These two mutants have been shown to abolish most interactions in 
CytoTrap®, even those mediated by the C-terminus of RP2 (Evans, 2007).  
The  pathogenic  R118H  RP2  mutation  did  not  disrupt  any  of  interactions  in 
CytoTrap® apart from rod arrestin. These data indicate the potential importance 
of this interaction for the pathogenesis of XLRP. Nevertheless, this disruption of 
interaction was not confirmed in biochemical experiments and therefore, needs 
further  investigation  by  other  methods  testing  protein-protein  affinity  such  as 
GST  pull-down  assays  and  other  techniques,  such  as  surface  plasmon 
resonance (Biacore). 
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Experiments involving mammalian expression of clone 46 protein were not very 
successful due to the myc tagged protein forming intracellular inclusions and 
such inclusions did not recruit co-expressed RP2 and vice versa. This could be 
due to the rod arrestin fragment being misfolded, which would affect binding site 
presentation to RP2. Sub-cloning in other mammalian expression vectors such 
as GFP did not result in detectable protein expression.  
Full length rod arrestin appeared to be soluble but when co-expressed with RP2 
it was found that they did not co-localise. A possible clue to this phenomenon is 
in  the  rod  arrestin  structure  and  its  ability  to  self-associate  into  a  stable 
tetramer.  The  Kd  for  the  dimer/tetramer  equilibrium  is  lower  than  for 
monomer/dimer  (Hanson  et  al.,  2008).  Therefore,  in  the  retina  or  when 
expressed in yeast or mammalian cell lines rod arrestin predominantly exists as 
a tetramer. The self-association described by Waker and colleagues (1987) is 
by N-N and C-C terminus interaction and the function of the tetramer is yet to be 
identified but is suggested to be a storage form of arrestin (described in section 
1.2.3.5) (Hanson et al., 2008).  
Clone  46  found  in  this  study  is  perhaps  more  likely  to  remain  as  a 
monomer/dimer due to its predicted inability to form a N-N connection since it 
lacks a significant part of rod arrestin N-terminus. Therefore clone 46 protein 
with an attached myristoylation tag from the pMyr expression vector is expected 
to remain in a monomeric state when it binds to RP2 in CytoTrap®.  
In immunoprecipitation experiments, rod arrestin could be monomerised by the 
RIPA  buffer,  which  contains  SDS  (Appendix)  disrupting  non-covalent  bonds. 
Thus, it is feasible to hypothesise that in the two methods, where RP2 and rod 
arrestin  demonstrated  binding,  rod  arrestin  was  presented  for  binding  as  a 
monomer.  
In immunofluorescence expreriments, arrestin would be expected to exist as a 
tetramer, therefore no co-localisation would be observed with RP2, suggesting 
that the rod arrestin tetramer does not bind RP2. This hypothesis would need to 
be investigated further. It could be explored by IP using non-denaturing, SDS 
free  buffers  to  find  whether  RP2  still  binds  to  rod  arrestin.  Under  SDS-free 
conditions, rod arrestin would be expected to stay as a tetramer due to the high Chapter III 
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concentrations when overexpressed in mammalian cells, and would show no 
interaction with RP2. Creation of soluble rod arrestin oligomerisation mutants 
and testing for co-localisation with RP2 in cells and by IP would shed light on 
such a hypothesis.  
Thus, the data obtained in this study suggest that RP2 preferentially binds to 
rod arrestin monomer rather than a tetramer. It has been demonstrated that 
only monomeric arrestin is able to quench phosphorylated rhodopsin, but not 
the tetramer (Hanson et al., 2007), highlighting the potential importance of the 
RP2 and rod arrestin interaction for retina function. 
However,  both  RP2  and  rod  arrestin  have  high  affinity  interacting  partners, 
creating competition for binding. RP2 interacts with Arl3 whereas rod arrestin 
binds  activated  phosphorylated  rhodopsin  (PhRho*)  (sections  1.2.3.3). 
Nonetheless, such high affinity interaction as arrestin - (PhRho*) occurs only 
when  light  strikes  the  retina  suggesting  that  other  interactions  with  arrestin 
could occur in the dark adapted state. 
RP2 binding to Arl3 is mediated via the N-terminus of RP2, which was also 
shown to bind rod arrestin in this study. However, GDP bound Arl3 has been 
shown to have a very low affinity for RP2 and they do not co-localise when co-
expressed in mammalian cells (Bartolini et al., 2002; Evans, 2007). Additionally, 
Arl3  is  thought  to  exist  predominantly  in  a  GDP  bound  state  in  the  retina, 
allowing  other interactions  mediated  by  the  N-terminus  of  RP2  to  potentially 
occur (Prof Mike Cheetham, personal communication). Importantly, it has been 
demonstrated in biochemical assays that Arl3 preferably binds RP2 when RP2 
is  not  myristoylated  (Bartolini  et  al.,  2002).  Therefore  the  interaction  of  rod 
arrestin and RP2 is more likely to happen when RP2 is myristoylated.  
An interesting finding of this study was a change in the mobility of the wild type 
RP2 and its mutants in the rod arrestin IP lanes when compared to input lanes 
on  the  Western  blot.  Proteins  are  known  to  change  SDS-PAGE  mobility 
depending on post-translational modifications, such as myristoylation, or binding 
to ions, such as calcium. Therefore, the observed mobility shift in RP2 bands 
could be due to RP2 being myristoylated or bound to calcium.  Chapter III 
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It is proposed in this study that RP2 could change its mobililty due to a potential 
calcium binding ability since the gel mobility shift was observed in the presence 
of  a  calcium  chelator,  EGTA.  Usually  calcium  binding  proteins  have  one  or 
several so-called EF hands, which are composed of a region of about 12 or 
more  amino  acids  with  structural  composition  helix-loop-helix  (Swan  et  al., 
1987;  Reddy  et  al., 2004).  An  EF  hand is also  known  to  have  a  conserved 
X*Y*Z-Y*X**Z motif with Glu as an essential component at position Z.  
Although  RP2  lacks  the  typical  structure  of  calcium  binding  proteins,  it  has 
similarity to an EF hand at the C-terminus, which is composed of two helixes 
roughly perpendicular to each other (figure 3.23a). They are connected by a 
loop-strand region rich in Glu, which would be able to provide oxygen ions for 
calcium binding (figure 3.23a).  
On the other hand, rod arrestin demonstrated change in RP2 bands mobility 
upon binding in IP experiments and showed binding to the N-terminus of RP2 in 
CytoTrap®.  Thus,  it  is  possible  to  suggest  that  potential  calcium  binding 
residues are located within the N-terminal region. The acidic region in the N-
terminus of RP2 is located at amino acids position 14-34 (figure 3.23b). The 
structure of this region is not solved by X-ray diffraction due to the fact that the 
first 34 amino acids including the dual acylation signal are hidden inside the 
cavity formed by β-sheets (Kuhnel et al., 2006).  
It  is  feasible  to  suggest  that  an  unknown  stimulus  changes  RP2  protein 
conformation  so  the  myristoylation  motif  becomes  exposed,  leading  to  RP2 
membrane localisation. Therefore, structural studies are needed to test whether 
calcium binding changes RP2 conformation by the suggested way, similar to a 
calcim-myristoyl  switch  mechanism  (described  in  section  1.2.3.6.3).  Site 
directed  mutagenesis  can  also  be  used  to  identify  residues  responsible  for 
potential calcium binding. 
The calcium binding ability of RP2 and its consequences for the protein remain 
to be elucidated. Therefore, the role of calcium in the interaction of RP2 with rod 
arrestin is unclear. A potential role of the RP2 interaction with rod arrestin is in 
the phenomenon of light dependent translocation (described in 1.5.3) and this  Chapter III 
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Figure 3.23. Potential calcium biding sites in the RP2 protein 
a. Top view of the crystal structure of RP2 (PDB 2bx6). Helix regions are shown 
in pink and extended strands are yellow. Arrows indicate the two helixes nearly 
perpendicular to each other. Below the secondary structure a putative calcium 
binding Glu rich region is highlighted by the red box. b. Side view of the crystal 
structure of RP2 (PDB 2bx6). Helix regions are shown in pink and extended 
strands  are  yellow.  Arrow  indicates  the  N-terminal  fragment  where  another 
putative  calcium  biding  region  starts.  The  N-terminal  RP2  sequence  below 
contains  the  suggested  calcium  biding  region  with  multiple  Glu  and  is 
highlighted with a red box. The double acylation motif of RP2 is underlined with 
a black line. 
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could  be  tested  as  this  process is important  for  the  retina  and  could  be  the 
pathway disrupted in XLRP.  
RP2 has been suggested to be a cilia-related protein and as suggested in this 
study  its  intracellular  localisation  could  be  regulated  by  a  calcium-myristoyl 
switch.  Other  cilia-localised  calcium  binding  proteins,  centrins,  have  been 
demonstrated  to  contribute  to  the  translocation  of  another  phototransduction 
cascade  component,  transducin  βγ  (Giessl  et  al.,  2006).  Another  pathway, 
where RP2 and rod arrestin could act together is nuclear transport. As shown in 
this study, a small amount of rod arrestin was detected in the nucleus. It has 
been shown that different arrestins, including rod arrestin, can bind JNK3 and 
MDM2 and relocalise these proteins from the nucleus to the cytoplasm (Song et 
al., 2006).  
RP2 is potentially involved in the nuclear transport pathway via interaction with 
TNPO3 and RAN (Evans et al., 2007). However, nuclear transport mediated by 
arrestin is directed to the cytoplasm, whereas the suggested nuclear transport 
involving  RP2  proceeds  in  the  opposite  direction.  Thus,  the  involvement  of 
nuclear transport in the pathogenesis of XLRP from the standpoint of the RP2 
interaction with rod arrestin is unclear. 
 
   Chapter III 
159 
   
3.5.6.  Other  potential  interacting  partners  identified  by  yeast 
two hybrid 
Several other interacting partners with a ubiquitous expression were identified 
by CytoTrap® screening with the N terminus of RP2. One of them was the C-
terminus of Hsc70.  
As described in this study, a fragment of Hsc70 can bind to the N-terminus of 
RP2. Since the cDNA encodes part of the substrate binding domain of Hsc70 it 
seems  possible  that  the  binding  occurred  due  to  Hsc70  chaperone  activity, 
representing  binding  to  partially  misfolded  RP2  or  its  fragment.  This  is 
supported by data showing more yeast growth  with the 1-200 RP2 fragment 
compared to the full length RP2. Binding to the RP2 mutants, especially the 
misfolded mutants, such as C67Y and C86Y, was expected to be stronger if this 
interaction was due to Hsc70 chaperone function. However, the interaction was 
disrupted by RP2 mutations suggesting that the interaction of RP2 with Hsc70 
could  be  functional.  Moreover,  the  clone  expressing  the  Hsc70  fragment 
contains an important co-chaperone binding EEVD motif (Freeman et al., 1995). 
It is possible that RP2, being a putative chaperone, is involved in one of the 
Hsc70 pathways. 
One of these pathways could be the proteasomal degradation pathway. It has 
been  shown  that  Hsc70,  together  with  co-chaperones  such  as  BAG1,  could 
promote proteasomal degradation of misfolded proteins (Elliott et al., 2007). In 
this  study  RP2  appeared  to  interact  with  the  26S  proteasome  subunit  4 
(PSMD4). This subunit is a key component for the recruitment of ubiquitinated 
substrates  to  the  26S  proteasome  (Ferell  et  al.,  1996).  PSMD4  has  been 
demonstrated to bind NEDD8 and NEDD8 ultimate buster 1 (NUB1) (Kamitani 
et al., 2001), which interact with another retinal disease causing protein, AIPL1, 
mutations in which cause Leber congenital amaurosis (LCA) (Sohocki et al., 
2000). Thus, this interaction places RP2 in another pathway implicated in retina 
degenerations. 
In this study it was shown that PSMD4 has a high affinity for the N-terminus of 
RP2 as well as full length RP2. Slow yeast growth was observed with the 41-Chapter III 
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200 fragment of RP2 with PSMD4 therefore suggesting first 41 amino acids of 
RP2  are  not  essential  for  this  interaction.  The  N-terminal  mutants  of  RP2 
demonstrated almost no effect on the PSMD4 and RP2 interaction in this study 
suggesting  that  this  binding  is  unlikely  to  be  affected  during  the  XLRP 
pathogenesis.  However,  this  interaction  is  still  interesting  for  general  RP2 
functional investigation. 
Another chaperone identified in the CytoTrap® screen was cytosolic chaperonin 
subunit  6  (CCT6).  CCT6  is  part  of  a  large  multisubunit  chaperone  cytosolic 
chaperonin complex (CCT), described in section 1.4.2. This clone represented 
the full length protein but appeared to interact only with the N-terminus of RP2 
and demonstrated no interaction with the full length protein. Surprisingly, the 
interaction with the mutants of RP2 had affinity as high as the binding to the N-
terminus. These data suggest that CCT6A, being a chaperone, bound a partially 
misfolded 1-200 RP2 fragment and misfolding RP2 mutants. It is unlikely that 
this subunit, expressed in pMyr vector, which attaches a myristoylation signal, 
became recruited in yeast homologue of CCT due to targeting of the clone to 
the  plasma  membrane.  These  data  indicate  that  this  subunit  of  the  CCT 
chaperone complex may be able to act independently on other members of the 
complex. 
Potentially, if mutants of RP2 bind CCT6 with high affinity, it could lead to its 
lack  of  function  in  photoreceptors,  causing cytoskeletal  protein  misfolding  by 
altering the CCT complex chaperone function. As described in section 1.3.3.2, 
mutations in homologues of the CCT complex subunits have been shown to 
cause a ciliopathy with retinitis pigmentosa, Bardet-Biedl syndrome (BBS). On 
the other hand, XLRP patients with RP2 mutations have not been reported to 
exhibit generalised ciliopathy to date.  
Thus, using CytoTrap® system allowed identification of several novel potential 
interacting partners of RP2. However, using only one method for searching for 
interactors  is  unlikely  to  result  in  identifying  all  potential  protein  interactors. 
Moreover,  CytoTrap®  is  known  to  have  several  disadvantages.  Many 
interactions in higher protein complexes may be too weak to be detected by 
two-hybrid  methods  (Mendelsohn  and  Brent,  1999).  Moreover,  potential Chapter III 
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interactors  of  those  membrane  proteins  are  unlikely  to  be  identified  by  this 
method. It also does not allow posttranslational modifications of the bait, and 
therefore  modification-dependent  interaction will  not  be  identified.  CytoTrap® 
system used in this study is designed for binary complexes identification and 
therefore higher complex formations could be missed. Thus, another method 
described in the following chapter was also applied to identify RP2 potential 
interacting partners. 
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Chapter IV. Transducin-β subunit as a 
putative interacting partner of RP2 
4.1. Introduction 
Previous work described in chapter 3 and PhD studies of Evans (2007) have 
identified novel RP2 interactors through the use of a yeast two-hybrid system, 
potentially shedding light on RP2 function. However, due to several CytoTrap® 
disadvantages, many putative interactions could potentially be missed. To make 
possible  identification  of  potential  interactors  of  membrane  bound  proteins, 
those  mediated  by  post  translational  modifications  or  by  forming  higher 
complexes a variant of a protein affinity assay, GST pull-down, with the retinal 
lysate was applied. Protein affinity assays with subsequent mass-spectrometry 
analysis have been extensively used previously and have proved themselves 
an efficient tool for identifying novel protein-protein interactions.  
For  such  experiments  the  protein  of  interest  needs  to  be  expressed  and 
purified. In order to identify protein-protein interactions in prokaryotes or yeast, 
gel filtration is often used for co-purification of “bait” complexes directly from the 
cells  which  express  “bait”  (Pinto  et  al.,  2005).  In  contrast,  when  identifying 
mammalian protein-protein interactions, a “bait” can be fused with a tag suitable 
for expression in an E.coli system and purified using affinity chromatography. 
Immobilised in this way, the purified protein can be incubated with mammalian 
cell lysate containing “prey” proteins, which are captured and then identified by 
mass-spectrometry. Some systems allow mammalian expression of tagged bait 
protein making possible co-purification of endogenous complexes (Jones et al., 
2008). 
The most common tags used for E.coli expression and purification are 6xHis 
and glutathione S-transferase (GST). Vectors for protein expression with these 
tags provide high expression level and easy purification. Six histidine residues 
at  the  N-terminus  or  C-terminus  act  as  a  metal  binding  domain  of  a  fusion 
protein and therefore it can be purified by metal affinity chromatography with 
Ni
2+ or Co
2+ resins. This technique has some disadvantages such as low protein Chapter IV  
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solubility and can involve using buffers with non-physiological compounds. The 
His tag is rarely used for a pull-down as proteins containing polyhistidine motifs 
can bind non-specifically to the resin.  
GST pull-down has been successfully used for identification of novel interacting 
partners of many proteins involved in retinal degeneration. For instance, it was 
found that a protein mutated in arRP, TULP1, interacted with F-actin (Xi et al., 
2005). The GST tag expression system is known to result in a good expression 
level with high protein solubility. Protein purification is based on GST affinity to 
glutathione,  immobilised  on  sepharose.  The  GST  tag  also  allows  a  flexible 
choice of buffers for protein purification and incubation with prey proteins. 
Prey  proteins  can  be  obtained  from  multiple  sources  including  recombinant 
purified  proteins,  cell  lysate  or  in  vitro  transcription/translation  reactions. 
Proteins bound to bait can be visualised by SDS-PAGE with detection methods 
depending  on  the  sensitivity  required.  Such  methods  include  Coomassie  or 
silver  staining,  Western  blotting  and  radioisotopic  detection.  Bands 
corresponding to potential interacting proteins can be excised and analysed by 
mass-spectrometry (Muzio et al., 1996).  
This technique identifies compounds on the basis of mass-to charge ratio (Q/m) 
of charged particles, which occurs by passing the particles through electric and 
magnetic fields in a mass spectrometer. It has been more than a century since 
mass  spectrometry  experiments  were  described  for  the  first  time  by  Eugen 
Goldstein in 1886. Some of the modern techniques of mass spectrometry were 
devised by A. Dempster and F. Aston in 1920s (reviewed in Budzikiewicz and 
Grisby, 2006).  
Mass-spectrometry was widely used for gas compound analyses. However with 
the  development  of  matrix-assisted  laser  desorption/ionisation  (MALDI)  by 
Hillenkamp and collegues (1990) and electrospray ionisation (ESI), invented by 
Fenn and collegues (1989), it has been used for protein analysis. Proteins could 
be  analysed  intact  or  enzymatically  digested  with  proteases  resulting  in  a 
collection  of  peptides  (Shevchenko  et  al.,  1996).  Most  commonly,  ESI  is 
coupled  with  liquid  chromatography  (LC)  that  separates  compounds 
chromatographically and introduces the ion source.  Chapter IV  
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After  ionisation  by  MALDI  or  ESI,  charged  particles  are  separated  by  mass 
analysers according to Q/m. It is known that the speed of a charged particle can 
be altered when it is passing through a magnetic field, where its speed and 
trajectory gets deflected depending on Q/m.  There are several types of mass 
analysers. A sector field mass-analyser uses electric and/or magnetic field to 
affect the path and velocity of a charged particle (Badman et al., 2000). The 
time-of-flight (TOF) analyser uses an electric field as well but measures the time 
a charged particle takes to reach the detector. Quadripole analysers apply a 
radio frequency oscillating field to selectively destabilise/stabilise ions and act 
as mass-selective filters (Badman et al., 2000). The final element of any mass-
spectrometer is a detector that records the ion charge when it passes or hits the 
detector’s surface. Recently, tandem mass spectrometry has been widely used 
for  protein  identification.  In  this  method  the  first  mass  analyser  isolates  a 
peptide and the second analyser stabilises the ions while they collide with a 
gas, causing them to fragment (collision induced dissociation). The third mass 
analyser then sorts the fragments produced from the peptides. 
Mass  spectrometry  produces  various  types of  data.  The  most  common  data 
representation  is  the  mass  spectrum.  The  interpretation  of  mass  spectra 
requires a combined use of techniques and is usually software assisted (Wilm 
et al., 1996). A characteristic pattern of peptides is used for protein identification 
in  a  peptide  fingerprinting  database,  it  is  called  peptide  mass  fingerprinting 
(PMF) (Iborra et al., 1979). If the identification is performed after using tandem 
MS it can be termed as de novo sequencing (Dancik et al., 1999, Horn et al., 
2000).  Such  sequences  are  used  to  compare  to  a  database  of  predicted 
proteins encoded by an organism’s genome.  
Therefore, GST pull-down was attempted to investigate novel RP2 interacting 
partners, which could be present with RP2 in complexes important for retina 
function.  Additionally,  this  assay  was  also  used  to  look  for  the  guanine-
exchange factor (GEF) for Arl3. As described in the general introduction (Veltel 
et  al.,  2008a),  RP2  is  a  GAP  for  Arl3,  but  a  GEF  of  Arl3  has  yet  to  be 
discovered. Presumably, the GEF for Arl3 is upstream of RP2 and is important 
for the retina. It has been shown that amino acid substitutions in Arl3, T31N and 
Q71L,  mimic  Arl3  conformations  when  bound  to  GDP  or  GTP  respectively Chapter IV  
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(Bartolini et al., 2002). Such a GDP- or GTP-“locked” condition can be used in a 
proteomic affinity assay to compare protein complexes which preferentially bind 
one form. 
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4.2. Results 
4.2.1. Expression and purification of recombinant GST-Arl3 and 
GST-RP2 in E.coli 
To perform GST pull-down experiments bait proteins first need to be produced 
and purified using affinity chromatography.  
Two forms of GST-Arl3 were constructed, expressed and purified, T31N and 
Q71L. These amino acid substitutions alter the Arl3 conformation and emulate 
the conformations of the GDP- or GTP-bound states respectively. Coding DNA 
sequences  for  these  constructs  were  amplified  by  PCR  (as  in  2.1.1)  using 
specific primers (table 2.1) from pCMV Tag3a Arl3 T31N and Q71L plasmids 
previously constructed in our lab. They were then TA-cloned into pGEM-T®easy 
and sub-cloned into pGEX-2T expression vector (2.1.2 and 2.1.8) using EcoRI 
restriction sites. The correct orientation of the insert was checked by protein 
expression. Several single colonies of pGEX-2T Arl3s were used to inoculate 5 
ml of LB and incubated as in 2.4.6, induced with IPTG at OD600≥0.2 and lysed 
after 2 hours of incubation. The total and soluble fractions of cells were resolved 
by SDS-PAGE and visualised by Coomassie staining (2.4.2-2.4.3).  
Clones  expressing  GST-Arl3  exhibited  a  unique  band  of  46  kDa,  which 
corresponded to the expected mobility for a GST-Arl3 fusion protein (data not 
shown). Western blotting (2.4.5) with anti Arl3 antibody (table 2.10) of clones 
expressing the 46 kDa protein showed specific bands of this size, confirming 
the identity of this band as GST-Arl3. It was found that the GTP form (Q71L) 
was  expressed  at  higher  levels  than  the  GDP  one  (T13N)  after  4  hours  of 
incubation. However, after 2 hours of incubation with IPTG the expression level 
of both mutants was similar and therefore this time point was chosen for future 
cell  harvests  (figure  4.1a).  The  expression  level  of  a  previously  constructed 
GST-RP2 plasmid (table 2.5) was checked in BL-21(DE3) pLysS E.coli strain. 
Several colonies were used to inoculate 5 ml of LB, induced with IPTG, lysed 
and analysed by SDS-PAGE as described for GST-Arl3. It was found that GST-
RP2 was expressed and was partly soluble after 4 hours of incubation at 37ºC 
(figure 4.1b). Chapter IV  
167 
   
 
 
 
 
 
Figure 4.1. Expression and solubility of GST-Arl3 and GST-RP2 
a.  Western  blot  with  anti-Arl3  antibody  of  soluble  fractions  of  cells  lysates, 
expressing GST-Arl3 T31N or GST-Arl3 Q71L after different incubation periods 
with IPTG as indicated. Immunostaining with anti Arl3 antibody (Arl3 854, table 
2.10) showed specific bands of 46kDa. b. Coomassie stained SDS-PAGE gel of 
soluble and total fractions of cells lysates expressing GST-RP2 in response to 
incubation with IPTG for 4 hours. Arrows indicate bands of approximately 65 
kDa which correspond to the predicted size of GST-RP2. 
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The  small-scale  experiments  were  scaled-up  and  GST-Arl3  and  GST-RP2 
proteins were purified as in described 2.4.8. The purified GST-fusion proteins 
were left bound to gluthatione-sepharose beads to use as an affinity “trap”. To 
control for non-specific binding of “prey” proteins to the beads alone and/or GST 
bound gluthatione sepharose was essential. Therefore, GST was expressed in 
the same strain of E.coli using an empty pGEX-2T vector (table 2.3). GST was 
then purified on gluthatione-sepharose beads using the same techniques as for 
GST-fused RP2 and Arl3. 
4.2.2. GST pull-down optimisation. 
In order to find the optimal conditions for protein-protein binding in GST pull-
down, the system was tested to identify conditions for the known interaction of 
RP2 with Arl3 to occur. A variety of factors such as pH, salt concentration and 
presence of detergents can influence protein-protein interaction affinity. On the 
one hand harsh conditions, such as high salt concentration or too high/low pH 
can disrupt interactions. On the other hand mild conditions (low salt or pH close 
to physiological) can lead to non-specific binding to the “bait” protein and give 
false positive results. Therefore, a balance between these two conditions needs 
to  be found.  The  presence  of  detergent  could  affect  the  potential interaction 
affinity as well, however, in many cases detergents are essential for efficient 
extraction of many proteins, for example those having trans-membrane domains 
or  cytoskeletal  proteins.  Thus,  the  right  choice  of  buffer  was  crucial  for  the 
success of the experiment. 
Several kinds of mammalian cell lysis buffers were tested to find the optimal 
one for the RP2-Arl3 interaction in GST pull-downs. For this purpose T31N and 
Q71L forms of GST-Arl3 were bound to the beads as described above in 4.2.1. 
They  were  then  incubated  with  different  HeLa  cell  lysates  prepared  using 
buffers from table 2.9, incubated with the beads bound to GST-Arl3 or GST and 
washed with the buffer used for cell lysis (described in section 2.4.9).  
Proteins from the beads were eluted with Laemmli buffer and the samples were 
resolved  by  SDS-PAGE,  stained  with  Coomassie  (as  in  2.4.2  and  2.4.3)  to 
visualise the equality of loading. Western blotting was performed with anti-RP2 Chapter IV  
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antibody to detect endogenous RP2 protein bound to GST-Arl3s (section 2.4.5; 
table 2.10).  
It  is  known  that  GTP-bound  Arl3  binds  to  RP2  stronger  than  GDP-Arl3 
(described in section 1.5.4.1), therefore it was expected that the Q71L mutant 
Arl3 would preferentially bind to endogenous RP2. This was observed by using 
buffer 3, which had pH 8.0 and 0.1 % Triton X-100 (table 2.9). Buffer 2 had the 
same detergent as buffer 3 but a lower pH (7.5) and such a change caused 
RP2 to bind GST-Arl3 T21N and even, to a lesser extent, the GST negative 
control lane. Using buffer at pH 7.5 but without detergent for the GST-Arl3 pull-
down did not demonstrate any binding of RP2 to Arl3, presumably due to poor 
RP2 protein extraction (figure 4.2a).  
Lysis buffer 3, which was found to be optimal for GST-Arl3 binding to RP2, was 
then tested in the reciprocal experiment. GST-RP2 was used as “bait” protein 
for binding endogenous Arl3 from human cells and porcine retina lysates. For 
this purpose HeLa cells and isolated pig retinae were lysed in buffer 3. They 
were  then  incubated  with  aliquots  of  GST-RP2  glutathione-sepharose  beads 
with all the procedures performed as described above for GST-Arl3 pull-down 
and  in  section  2.4.9.  The  samples  were  then  analysed  by  SDS-PAGE  with 
Coomassie stain and Western blotting (2.4.2-2.4.6).  
The eluates from the GST-RP2 pull-downs were visualised by SDS-PAGE and 
a strong unique band was observed in the lane where GST-RP2 was incubated 
with the pig retina lysate compared to the one incubated with HeLa cell lysate 
(figure 4.2b). It had mobility similar to GST. It is possible that it was a porcine 
GST  (predicted  Mw  23  kDa)  bound  by  glutathione-sepharose  beads.  These 
data suggest that the sepharose beads were not saturated by the recombinant 
protein and therefore, endogenous GST from the library of “prey proteins” was 
captured. 
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Figure 4.2. GST pull-down with GST-Arl3 and GST-RP2  
a. Coomassie stained gel of the samples of the GST pull-down experiment of 
GST-Arl3 T31N and Q71L with HeLa cell lysates lysed using different buffers as 
in table 2.9. Eluate from GST bound beads (24 kDa) was used as a control for 
non-specific  binding.  Both  GST-Arl3  forms  showed  the  expected  mobility  at 
around 46 kDa. Western blot immunostained with anti RP2 antibody below the 
gel demonstrates specific bands of the bound endogenous RP2 (39kDa) from 
HeLa cell lysates. b. Coomassie stained gel of the GST pull down experiment 
using GST-RP2 as “bait” with HeLa cells and pig retina lysate (as indicated). 
The arrows indicate the mobility of GST-RP2 at 65 kDa and GST at 24 kDa. An 
asterisk indicates the position of a 23 kDa potential porcine GST band. The 
Western blot below is immunostained with anti Arl3 antibody demonstrating 20 
kDa specific bands. 
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It  was  shown  by  Western  blotting  that  under  the  chosen  conditions  the 
interaction of GST-RP2 with endogenous Arl3 from both HeLa cell lysate and 
the retinal lysate occurred (figure 4.2b). At the same time there were no bands 
observed  in  the  GST  negative  control  lane,  demonstrating  the  specificity  of 
binding of GST-RP2 to Arl3 in this assay. The Arl3 band from the pull-down with 
the retinal lysate appeared to be stronger than the one in the lane with the HeLa 
cell lysate. This difference could be due to the different concentration of Arl3 in 
these lysates possibly due to different expression level (data not shown).  
4.2.3. Identification of transducin-β subunit as a potential RP2 
interacting partner 
The optimal conditions for the interaction of RP2 with Arl3 were used for further 
experiments  aimed  at  identifying  novel  interacting  partners  of  RP2  and  to 
identify a GEF for Arl3 by GST pull-down followed by mass-spectrometry. 
For this purpose beads with GST, GST-RP2, and both forms of GST-Arl3 were 
incubated  with  porcine  retinal  lysate  in  buffer  3  and  all  the  experimental 
procedures  were  performed  as  in  section  2.4.9.  As  an  additional  negative 
control  for  possible  bacterial  protein  contamination,  GST-RP2  or  GST-Arl3 
beads were incubated in buffer 3 but without retinal lysate added and treated as 
all other samples. The beads were eluted with 100  l of Laemmli buffer and 80 
 l of each eluate was resolved using a Midi-Vertical SDS-PAGE (2.4.2) in order 
to achieve a maximal concentration of protein for each sample and for better 
band  separation.  The  proteins  on  the  gel  were  visualised  with  mass-
spectrometry compatible silver stain as described in section 2.4.4.  
In the lanes with GST-Arl3 T31N and GST-Arl3 Q71L pull-down there were no 
bands observed which appeared to be unique to T31N mutant and likely to be a 
GEF, therefore no bands were excised from GST-Arl3 pull-down lanes (figure 
4.3). However, as seen from figure 4.3 the loading of GST-Arl3 T31N protein 
was not equal to GST-Arl3 Q71L on the beads, therefore this experiment would 
need further optimisation. 
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Figure  4.3.  Pull-down  assay  of  GST-RP2  and  GST-Arl3  mutants  with 
porcine retinal lysate 
Silver stained midi-vertical SDS-PAGE gel of the GST pull-down experiment. 
The experimental lanes are as indicated above the gel. The numbered arrows 
on the gel (1-8) indicate the bands that were excised from the gel for mass-
spectrometry analysis. The arrows on the left of the gel show the mobility of 
bands of the pre-stained molecular weight standard (see section 2.4.2). 
   Chapter IV  
173 
   
In the GST-RP2 pull-down with the retinal lysate lane there were six unique 
bands found that were not apparent in the GST negative control lane or GST-
RP2 beads control lane. The bands were of the following approximate sizes: 
about 37 kDa (1), 45kDa (2), 47kDa (3), 49kDa (4), 130 kDa (5), 180 kDa (6).  
These bands were excised (figure 4.3) and further analysed by ESI-MS/MS as 
described in section 2.4.10 by Dr. R Wait (Kennedy Institute of Rheumatology 
Division, Imperial College, London). Two other bands were excised from the 
GST negative control lane – one at approximately 50 kDa (band 7) and the 
band 8, corresponding to GST (25 kDa), and these were analysed the same 
way. 
The data obtained after ESI-MS/MS was analysed with the MASCOT program 
and  searched  for  matching  peptides  in  the  NCBInr  database  (section  2.6). 
Proteins were considered “identified” when they were represented by at least 
two unique peptides with a MASCOT ion score >35, or at least one peptide with 
MASCOT ion score >70 and that manual interpretation confirmed agreement 
between spectra and peptide sequence (analysis performed by Dr R. Wait).  
Most of the bands did not show any significant match to known proteins but 
RP2, GST and enolase, which is frequently observed as a contaminant in pull-
down assays with mammalian cell lysates (personal communication, Dr R Wait). 
The protein sequences obtained from each band are represented in table 4.1 
and MS/MS data are attached to the thesis (compact disc). 
Only one band (figure 4.3, band 1) resulted in five peptides with a MASCOT 
score  >35.  The  comparison  was  performed  based  on  the  similarity  between 
species due to the fact that the database for Sus scrofa is incomplete. ESI-
MS/MS analysis of the band number 1 resulted in three peptides with significant 
ions score (35, 43 and 55). Three peptide sequences matched across species 
to a highly conserved protein, transducin-β (figure 4.4a). Other peptides from 
this band corresponded to either RP2 or GST.  
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Band   ~Mw 
(kDa) 
Proteins identified 
by at least two 
peptides with 
mascot score>35 
 
Eukaryotic proteins 
predicted from 
unmatched peptides 
(mascot score<35) 
Bacterial proteins 
predicted from 
unmatched 
peptides  
(mascot score<35) 
1  37  transducin-β 37 kDa 
gi| 6680045 
  ABC transporter 
transmembrane 
ATP-binding protein   GST 25 kDa  
gi|84402 
RP2 39 kDa 
gi| 5902060  
2  45  enolase 49 kDa 
gi|119338 
RP2 39 kDa 
 
flagellar biosynthesis 
protein; 
NERD domain 
protein; 
ankyrin repeat 
domain protein; 
GST 25 kDa  
gi|84402 
RAD10 domain 
protein (Mw range 32-
42 kDa) 
3  47  actin, ~42 kDa 
gi|113292 
enolase 49 kDa 
 
TufB domain protein; 
inorganic 
pyrophosphatase  GST 25 kDa  
gi|84402 
4  49  enolase 49 kDa 
gi|119338 
PolyA polymerase 
(testis specific) 112 
kDa 
 
squalene photoene 
synthase; 
DNA helicase; 
serine/threonine 
transferase; 
DHH family protein 
GST 25 kDa  
gi|84402 
5  130  enolase 49 kDa 
gi|119338 
CAATT-binding 
protein (Drosophila)  
~120 kDa 
ribonucleotide 
transferase; 
phytoene 
desaturase; 
oxidoreductase; 
GST 25 kDa  
gi|84402 
RP2 39 kDa 
 
6  180  GST 25 kDa  
gi|84402 
hypothetic protein 
DDBDRAFT 0184139 
 
aspartyl tRNA 
synthase;  
serine/threonine 
transferase 
squalene photoene 
synthase 
TIP120 ~140kDa 
 
7  50  enolase 49 kDa 
gi|119338 
GST 25 kDa  
 
β-gluconase; 
50S ribosomal 
protein; 
squalene photoene 
synthase 
8  25  GST 25 kDa  
gi|84402 
   
Table 4.1. The proteins and peptides identified in ESI-MS/MS analysis of 
GST-RP2 pull-down with the retinal lysate 
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Figure 4.4.  Transducin-β subunit identification 
a.  The  peptides  highlighted in  red  boxes  were  obtained  from  ESI-MS/MS  of 
band  1  (collaboration  with  Dr  R  Wait)  correspond  to  highly  conserved 
transducin-β sequences from different species as indicated (the sequences are 
aligned using Clustal W). b. Western blot with anti transducin-β antibody (table 
2.9)  of  the  GST  pull-down  experiment  showing  presence  of  a  37  kDa 
transducin-β  band  in  the  GST-RP2  pull-down  lane  and  not  in  the  negative 
control GST pull-down lane. 
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4.2.4.  Confirmation  of  transducin-β  interaction  with  RP2  in 
retinal lysate 
To  test  whether  the  protein  in  band  1  identified  by  mass  spectrometry  did 
correspond  to  porcine  transducin-β,  the  aliquots  of  the  samples  from  the 
experiment described above in 4.2.3 were resolved by mini SDS-PAGE  with 
subsequent  Western  blotting  (2.4.2  and  2.4.5).  Immunostaining  with  anti 
transducin-β  antibody  revealed  an immunoreactive  37  kDa  specific  bands in 
lanes  with  GST-RP2  pull-down  and  the  retinal  lysate  input.  There  was  no 
transducin-β band observed with the negative control GST alone pull-down with 
the  retina  lysate,  demonstrating  the  specificity  of  binding  (figure  4.4b).  The 
mobility of the transducin-β band on the Western blot complemented the Mr of 
band 1 from the silver stained gel (section 4.2.3, figure 4.3), suggesting that the 
excised band did correspond to porcine transducin-β. 
4.2.5.  Interaction  of  transducin-β  with  RP2  in 
immunoprecipitation assay 
In order to test whether transducin-β was a potential interacting partner of RP2, 
co-immunoprecipitation (IP) assays were used as a complementary technique.  
SK-N-SH human neuroblastoma cells with an undetectable level of endogenous 
RP2  were  chosen  for  the  IP  experiment.  Cells  were  co-transfected  (as 
described  in  2.3.2)  with  human  RP2-GFP  and  human  FLAG-transducin-β 
plasmid (Missouri S&T cDNA Resource Center, section 2.1.8, table 2.5). The 
transfected cells were lysed with buffer 7 (table 2.8), which had been shown to 
be optimal for co-IP of Tctex-1 and transducin-β (Sachdev et al., 2007), and 
incubated with anti-FLAG antibody (table 2.10). The co-IP was then incubated 
with Protein G sepharose, washed and eluted with Laemmli buffer (described in 
section  2.4.11).  To  control  for  non-specific  binding  the  cell  lysates  were 
incubated  with  mouse  non-specific  IgG  and  treated  the  same  way  as  the 
samples  with  anti-FLAG  antibody.  The  eluates  obtained  from  protein  G 
sepharose were resolved by SDS-PAGE and analysed by Western blotting (as 
in sections 2.4.2 and 2.4.5).    Chapter IV  
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Figure 4.5. Interaction of transducin-β with RP2 
a.  Western  blots  of  immunoprecipitation  (IP)  with  anti-FLAG  of  FLAG-
transducin-β  and  RP2-GFP,  expressed  in  SK-N-SH  cells.  The  upper  panel 
shows a Western blot immunostained with M2 anti-FLAG (table 2.10) antibody 
detected  a  37  kDa  specific  band  of  FLAG-transducin-β.  The  lower  panel 
represents  a Western  blot  stained  with  anti-RP2  antibody (S974,  table  2.10) 
showing a specific band of 66 kDa in the input and FLAG IP lanes but not in the 
IgG negative control lane. b. Western blots of IP of endogenous RP2 from pig 
retinal  lysate  using  anti-RP2  antibody  detected  two  specific  bands  of 
approximately  39  kDa  (indicated  with  arrow)  and  40  kDa  (indicated  with 
asterisk)  (upper  panel).  The  lower  panel  shows  a  Western  blot  with  anti 
transducin-β  of  transducin-β  co-precipitated  with  RP2  from  the  retinal  lysate 
using anti-RP2 antibody as above and immunostained with anti- transducin-β 
antibody (table 2.10) detected a 37 kDa transducin-β band in the input lane and 
RP2 IP lane.   Chapter IV  
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It was observed that the anti-FLAG antibody successfully precipitated FLAG-
transducin-β from the cell lysate and that FLAG-transducin-β was able to co-
precipitate  RP2-GFP  whereas  the  non-specific  IgG  did  not  (figure  4.5a), 
suggesting that an interaction between transducin-β and RP2 had occurred. 
Several  attempts  were  made  to  precipitate  an  endogenous  complex  of 
transducin-β  with  RP2  from  the  pig  retina  lysate.  However,  the  result  was 
inconsistent  and  the  antibodies  to  RP2  or  transducin-β  either  failed  to 
precipitate appropriate proteins or precipitated hardly detectable amounts (an 
example is shown in figure 4.5b). This problem did not allow the detection of 
Arl3 co-precipitated with RP2 from the retinal lysate (data not shown). Thus, it 
remains to be clarified whether an endogenous complex of RP2 with transducin-
β is formed in retina lysates. 
4.2.6.  The  effect  of  RP2  mutations  on  the  interaction  with 
transducin-β 
The binding of transducin-β to mutants of RP2 was tested by co-IP. SK-N-SH 
cells were transfected with the wild type RP2 or the four mutants (C67Y, C86Y, 
R118H  and  L253R)  and  the  FLAG-transducin-β  construct  (table  2.4,  section 
2.1.8). The experiment was performed as described above. β-arrestin-2-FLAG 
was chosen as a negative control as it was shown in chapter 3 (section 3.3) that 
RP2-GFP did not bind this protein in co-IP.  
The results of the experiment are shown in figure 4.6. It was shown by Western 
blot with anti GAPDH antibody (table 2.9) that the protein concentration loading 
was roughly equal in all the input lysates. The IP samples did not demonstrate 
any bands of contamination with GAPDH. The anti-FLAG antibody precipitated 
equal  amounts  of  FLAG-transducin-β  from  all  the  lysates  despite  different 
expression level.  The β-arrestin-2-FLAG was expressed at comparable levels; 
however, the band of precipitated protein was likely to be covered by the band 
of anti-FLAG IgG heavy chains.  
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Figure 4.6. Interaction of RP2 mutants with transducin-β. 
Western  blots  of  IP  of  FLAG-transducin-β  with  wild  type  RP2-GFP  and  its 
mutants  as  indicated.  The  upper  panel  represents  a  Western  blot 
immunostained with anti-RP2 antibody (S974, table 2.10) demonstrating 66 kDa 
RP2-GFP bands of different intensity in input lanes and in co-IP lanes. Middle 
panel shows Western blot stained with M2 anti-FLAG antibody (table 2.10), the 
bands of 37 kDa of FLAG-transducin-β and a 46 kDa band of β-arrestin 2-FLAG 
in  lanes  as  indicated.  The  asterisk  shows  the  position  of  mouse  IgG  heavy 
chain. The bottom panel shows bands of 36 kDa on the Western blot with anti 
GAPDH antibody (table 2.10). 
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The Western blot immunostained with anti-RP2 antibody showed specific bands 
of 66 kDa in most input and IP lanes but the negative control β-arrestin-2-FLAG 
lane, indicating that binding of RP2-GFP to FLAG-transducin-β occurred.  
The expression of wild type RP2-GFP and the R118H mutant was higher than 
the  other  RP2  constructs.  RP2-GFP  C67Y  and  L253R  mutants  had  a  lower 
expression level compared to the wild type RP2 (figure 4.6).  Wild type RP2 
appeared  to  be  co-precipitated  with  FLAG-transducin-β  by  the  anti-FLAG 
antibody.  However,  in  the  lane  where  transducin-β  was  co-transfected  with 
C67Y the RP2 specific band appeared to be weaker compared to the wild type 
RP2 and the R118H mutant.  
There  was  a  very  weak  band  observed  in  the  IP  lane  with  the  L253R  RP2 
mutant, suggesting that this mutation in the C-terminus of RP2 could disrupt the 
interaction  with  transducin-β.  The  R118H  “arginine  finger”  mutation  did  not 
demonstrate significant disruption of the transducin-β interaction (figure 4.6). 
4.2.7.  The  subcellular  localisation  of  transducin-β  and  RP2 
overlap 
To investigate the nature of putative interaction of RP2 with transducin-β, these 
proteins were studied in cell culture using immunofluorescence. SK-N-SH cells 
were transfected with GFP or RP2-GFP and FLAG-transducin-β (as in 2.3.1 and 
2.3.2). The cells were then fixed, immunostained with anti-FLAG antibody as 
described in 2.3.4 and table 2.8. Cells were analysed by confocal microscopy 
(2.3.5).  
It  was  observed  that  in  cells  co-transfected  with  FLAG-transducin-β  and  an 
empty GFP vector the staining of transducin-β was predominantly cytoplasmic 
with small cytosolic and often perinuclear intracellular inclusions (figure 4.7a). 
Some cells exhibited predominant plasma membrane localisation of transducin-
β (figure 4.7b) and cell counting estimated the proportion of such cells at 33 % 
of the population (figure 4.10a). There was no similarity in the staining pattern of 
transducin-β and GFP (figure 4.7a, b).   Chapter IV  
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Figure 4.7. Subcellular localisation of transducin-β and RP2 
Confocal  microscopy  images  of  SK-N-SH  cells  co-transfected  with  FLAG-
transducin-β and empty  GFP  (a, b)  or  RP2-GFP  (c, d), immunostained  with 
anti-FLAG antibody. FLAG-transducin-β is shown in red whereas GFP or RP2-
GFP is in green.  Arrows on panel a highlight intracellular inclusions formed by 
FLAG-transducin-β when co-transfected with GFP (zoomed inset). b shows an 
example  of  a  cell  expressing  FLAG-transducin-β  without  inclusion  formation 
with some localisation on the plasma membrane. Arrows with asterisks on panel 
c shows plasma membrane localisation of FLAG-transducin-β in the presence 
of RP2-GFP. Panel d shows intracellular FLAG-transducin-β and RP2-GFP co-
localisation as indicated with arrows with crosses. Scale bars are 10 m. Chapter IV  
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Upon  co-transfection  of  FLAG-transducin-β  with  RP2-GFP,  a  change  in  the 
localisation  of  transducin-β  was  observed.  In  68  %  of  co-transfected  cells 
transducin-β  was localized predominantly  on  the plasma  membrane  together 
with RP2-GFP (figure 4.7c, d). This observation was highly reproducible and 
quantified in at least three independent experiments (figure 4.10). It had been 
shown  previously  that  RP2,  when  over-expressed,  can  form  intracellular 
inclusion-like  structures  (Evans,  2007).  This  phenomenon  was  observed  in 
some cells transfected with RP2-GFP and when RP2-GFP was co-transfected 
with FLAG-transducin-β. It was found that FLAG-transducin-β was recruited to 
RP2-GFP intracellular inclusions in 88 % of cells with such inclusions (figures 
4.7d and 4.10c). 
4.2.8. Subcellular localisation of other Gβ proteins and RP2 
To  reveal  whether  the  potential  interaction  of  RP2  with  transducin-β  was 
specific to transducin-β and not other types of Gβ proteins, SK-N-SH cells were 
co-transfected  with  RP2-GFP  and  different  N-terminally  FLAG-tagged 
constructs of Gβ3, Gβ5 and Gβ5L proteins (cDNA Resource Center, table 2.5) 
as  described  in  section  2.3.2.  The  cells  were  then  fixed  with  methanol  and 
immunostained with anti-FLAG antibody with subsequent confocal microscopy 
(table 2.7 and section 2.3.5).  
The  staining  of  Gβ3  protein  was  predominantly  cytoplasmic  with  occasional 
intracellular  inclusions.  This  staining  pattern  did  not  overlap  with  RP2-GFP 
distribution on the membrane or in occasional intracellular inclusions formed by 
RP2 (figure 4.8). Gβ5L was observed mostly on the plasma membrane with a 
relatively small portion in the cytoplasm and the staining overlapped with RP2-
GFP  localisation  on  the  membrane.  However,  when  RP2-GFP  formed 
inclusions, they did not appear to co-localise with Gβ5L staining (figure 4.8). Co-
transfection  of  RP2-GFP  with  Gβ5  protein  resulted  in  the  same  pattern  as 
described for its longer isoform Gβ5L (figure 4.8). Thus, the localisation of RP2-
GFP and other Gβ proteins did not seem to overlap as closely as transducin-β. Chapter IV  
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Figure 4.8. Subcellular localisation of transducin-β, Gβ3, Gβ5L, Gβ5 and 
RP2-GFP in SK-N-SH cells 
Confocal microscopy images of SK-N-SH cells co-transfected with different Gβ 
proteins and RP2-GFP as indicated. After methanol fixation cells were stained 
with M2 anti-FLAG antibody (table 2.10) to visualise N-terminally FLAG tagged 
Gβ proteins (red). RP2-GFP is shown in green. Scale bars are 10  m.   Chapter IV  
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4.2.9.  L253R  mutation  in  the  C-terminus  of  RP2  affects 
transducin-β co-localisation with RP2 
To confirm the previous data that suggested that the pathogenic L253R RP2 
mutation  decreased  the  affinity  of  the  transducin-β  interaction  with  RP2, 
immunofluorescence was used to study this interaction further. 
SK-N-SH cells were co-transfected with FLAG-transducin-β and the wild type 
RP2-GFP  or  its  mutants  (C67Y,  C86Y,  R118H  and  L253R)  as  described  in 
sections  2.3.1-2.3.2.  After  methanol  fixation  and  staining  with  anti-FLAG 
antibody  the  cells  were  analysed  using  confocal  microscopy  (table  2.7  and 
section 2.3.5). 
The  co-transfection  of  cells  with  FLAG-transducin-β  and  wild  type  RP2-GFP 
demonstrated a shift in localisation FLAG-transducin-β from the cytoplasm to 
the  plasma  membrane  as  described  in  4.2.8,  indicating  that  the  data  were 
reproducible (figure 4.9). Upon transfection with the C67Y RP2-GFP mutant, the 
formation of large intracellular inclusions was observed and cells appeared to 
be significantly smaller in size with abnormal nuclei.  
Therefore when the cells were co-transfected with the FLAG-transducin-β and 
C67Y  RP2  mutant,  the  result  was  difficult  to  assess  due  to  such  changes. 
However, in some cells staining of FLAG-transducin-β and RP2-GFP mutants 
overlapped.  Unfortunately,  correct  counting of  the  overlap incidence  was  not 
feasible due to poor anti-FLAG antibody penetration into the inclusions formed 
by C67Y RP2-GFP mutant (figure 4.9). 
Co-transfection  of  cells  with  the  R118H  RP2  mutant  and  FLAG-transducin-β 
resulted  in  no  change  in  localisation  compared  to  wild  type  RP2-GFP. 
Transducin-β was present on the plasma membrane and co-localised with R118 
RP2-GFP. Some cells, where interacellular staining of R118H RP2-GFP was 
observed, showed overlap in staining of intracellular transducin-β with R118H 
RP2-GFP (83 %) (figure 4.10 b, c). This overlap was comparable to the wild 
type RP2-GFP (88 %) (figure 4.10c).  
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Figure 4.9. Effect of RP2 mutations on transducin-β intracellular staining 
Confocal  microscopy images  of  cells  co-transfected  with  wild type (wt)  RP2-
GFP or the RP2-GFP mutants (green) and FLAG-transducin-β (red). Scale bars 
are 10  m.  
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Figure 4.10. Effect of RP2 mutants on transducin-β localisation 
a. The graph represents the percent of cells with FLAG-transducin-β staining 
localised  predominantly  on  the  plasma  membrane  when  co-transfected  with 
different  RP2-GFP  plasmids  as  indicated  on  the  x  axis.  Error  bars  show 
standard  deviation  (±1  SD)  b.  Confocal  images  of  cells  co-transfected  with 
FLAG-transducin-β and RP2-GFP or R118H RP2-GFP mutant with intracellular 
staining indicated with arrows. c. Graph showing the percent of cells with co-
incidence of overlap in the intracellular staining of RP2-GFP/R118RP2-GFP and 
transducin-β. Error bars are standard deviation (±1 SD).   Chapter IV  
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Cells  transfected  with  the  L253R  RP2-GFP  mutant  exhibited  some  plasma 
membrane  staining  with  small  intracellular  inclusions.  In  cells  co-transfected 
with this mutant and FLAG-transducin-β, the L253R mutant did not change its 
localisation  (data  not  shown).  However,  FLAG-transducin-β  staining  was 
observed predominantly in the cytoplasm and was similar to cells co-transfected 
with  FLAG-transducin-β  and  GFP  alone  (figure  4.9).  In  20  %  of  cells, 
transducin-β  staining  was  still  observed  on  the  plasma  membrane  (figure 
4.10a). Therefore, the L253R C-terminal mutation of RP2 was found to have a 
strong effect on the RP2 interaction with transducin-β. 
4.2.10.  Subcellular  fractionation  assay  of  transducin-β 
localisation upon co-transfection with RP2 
In order to confirm the translocation of transducin-β from the cytoplasm to the 
plasma membrane upon co-transfection with RP2, subcellular fractionation was 
used  to  test  whether  there  was  a  shift  in  transducin-β  into  the  membrane 
fraction when co-transfected with RP2. 
SK-N-SH cells were co-transfected with FLAG- transducin-β and empty GFP 
vector to test which fraction FLAG-transducin-β was present. A parallel SK-N-
SH cell population was co-transfected with FLAG-transducin-β and RP2-GFP to 
determine  whether  RP2  is  able  to  change  FLAG-transducin-β  subcellular 
localisation.  
The cells were then fractionated using the protocol described in section 2.3.6. 
This technique separates cells into cytosolic, membrane, cytoskeletal and SDS-
insoluble proteins (pellet) fractions. For the extraction of the cytosolic proteins, 
the plasma membrane was disrupted mechanically to release proteins into the 
buffer. After the cytosolic fraction was isolated, Triton X 100 was included in the 
next  extraction  buffer  to  solubilise  membrane-bound  proteins.  When  the 
membrane protein fraction is collected, the next buffer uses SDS to solubilise 
cytoskeletal  proteins.  The  pellet  fraction  obtained  after  the  final  extraction 
represents cell proteins that are not soluble in SDS. 
However, it is not possible to accept that the cytoskeletal fraction contains only 
cytoskeleton components. The buffer for extraction of proteins for this fraction Chapter IV  
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contains SDS, which solubilises not only cytoskeletal proteins, but also those, 
which are insoluble in Triton X100 of the membrane extraction buffer. Thus, the 
fraction is conditionally called “cytoskeletal” although this name does not refer to 
its content exclusively. 
When performing the cell fractionation technique it is possible to contaminate 
the cytosolic fraction with membrane proteins and vice versa. Therefore, the 
efficiency of fraction separation was checked. GAPDH was chosen as a marker 
for soluble cytosolic proteins and the endoplasmic reticulum (ER) chaperone 
calnexin for membrane proteins.  
Each fraction was resolved by SDS-PAGE and analysed by Western blotting. It 
was shown that fraction separation was achieved (figure 4.11) and there was no 
contamination of the membrane and subsequent fractions with soluble cytosolic 
proteins  as  GAPDH  was  present  only  in  the  cytosolic  fractions.  However,  a 
minor contamination of cytosolic and cytoskeletal fractions with calnexin was 
observed. This contamination was equal in both GFP and RP2-GFP transfected 
cells lysates and was considered not a significant problem for this experiment. 
RP2-GFP showed a predominant localisation in the membrane fraction although 
a  small  amount  was  also  present  in  cytoskeletal  and  pellet  fractions  (figure 
4.11).  
When co-transfected with empty GFP, FLAG-transducin-β was mainly present 
in the cytoskeletal and the pellet fractions with a trace amount in the membrane 
fraction. There was no band detected in the soluble cytosolic protein fraction. 
Upon  co-transfection  of  FLAG-transducin-β with  RP2-GFP,  it  was  found  that 
transducin-β  was  present  only  in  the  membrane  protein  fraction  with  a 
significant amount of transducin-β retained in the stacking gel as seen in figure 
4.11. 
Thus, this experiment showed that the majority of transducin-β shifted from the 
“cytoskeletal” fraction to the membrane fraction upon co-transfection with RP2. 
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Figure 4.11. Changes in the subcellular localisation of transducin-β upon 
co-transfection with RP2 
Western  blots  of  subcellular  fractions  of  cells  co-transfected  with  FLAG-
transducin-β and GFP or RP2-GFP. The upper panel shows the predominant 
presence  of  endogenous  calnexin in  the  membrane  fraction. The next  panel 
demonstrates the presence of GAPDH in the cytosolic fraction only. Western 
blot of fractions immunostained with anti RP2 antibody showed its fractionation 
mainly with the membrane fraction. The last two panels show Western blots of 
the resolving and stacking parts of the SDS-PAGE gel of fractions stained with 
anti-FLAG antibody, demonstrating higher intensity bands of FLAG-transducin-β 
in the membrane fraction upon co-transfection with RP2-GFP. 
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4.2.11.  Detergent  resistant  membrane  isolation  from  cells  co-
transfected with transducin-β and RP2 
It has been shown that RP2 is partly localised to detergent resistant membranes 
(DRM) (Chapple et al., 2003). In order to test if RP2 recruits transducin-β to 
DRM, the membrane fraction isolation was performed. 
First  the  procedure  was  tested  for  the  optimal  conditions  such  as  gradient 
density  and  buffers.  Thereby,  a  protocol  of  sucrose  gradient  fractionation 
described in section 2.3.7 was developed and a test fractionation of ARPE19 
cells was performed.  
GM1 was used as a marker for the DRM fraction, which was detected by binding 
to HRP-conjugated cholera-toxin subunit B. It was found that fractions 3-5 of the 
gradient contained DRM (figure 4.12). Calnexin was chosen as a marker for 
detergent soluble membranes and was co-fractionated with fractions 7-12 and 
the pellet. 
Western blotting for endogenous RP2 revealed that RP2 gradient distribution 
was  similar  to  calnexin,  with  the  difference  that  RP2  was  also  present  in 
fractions 3-5, which contained DRM (figure 4.12). Endogenous Arl3 was present 
in fractions 10-12 only, as previously described (Chapple et al., 2003). 
ARPE19 cells were co-transfected with FLAG-transducin-β and empty GFP or 
RP2-GFP. After that the cells were lysed in buffer 2 (table 2.8) and the sucrose 
gradient  fractionation  was  performed  as  described  above.  However,  the 
antibody to RP2, GFP and FLAG could not detect the transfected proteins in the 
Western blot after sucrose gradient fractionation. This could be a consequence 
of  the  expression  level  being  too  low  for  the  dilution  by  the  fractionation 
procedure. Another possibility is that the tested proteins were not solubilised in 
Laemmli  buffer  after  TCA  precipitation  (as  described  in  section  2.4.2).  The 
potential  effect  of  RP2  on  DRM  recruitment  of  transducin-β  needs  to  be 
investigated further. 
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Figure 4.12. Detergent resistant membrane fractionation of ARPE19 cells 
Lanes 1-12 represent sucrose gradient cell lysate separation. The number of 
each fraction indicates collection from top to the bottom of the gradient. The first 
panel shows a dot-blot of the gradient obtained after DRM isolation, incubated 
with HRP-cholera-toxin subunit B to bind GM1. Fractions 3-5 contain the highest 
concentration of GM1. Western blot with anti-calnexin antibody revealed specific 
bands of 90 kDa calnexin in fractions 7-12 and in the pellet. The next panel 
shows  Western  blotting  with  anti-RP2  antibody  showing  39  kDa  bands  of 
endogenous  RP2  in  lanes  3-12.  The  Western  blot  stained  with  anti  Arl3 
antibody showed specific bands of 20 kDa of endogenous Arl3 in fractions 10-
12. 
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4.2.12. Arl3 siRNA does not alter the overlap in subcellular co-
localisation of transducin-β and RP2 
In order to check if RP2 and transducin-β form a binary complex or RP2 acts 
together with Arl3 in this interaction, a GST-pull down assay of porcine retinal 
lysate  with  GST-Arl3  was  performed.  The  experiment  showed  presence  of 
specific transducin-β bands in the lanes of both GST-Arl3 fusion proteins with a 
stronger intensity band with the GST-Arl3 Q71L mutant elution (figure 4.13a). 
This result indicated the possible involvement of Arl3 in the RP2 interaction with 
transducin-β.  
In order to test if Arl3 was required for the interaction of RP2 with transducin-β, 
siRNA for Arl3 was used reduce Arl3 expression. SK-N-SH cells were chosen 
for  this  experiment  as  previous  experiments  on  the  RP2  interaction  with 
transducin-β were performed using this line (sections 4.2.5-4.2.10).  
Cells were transfected with siRNA for Arl3 or a negative control of scrambled 
siRNA as described in 2.3.3. After 76 hours of incubation with siRNA, the cells 
were  co-transfected  with  RP2-GFP  and  FLAG-transducin-β  constructs  and 
incubated for another 24 hours. The cells were then fixed with methanol and 
immunostained with anti-FLAG antibody (table 2.6) as in section 2.2.4. Cells 
transfected with scrambled and Arl3 siRNAs were immunostained with anti Arl3 
antibody to confirm that the Arl3 expression level was decreased (figure 4.13b).  
The  efficiency  of  endogenous  Arl3  knock  down  was  assessed  using 
epifluorescent  microscopy  with  software  as  described  in  2.3.5  section.  The 
images  of  the  negative  control  with  scrambled  siRNA  and  Arl3  siRNA  were 
taken on the same microscope using identical exposure settings. It is shown in 
figure  4.13b  that  the  Arl3  staining  was  less  intense in  cells  transfected  with 
siRNA Arl3 compared to scrambled siRNA control. Arl3 siRNA had been tested 
in  our  lab  before  by  Western  blotting  and  had  demonstrated  up  to  70  % 
decrease in  Arl3 protein  compared  to  the  scrambled  siRNA  negative  control 
(data not shown).   Chapter IV  
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Figure 4.13. GST-Arl3 pull down with retina lysate and the effect of Arl3 
siRNA on RP2 co-localisation with transducin-β 
a. Western blot of GST pull-down using T31N and Q71L forms of GST-Arl3 with 
pig retinal lysate. The 37 kDa porcine transducin-β bands were detected with 
GST-Arl3 pull-down but not in GST negative control pull-down. b. Epifluorescent 
microscopy images of SK-N-SH cells transfected with scrambled siRNA or Arl3 
siRNA immunostained with anti-Arl3 antibody (green). The nuclei are visualised 
with DAPI (blue). Scale bars are 10 µm. c. Confocal images of SK-N-SH cells 
co-transfected with scrambled siRNA (top) or Arl3 siRNA (lower), RP2-GFP and 
FLAG-transducin-β.  Cells  were  immunostained  with  anti-FLAG  antibody 
visualising transducin-β (red), RP2-GFP is in green. Scale bars are 10 µm. Chapter IV  
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No difference in cells with or without Arl3 expression knock-down was observed 
(figure 4.13c). Thus, Arl3 siRNA does not appear to affect the intracellular co-
localisation of RP2 with transducin-β. 
4.2.13.  Arl3  is  able  to  alter  co-localisation  of  RP2  with 
transducin-β 
In order to test if over expression of GDP- or GTP-bound conformations of Arl3 
can influence the overlap in localisation of RP2 and transducin-β, SK-N-SH cells 
were co-transfected with FLAG-transducin-β, RP2-GFP and non-tagged T31N 
or  Q71L  Arl3.  After  24  hours  the  cells  were  fixed  with  methanol  and 
immunostained with anti-FLAG antibody to visualise transducin-β (section 2.3.4, 
table 2.6).  
It was observed that T31N Arl3 did not change the overlap in plasma membrane 
localisation  of  FLAG-transducin-β  with  RP2-GFP  (figure  4.14).  Q71L  Arl3 
caused RP2-GFP to partially localise to a perinuclear region within the cell, an 
effect  that  had  been  observed  previously  (Evans,  2007).  Similar  effect  was 
observed with transducin-β co-transfected with RP2-GFP and GTP-Arl3. The 
subcellular localisation of transducin-β changed to a more intracellular staining 
pattern but this did not appear to overlap with the intracellular  localisation of 
RP2-GFP (figure 4.14).  
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Figure  4.14.  Subcellular  localisation  of  transducin-β  and  RP2  upon  co-
transfection with Arl3 
Confocal  microscopy  images  of  SK-N-SH  cells  co-transfected  with  FLAG-
transducin-β,  RP2-GFP  and  GDP-  or  GTP  conformational  forms  of  Arl3  as 
indicated. Cells were immunostained with M2 anti-FLAG antibody to visualise 
transducin-β (red). RP2 is shown in green and the nuclei are visualised with 
DAPI (blue). Scale bars are 10 µm.  
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4.3. Discussion 
This chapter demonstrates that a GST pull-down protein affinity approach was 
an  efficient  tool  for  finding  of  interacting  partners  for  RP2.  Using  such  an 
approach another potential novel interacting partner for RP2, transducin-β, was 
identified. Transducin-β is a subunit of the transducin heterotrimeric complex 
that takes part in the phototransduction cascade (described in section 1.2.3.3). 
The  identification  of  this  protein  was  possible  due  to  mass  spectrometric 
analysis of three peptides of transducin-β. However, two of these peptides were 
identical to another G protein β subunit involved in β-adrenoreceptor signalling, 
Gβ3, but one peptide demonstrated identity to transducin-β and not to other Gβ 
proteins  (figure  4.15).  Thus,  transducin-β  was  another  putative  interacting 
partner identified in this study that puts RP2 in a retina specific pathway.  
However, this experiment was not reproducible possibly due to the pig retinal 
lysate properties varied from different pig eyes delivery. Attempts to detect the 
endogenous  complex  of  these  proteins  in  retinal  lysates  using 
immunoprecipitation were not successful.  When the anti-RP2 antibody used for 
the  IP  appeared  to  precipitate  RP2  protein  from  the  pig  retinal  lysate,  this 
recovery  was  of  low  yield  and  therefore  not  sufficient  for  detection  of  any 
proteins which could have been co-precipitated, including Arl3. The staining of 
porcine  retina  cryosections  with  anti-RP2  antibody  and/or  anti  transducin-β 
antibody was also not successful (data not shown). It is possible that the anti-
RP2 antibody did not cross-react well with the pig protein. Delay in harvesting of 
pig  retinas  could  also  affect  the  result.  Therefore  this  experiment  could  be 
improved by using retinal lysate from other species, such as mouse.  
Despite  these  concerns  the  RP2-  transducin-β  interaction  was  confirmed  by 
immunoprecipitation assays when transducin-β and RP2 were overexpressed in 
a  cell  culture,  which  showed  that  RP2  specifically  bound  transducin-β.  This 
study  also  demonstrated  that  co-localisation  of  RP2  and  transducin-β  was 
specific  to  transducin-β rather  than  other Gβ  family  proteins  tested,  such  as 
Gβ3.  Chapter IV  
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Figure 4.15. Alignment of transducin-β protein to other Gβ proteins 
Multiple  sequence  alignment  of  human  protein  sequences  of  transducin-  β, 
Gβ3,  Gβ5  and  Gβ5L.  Residues  highlighted  in  red  demonstrate  identity; 
conserved WD repeats are shown in green. Transducin-β shares approximately 
40 % of amino acid identity with other Gβ proteins (Alignment was performed by 
ClustalV). The peptides identified in this study in GST pull-down experiment are 
underlined in transducin-β sequence with the red line highlighting the peptide 
specific to transducin-β. Chapter IV  
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A SNP in the GNB3 gene is associated with essential hypertension and obesity 
(Dong et al., 2004). Gβ5 is found predominantly in brain but its longer isoform, 
Gβ5L, is expressed in the retina where it forms a complex with RGS9 taking part 
in  phototransduction  (described  in  section  1.2.3.3;  He  et  al.,  2000).  All  Gβ 
proteins are structurally similar (figure 4.15), especially transducin-β and Gβ3, 
but  my  data  show  that  RP2  was  unlikely  to  interact  with  Gβ3,  however  this 
hypothesis needs to be investigated further by biochemical tests, such as IP.  
Construction  of  transducin-β  fragments  and  testing  them  using  IP  and 
immunofluorescence would be useful to identify the binding site responsible for 
binding to RP2. 
It was revealed that transducin-β was translocated from the cytoplasm to the 
plasma  membrane  upon  RP2  co-expression.  This  effect  was  quantified  and 
proved to be statistically significant. It was also reproduced using a biochemical 
method  that  demonstrated  a  shift  in  transducin-β  co-fractionation  into  the 
membrane fraction. 
It is known that transducin complex subunits shuttle rapidly between the plasma 
membrane and Golgi apparatus membranes (Chisari et al., 2007). This process 
is  vesicle-independent  and  can  be  inhibited  by  the  palmitoylation  and 
myristoylation inhibitor 2-bromopalmitate. Transducin-β has not been found to 
be  myristoylated  or  palmitoylated  and  can  translocate  independently  of 
transducin-α. Transducin-γ was suggested to mediate the translocation since it 
has been described to be prenylated but this modification cannot be blocked by 
2-bromopalmitate treatment, therefore transport by transducin-γ does not seem 
to be a possible mechanism (Chisari et al., 2007).  
As  described in  sections  1.5.2-1.5.3,  RP2 is  myristoylated  and  palmitoylated 
and there are pathogenic mutations described in this motif which affect RP2 
membrane  localisation  (Chapple  et  al.,  2002).  The  Gβ5L-RGS9  complex  is 
anchored to the photoreceptor disc membranes by R9AP protein, and its knock 
down in mice leads to a slow light response (Keresztes et al., 2004). Therefore, 
RP2 may act in a similar way with transducin-β. 
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Thus, it is possible to suggest that RP2 is a protein which mediates transducin-β 
translocation  to  the  plasma  membrane  and  possibly  into  detergent  resistant 
membranes (DRM). A test of whether there was a translocation of transducin-β 
into the detergent resistant membranes fraction in the presence of RP2 was 
attempted. However, the experiment was not successful due to transfected RP2 
or  transducin-β  protein  not  being  expressed  at  a  high  enough  level  to  be 
detected.  Thus,  the  hypothesis  of  RP2  dependent  transducin-β  translocation 
into DRM needs to be investigated further by optimising the sucrose gradient 
protocol, increasing the transfection efficiency and trying different antibodies. 
The pathogenic mutation L253R in the C-terminus of RP2 caused significant 
decrease of the RP2-transducin-β interaction affinity by IP. It was revealed by 
immunocytochemistry that this mutation did not result in targeting of transducin-
β to the plasma membrane. Transducin-β staining in such cells resembled the 
FLAG-transducin-β intracellular distribution in the absence of RP2, suggesting 
no  interaction  occurred.  RP2  mutations  located  at  the  N-terminus  did  not 
demonstrate  any  significant  effect  on  the  interaction  by  both  IP  and  ICH. 
Therefore, it is likely that the region for binding of transducin-β lies within the C-
terminus  of  RP2,  which  is  homologous  to  nucleoside  diphosphate  kinase 
(NDPK)  (Kuhnel  et  al.,  2006).  Interestingly,  NDPK  can  interact  with  the 
transducin-βγ complex and intermediately phosphorylate His266 in transducin-β 
(Cuello et al., 2003) (figure 4.16). This promotes the formation of GTP on the 
transducin-α subunit and results in transducin-αβγ complex dissociation. This 
mechanism is proposed to be regulatory for the basal effector activity (Wieland, 
2007).  
RP2  does  not  share  homology  with  NDK  in  the  His122  catalytic  residue 
therefore it is doubtful that this interaction results in an NDPK-like effect on the 
transducin complex. On the other hand, RP2 acts as a GAP for Arl3 (Veltel et 
al., 2008a) and there is a possibility that the phosphate from the Arl3 catalysis 
by  RP2,  could  be  transferred  to  His  266  of  transducin-β  and  thus,  activates 
transducin  complex.  If  transducin-β  binds  to  the  C-terminus  of  RP2,  the  N-
terminus of RP2 could be free for binding to Arl3 and therefore, form a ternary 
complex.    Chapter IV  
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Figure 4.16. G protein coupled receptor dependent and alternative NDK 
dependent G protein activation 
Schematic  of  two  possible  mechanisms  modulating  the  G  protein  activation 
pathway are shown. Agonist binding to a G protein coupled receptor (GPCR) 
triggers  GDP/GTP  exchange  on  Gα  and  release  of  Gβγ,  leading  to  effector 
responses (left side). When heterotrimeric G proteins complexes with NDK, a 
phosphotransfer onto His266 of Gβ promotes the formation of GTP, leading to 
GPCR-independent G protein activation and thus, regulation of basal effector 
activity (right side). Phosphohistidine phosphatase (PHP), which can specifically 
dephosphorylate  Gβ,  is  a  potential  counter  regulator  of  NDP  dependent  G 
protein activation (from Wieland, 2007).     
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This hypothesis is already supported by the data obtained in a GST pull-down 
assay  with  GST-Arl3  and  the  retinal  lysate.  On  the  other  hand,  the  gene 
silencing  of  Arl3  did  not  change  the  overlap  in  co-localisation  of  RP2  with 
transducin-β,  indicating  that  this  protein  may  be  unlikely  to  mediate  the 
interaction or is not essential. However, siRNA techniques do not lead to an 
absolute knock-down, therefore there is still some protein produced. Possibly, 
even a small amount of Arl3 is sufficient to form a ternary complex. 
On the other hand, data obtained in GTP-Arl3 overexpression experiments with 
RP2  and  transducin-β  suggest  that  Arl3  did  not  form  a  ternary  complex  but 
competed with RP2 for binding with transducin-β and caused it to re-localise to 
the cytoplasm. As no overlap was observed in intracellular localisation of RP2 
with  transducin-β  upon  GTP-Arl3  expression,  there  is  a  possibility  that  RP2 
becomes bound to GTP-Arl3 and therefore is less available for the interaction 
with transducin-β. However, immunofluorescence studies are not sufficient to 
fully understand the role of Arl3 in the RP2/transducin-β interaction. Biochemical 
studies of transducin complex dissociation in the presence of RP2 with/without 
Arl3 are needed to test the effects of Arl3. 
The role of the RP2 interaction with transducin-β in the retina still remains to be 
investigated.  Functional  studies,  such  as  transducin  complex  dissociation  by 
activated  rhodopsin  in  the  absence/presence  of  RP2,  would  potentially 
demonstrate  whether  RP2  affects  phototransduction  cascade  activation. 
Studies  on  how  activated  transducin  activates  the  PDE  complex  in  the 
presence/absence of RP2 with or without Arl3, which is known to bind PDEd 
(van Vaklenburgh et al., 2001), would be another way of answering the question 
about RP2 involvement in transducin function. 
Experiments to investigate the dynamics of these proteins in the retina could be 
performed. The hypothesis of light dependent translocation of transducin could 
be explored. It has been shown that transducin subunits translocate upon light 
exposure and this process is considered to be mediated by cilia proteins (Giessl 
et al., 2006). Thus, RP2 and Arl3 might be the proteins that mediate such a 
translocation.  This  translocation  has  been  suggested  to  be  essential  for  the Chapter IV  
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retinal  physiology  (Slepak  et  al.,  2008)  and  therefore,  disruption  of  this 
mechanism could cause retinal degeneration. 
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Chapter V. Prefoldin 5 as a candidate gene 
for retinal degeneration 
5.1. Introduction 
It has been reported that a homozygous point mutation (L110R) in Pfdn5 in 
mice  could lead  to  abnormal  outer  segment  development  and  severe  retinal 
degeneration (Lee et al., 2005). Mice appeared to have thinner outer and inner 
segments.  Rhodopsin  and  ROM-1  were  mislocalised,  indicating  that  their 
transport via the connecting cilium to the outer segment might be impaired. The 
phenotype  was  apparently  not  restricted  to  the  retina  as  mice  exhibited 
hydrocephaly, Purkinje cell degeneration and male infertility (Lee et al., 2006). 
These findings suggest that mutant Pfdn5 mice could have a syndromic type of 
retinal degeneration. 
5.1.1. The human PFDN5 gene 
The human PFDN5 gene maps to chromosome 12q12 spanning approximately 
4 kb of genomic sequence and consists of at least 6 coding exons. PFDN5 is 
alternatively  transcribed  with  5  reported  isoforms  (figure  5.1).  The  largest 
reported isoform of PFDN5 represents a fusion transcript containing a region of 
chromosome 14 at the 5’ end (Hagio et al., 2006) and probably represents a 
cloning  artefact.  Other  isoforms,  PFDN5  α,  β,  γ  and  δ,  are  derived  from 
chromosome 12q12 (figure 5.1).  
5.1.2. PFDN5 protein 
The α isoform of PFDN5 (NP 002615) is a protein of 167 amino acids with a 
molecular weight (Mw) of approximately 17 kDa and pI 5.94. It has a common 
domain  for  other  PFDN  complex  subunits  structure  of  two  coiled-coils 
connected by a linker region with five loops and four extended strands (figure 
5.2).  This  protein  has  been  shown  to  bind  c-myc  (Mori  et  al.,  1998),  p73 
(Watanabe et al., 2002) and PFDN6 (Simons et al., 2004). Chapter V 
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Figure 5.1. Organisation of human PFDN 5 isoforms 
Schematic of the reported isoforms (PFDN5, PFDN5 α, β, γ and δ) is shown.  
Exons are represented as boxes with the coding regions as black. Untranslated 
regions are shown with grey boxes. The numbers on the boxes indicate the 
exon number. The length of the coding sequence and of the protein product is 
indicated (modified from Hagio et al., 2006 and UCSC database as described in 
2.6). 
 
Figure 5.2. Proposed model of the PFDN complex structure 
a.  Three  dimentional  diagram  of  archeal  PFDN  (PDB:  1FXK).  b.  Model  of 
interaction of PFDN complex with denaturated actin (Martin-Benito et al., 2002). 
c. PFDN5 subunit structure (Siegert et al., 2000). Chapter V 
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5.1.3. PFDN5 as a part of a chaperone complex 
Prefoldin (PFDN), alternatively called Gim complex (GimC), is a chaperone that 
works in conjunction with the cytosolic chaperonin (CCT) in assisting with the 
folding  of  actin  and  tubulin  in  archea  and  eukaryotes  (described  in  chapter 
1.4.3.2).  PFDN  is  composed  of  six  different  subunits,  which  are  able  to 
assemble spontaneously into a complex (figure 5.2) (Leroux et al., 1999). The 
prefoldin  5  subunit  (PFDN5),  one  of  the  most  evolutionary  conserved in  the 
complex, has been shown to be essential for PFDN complex association. It was 
able to form intermediates with prefoldin 6 subunit and this sub-complex was 
shown to donate subunits for the PFDN assembly reaction. Moreover, it was 
demonstrated that the prefoldin complex with a truncated prefoldin 5 subunit 
failed  to  bind  its  target  substrate  tubulin  and  therefore  was  important  for 
actin/tubulin PFDN folding function (Simons et al., 2004). 
It is known that the archeal prefoldin complex is able to replace the function of 
Hsp70 in archeae (reviewed in Macario and Conway di Macario, 2001). The 
mammalian prefoldin complex has been demonstrated to assist in not only the 
folding of actin and tubulin, but misfolded proteins, such as amyloid β. It was 
demonstrated that prefoldin was able to solubilise β-sheet-rich fibrils formed by 
amyloid β peptides into a soluble state (Sakono et al., 2008). However, it has 
been  suggested  that  such  soluble  misfolded  peptides  are  more  toxic  for 
neurons (Klein et al., 2001). 
5.1.4. PFDN5 as a candidate gene for retinal degeneration. 
There is evidence that subunits of prefoldin could be involved in cilia-related 
retina degeneration. Recently it was demonstrated that PFDN1 deficient mice 
develop severe abnormalities including ciliary dyskinesia, loss of neuron tracts 
in the brain, and defects in B and T cell development (Cao et al., 2008). 
Another PFDN complex subunit, PFDN3, is also known as von Hippel-Lindau 
binding protein 1 (VBP1), binds the tumor suppressor von Hippel-Lindau protein 
(pVHL)  which  mutated  in  the  disease  of  the  same  name  (OMIM  300133) 
(Tsuchiya et al., 1996). VHL is characterised by highly vascularised malignant Chapter V 
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tumors in many organs and form renal clear-cell carcinomas (RCCs). pVHL is 
localised to the cilium, although not exclusively, and is thought to have multiple 
functions,  such  as  polyubiquitination,  regulation  of  hypoxia-inducible  factors 
(HIF1a, HIF2a) and cell cycle control via cyclin D (reviewed in Shehata et al., 
2008). However, the most important role is now considered to be regulation of 
cilia  formation in  kidneys  (Thoma  et  al.,  2007,  Lolkema  et  al.,  2008).  It  was 
shown that RCCs in patients develop from renal cysts which are believed to be 
the  most  serious  VHL  manifestation  (Kim  et  al.,  2005).  Therefore,  PFDN3 
protein acts as a chaperone as a part of PFDN complex and also has another 
role via the interaction with pVHL. 
Non folding roles for PFDN5, which may also be important for fundamental cell 
biology and retinal function, have also been suggested. PFDN5, also referred to 
as MM-1 (Myc Modulator-1), was isolated as a c-myc interacting protein in yeast 
two-hybrid  screening  (Mori  et  al.,  1998).  C-myc  is  a  transcription  factor  that 
plays pivotal roles in cell proliferation, differentiation and apoptosis regulation 
(Dang  et  al.,  2006).  PFDN5  was  shown  to  repress  the  E  box-dependent 
transcription activity of c-myc by itself or by recruiting HDAC1 via TIF1, a co-
repressor.  This  pathway  targets  another  proto-oncogene  c-fms  (Satou  et  al., 
2001, 2004). 
Further,  it  was  revealed  that  PFDN5  could  bind  the  p73  tumour  suppressor 
protein and b-myc, an N-terminal homologue of c-myc (Watanabe et al., 2002, 
Burton  et al.,  2006). These  data  suggest that  prefoldin  5  may  function  as a 
tumour suppressor protein. This hypothesis is supported by the genetic survey 
made by Fijioka and colleagues (2001) suggesting that an A157R sequence 
change in PFDN5 was associated with leukaemia and lymphoma.  
Tumourigenesis involves numerous pathways and one of them is wnt signalling 
which  is  now  considered  to  be  a  potential  therapeutic  target  for  cancer 
(reviewed in Ewan et al., 2008). Recently prefoldin 5 was shown to negatively 
regulate the wnt signalling pathway by inhibiting of the expression of the wnt4 
gene (Yoshida et al., 2008). The wnt pathway is a network of proteins which is 
involved in a large variety of processes including retinal degeneration (Yi et al., 
2007). Wnt proteins are a family of secreted growth factors. The signal triggered Chapter V 
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by  these  factors  can  be  transmitted  in  two  ways  –  the  canonical  or  non-
canonical pathways (figure 5.3).  
The  canonical  epithelial  pathway  is  also  known  as  wnt/  β-catenin  pathway 
(figure  5.3).  In  differentiated  cells,  β-catenin  is  associated  with  adherens 
junctions  at  the  cell  membrane.  In  the  absence  of  wnt  proteins  β-catenin  is 
complexed  with  axin,  glycogen  synthase  kinase-3β  (GSK-3β),  and 
adenomatous  polyposis  coli  (APC)  (Liu  et  al.,  2002,  Amit  et  al.,  2002).  This 
large  complex  prevents  accumulation  of  β-catenin  in  the  cytoplasm  through 
proteasomal degradation (Liu et al., 2002). Wnt proteins bind to the receptor 
Frizzled (Bhanot  et  al.,  1996),  which  protects  complex  formation  between  β-
catenin, GSK-3β, axin and APC. The cytoplasmic non-phosphorylated β-catenin 
then translocates to the nucleus and acts as a transcription factor for several 
genes, such as c-myc, c-jun and cyclin D1 (reviewed in Sakanaka et al., 2000). 
It was demonstrated that stabilisation of β-catenin causes onset of cancer and it 
was found to be the most common cause of colorectal cancer (Karim et al., 
2004). 
The  non-canonical  wnt  pathway  (figure  5.3),  or  wnt/Ca
2+,  is  important  for 
dictating the plane of the epithelium to be perpendicular to the cells' apical–
basal axis and the orientation of the mitotic spindle (Gong et al., 2004). When 
wnt  ligand  binds  its  receptor,  an  early  event  involving  a  protein  called 
dishevelled (Dsh) determines whether canonical or non-canonical wnt signalling 
is initiated.  
Several studies have implicated cilia and ciliary proteins to be involved in this 
regulation  (Corbit  et  al.,  2008,  Mans  et  al.,  2008).  For  example  inversin  is 
expressed upon increase of intracellular Ca
2+ caused by mechanosensation of 
cilia  by  fluid  flow  (Kishimoto  et  al.,  2008).  Mutations  in  the  gene  encoding 
inversin  are  suggested  to  causes  nephronophthisis  (Simons  et  al.,  2005).  A 
group of cilia-localised proteins, mutations in which have been shown to cause 
BBS, also involve the wnt signalling pathway.  
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Figure 5.3. Schematic of the wnt signaling pathway in a ciliated cell 
In the absence of flow (left panel), canonical wnt signalling can occur when the 
ligand  binds  the  frizzled  receptor,  thereby  recruiting  dishevelled  (DSH)  and 
inactivating  GSK3β.  β-catenin  (β-cat)  becomes  subsequently  stabilized  and 
translocates to the nucleus where it acts as a transcriptional co-activator. Upon 
mechanosensation by fluid flow (right panel) the increased level of intracellular 
Ca
2+ triggers expression of inversin that binds DSH. Thus, β-catenin is guided 
for  degradation  by  axin, adenomatous  polyposis  coli (APC)  and  GSK3β  and 
therefore does not act as a transcription factor (Mans et al., 2008). 
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Numerous studies in mouse  mutants for BBS proteins 1, 4, and 6 display a 
strikingly  similar  array  of  developmental  defects  as  mutants  in  the  wnt/Ca
2+ 
signalling pathway. When BBS4 heterozygous healthy mice were crossed with 
the  wnt/Ca
2+  signalling  component  van  Gogh-like-2  (VANGL2)  heterozygous 
mice,  the  heterozygous  offspring  for  both  genes  displayed  the  same  severe 
phenotype as homozygous wnt/Ca
2+ (Ross et al., 2005). In another study using 
zebrafish, suppression of bbs4 in vangl2 mutant embryos similarly resulted in a 
phenotype  typically  caused  by  defective  wnt/Ca
2+  signalling  (Badano  et  al., 
2006). Together, these in vivo data strongly argue for a functional link between 
wnt/Ca
2+ signalling and cilial function.  
In the study of Yoshida and collegues (2008) it was demonstrated that PFDN5 
was able to down regulate the wnt/β-catenin pathway. Cells knocked down for 
expression of PFDN5 protein had increased expression levels of the wnt4 gene, 
accumulation and translocation of β-catenin and upregulation of TCF/Lef-1, one 
of the target proteins of wnt/ β-catenin pathway. It was shown that, together with 
the zinc-finger protein Egr-1, PFDN5 down-regulated the promoter activity of the 
wnt4 gene. 
Additionally it has been suggested that PFDN5 could be involved in the non-
canonical pathway regulation. Henkel and colleagues (2001) have shown that 
the yeast homologue of PFDN5, Bob1, interacts with the MAP kinase kinase 
(MAPKK) Byr1 and regulates sexual differentiation in fission yeast. This kinase 
is  one  of  the target  genes  for  wnt  signalling  regulated by  wnt4  via  the  non-
canonical pathway (Chang et al., 2007b). Therefore it is feasible to suggest that 
PFDN5 may act as one of the proteins modulating the wnt signalling pathway 
via both canonical and non-canonical pathways. 
Thus, PFDN5 is suggested to have multiple functions – on one hand it is an 
important transcription repressor of c-myc pathway, on the other hand PFDN5 
plays  an  important  role  in  cytoskeleton  biogenesis  as  a  part  of  the  PFDN 
complex.  At  the  same  time  PFDN5  is  shown  to  regulate  the  wnt  signalling 
pathway,  which is involved in the pathogenesis of Bardet-Biedl syndrome.  A 
mutation in PFDN5 could potentially affect one of these pathways and result in 
syndromic or non-syndromic retinal degeneration.  Chapter V 
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A study into whether mutations in PFDN5 cause retinal degeneration in human 
patients has not been reported to date, and therefore forms the basis of this 
chapter. 
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5.2. Results 
5.2.1. Screening of patients with non-syndromic and syndromic 
forms of retinal degeneration 
A panel of 96 DNA samples from patients with an early onset form of retinal 
degeneration (EORD) was obtained from Moorfield’s Eye Hospital (provided by 
Prof. Anthony T. Moore).  These unrelated patients were diagnosed with severe 
non-syndromic, early onset, retinal degeneration and were from different age 
groups. Most of the patients presented as children of 2-10 years age (39 %); 
two large groups were formed by patients of age from 10 to 20 years (27 %) 
and 20-40 years (26 %). The smallest age group screened was represented by 
DNA from people older than 40 years (8 %). All the patient samples had proved 
negative in a variety of previous LCA and RP disease gene mutation screens. 
Another panel of 48 DNA samples from patients with a recessive syndromic 
form of retinitis pigmentosa was donated by Prof. Phillip L. Beales (Institute of 
Child  Health,  UCL).  All  these  patients  were  diagnosed  with  Bardet-Biedl 
Syndrome (BBS, described in section 1.3.3.2) of unknown aetiology.  The age 
range and sex was not known, however, all 48 patient samples were negative in 
reported BBS gene mutation screens.  
In  order  to  obtain  PCR  products  of  each  PFDN5  exon  for  subsequent  DNA 
sequencing,  specific  primers  were  designed  approximately  60  bp  from  the 
exon/intron  boundaries  (figure  5.4a).  An  aliquot  of  patient  DNA  (50  ng)  was 
PCR amplified using exon specific primers (table 2.2) as described in section 
2.1.1. Following amplification, each PCR product (5  l) was electrophoresed on 
an agarose gel (as in 2.1.7). Examples are represented in figure 5.4b, which 
shows that all specific primer pairs resulted in the amplicons of the expected 
size.  Each  PCR  product  was  purified  and  sequenced  bidirectionally  (section 
2.5.1). The resulting ABI electrophoregrams were read using DNA sequence 
analysis tools as described in section 2.6. The presence of sequence changes 
was identified by comparison to the reference sequence of the PFDN5 gene, 
obtained from UCSC database (section 2.6).   Chapter V 
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Figure  5.4.  Primer  design  for  PFDN5  screening  and  examples  of  PCR 
products amplified from patient DNA samples 
a. Exons are shown as grey boxes with E1 to E6 representing the exon number 
and untranslated regions as black boxes. The size of each exon is shown below 
exons. The position of intronic primers designed to amplify the gene are shown 
by arrows. b. Patient DNA amplification of PFDN5 fragments as indicated. The 
first lane on each of the agarose gels is a 1 kb DNA size marker. “+” represents 
PCR  products  obtained  with  positive  control  DNA,  “-“  represents  negative 
control PCR without DNA. The size of the amplicons for each PFDN5 fragment 
is indicated with arrows. 
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Upon  analysis  of  exon  1,  the  electropherogram  of  patient  30  DNA  from  the 
EORD panel showed the presence of two alleles in the 5’ untranslated region 
21 bp upstream of the start codon. The reference sequence and the control 
DNA sequence have a C at this position, whereas patient 30 DNA had a C 
allele  and  a  T  allele.  This  finding  indicates  that  the  patient  is  heterozygous 
(figure 5.5a). 
Examining the data for exon 2, a sequence change was detected in intron 1 of 
patient 55 DNA of the EORD panel. The change was 27 bp upstream of the 
splice acceptor site of exon 2. The electropherogram of the control DNA and the 
reference sequence have a T allele but in patient 55 DNA this was a C. This 
finding  suggests  that  this  sequence  change  is  present  on  both  alleles  and 
represents a homozygous sequence change. However, it is possible that this 
sequence change is present on one allele and the other allele could be deleted 
(figure  5.5  b).  The  SNP  database  was  examined  for  the  sequence  changes 
identified in the EORD panel (NCBI, section 2.6) and these changes have not 
been previously annotated as SNPs.  
All the other 94 DNA samples from the EORD panel and 48 from the BBS panel 
appeared to have no sequence changes in any of the fragments of the PFDN5 
gene screened. 
5.2.2. PFDN5 protein purification 
To  initiate  investigation  of  the  biological  properties  of  the  PFDN5  protein  a 
recombinant protein was produced. For this purpose the coding sequence of the 
PFDN5α isoform (NM 002624) was amplified by PCR from an I.M.A.G.E. clone 
as described in section 2.1.1 and using primers from table 2.1.  
The obtained PCR product was analysed by agarose gel electrophoresis which 
showed a single band of the expected size of approximately 470 bp (2.1.1). This 
amplicon was then subcloned into the E. coli expression vectors pGEX-2T and 
pTrc-HisA  (2.1.7)  to  produce  GST  and  His  tag  constructs  as  described  in 
sections 2.1.2-2.1.5.  
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Figure 5.5. Sequence changes found in the PFDN5 gene in patients with 
retinal degeneration 
a. Heterozygous sequence change (C to T) in the 5’ UTR of patient 30 DNA is 
shown on the electropherogram obtained using 1F forward (30F) or 1R reverse 
(30R) primers and is highlighted by an arrow. b. Homozygous sequence change 
(T  to  C)  in  intron  1  of  patient  55  DNA  is  highlighted  with  an  arrow  on  the 
electropherogram obtained using 2F forward or 2R reverse primers (55F and 
55R respectively). c. Approximate position of the sequence changes identified 
in patient 30 DNA and patient 55 DNA in PFDN5 gene. Exons are shown as 
grey boxes (E1-E6) and untranslated regions as black boxes. 
   Chapter V 
 
215 
   
The  competent  E.  coli  were  then  transformed  with  the  plasmid  DNA  and 
induced with IPTG to activate the promotor (section 2.4.6-2.4.7). The PFDN5 
protein  expression  level  was  analysed  by  SDS-PAGE  with  Coomassie  stain 
(section  2.4.2.  and  2.4.3)  of  total  and  soluble  fractions  of  lysates  of  cells 
expressing  either  GST-PFDN5  or  His-PFDN5.  The  expression  of  the  protein 
was compared to the control lysates of non-transformed E.coli cells. The size of 
proteins  was  determined  by  comparison  to  a  prestained  protein  ladder.  The 
PFDN5  protein  had  a  predicted  molecular  weight  17  kDa  and  therefore  the 
expected molecular weight for PFDN5 with a His tag was approximately 20 kDa 
and for GST-fused protein approximately 43 kDa.  
His-PFDN5 protein appeared in the total fraction but not in the soluble fraction 
and all attempts at purification failed (data not shown). GST-PFDN5 appeared 
to  be  present  in  the  soluble  fraction as  well  as in  total. The  procedure  was 
optimised for expression level in One-Shot Top10® cells. The solubility of GST-
PFDN5 was improved by incubating at 33° C for 5 hours aft er induction with 
IPTG rather that at 37° C (Figure 5.6a). Tag free PF DN5 was purified by on-
column  thrombin  cleavage  with  subsequent  passing  through  benzamidine-
sepharose column to remove the thrombin as described in section 2.4.7 (figure 
5.6b). 
5.2.3. GST pull-down with mammalian cell lysates 
To  reveal  whether  PFDN5  could  act  independently  of  other  PFDN  complex 
subunits by binding substrates, or whether it could interact with other proteins 
which are known to be involved in cytoskeleton biogenesis, a GST pull-down 
assay was performed as described in section 2.4.9. GST tagged PFDN5 was 
expressed  as  described  above  in  E.coli.  Glutathione  sepharose  beads  were 
then  used  to  bind  recombinant  GST-PFDN5  from  the  bacterial  lysate.  The 
purified protein was left on the column and used for incubation and pull-down of 
interacting proteins from mammalian cell lysates.  
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Figure 5.6. PFDN5 protein purification 
a.  Coomassie  stained  SDS-PAGE  gel  showing  E.coli  cell  lysate  soluble 
fractions transformed with two different clones (1 and 2) for pGEX2T alone and 
pGEX2T-PFDN5  incubated  at  different  times  and  temperatures  after  IPTG 
induction as indicated. The position of the expected mobility of GST and GST-
PFDN5 are highlighted with arrows. Molecular weight markers are on the left 
with Mr in kDa as indicated. b. Coomassie stained SDS-PAGE gel of purified 
PFDN5 (predicted Mr 17 kDa) after on-column cleavage with thrombin (THN, 
predicted Mr 35 kDa). The first lane shows GST-free PFDN5 and thrombin in 
the  eluate  after  overnight  thrombin  cleavage.  The  second  lane  represents 
purified  PFDN5  (GST  free  and  thrombin  free)  after  passing  through 
benzamidine-sepharose (BS). Molecular weight markers are on the left with Mr 
in kDa as indicated. 
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Two cell lines, HeLa and SK-N-SH (treated as described in section 2.3.1) were 
used for extraction of soluble protein using 0.1 % Triton X100 in PBS (table 
2.8). The lysates were then incubated with GST- or GST-PFDN5 beads. The 
bound  proteins  were  eluted  and  analysed  by  Western  blotting  as  shown  in 
figure 5.7 (described in sections 2.4.2 and 2.4.5). GST- bound resin, incubated 
with the same lysates, was used as a control for non-specific binding. Analysis 
with anti β-tubulin antibody showed specific bands of the 50 kDa expected size 
only in the lanes where GST-PFDN5 was incubated with the lysates and in the 
lane with a HeLa lysate control, but not in any other lanes (figure 5.7). Western 
blotting of this GST pull-down for other proteins, such as Arl3 or RP2, did not 
show any specific binding (data not shown).       
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Figure 5.7. Binding of β-tubulin by GST-PFDN5 in an affinity pull-down 
assay. 
a. Coomassie stained gel of a GST pull-down assay with extracts of SK-N-SH 
and HeLa cells. The position of expected mobility of GST and GST-PFDN5 is 
indicated  with  arrows.  b.  Western  blot  of  the  samples  from  the  same 
experiment immunostained for beta-tubulin is shown. The last lane shows 25 
µg/ml of HeLa total lysate input.  
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5.2.4. PFDN5 in CytoTrap® 
The tubulin folding pathway is facilitated by a variety of chaperones including 
PFDN  and  tubulin  folding  cofactors  (section  1.4.4).  The  yeast  two-hybrid 
approach,  CytoTrap®,  described in  chapter 3.1.1,  was  chosen  as  an  in  vivo 
system  for  studying  potential  interactions  of  PFDN5.  This  experiment  was 
performed with the aim of determining whether PFDN5 could interact with other 
proteins taking part in tubulin biogenesis such as RP2, Arl3, Arl2 or Arl6.  
For this purpose PFDN5α coding sequence was amplified from an I.M.A.G.E. 
clone with specific primers (table 2.1) resulting in an amplicon of the expected 
size of 470 bp. This PCR product was then cloned into pSos and pMyr vectors 
following  the  protocols  described  in  2.1.2-2.1.8.  Cdc25-H  yeast  cells  were 
cultivated as described in 2.2.1 and then transformed (2.2.2). Yeast growth was 
tested  at  two  temperatures  –  the  permissive  temperature  (24  ° C)  and  the 
restrictive temperature (37 ° C) on the appropriate sele ctive media (described in 
2.2).  Growth  at  the  restrictive  temperature  (37° C)  indicated  a  protein-protein 
interaction  had  occurred.  If  growth  was  not  observed  after  168  hours  of 
incubation at 37° C on the selective media, the proteins  were considered not to 
interact. Examples of positive and negative growth are shown in figure 5.8. 
Yeast  transformed  with  PFDN5  in  pSos  and  the  positive  control  (pMyr  SB) 
exhibited quick growth and formed colonies after only 96 hours of incubation 
under  restrictive  conditions.  This  control  was  interpreted  as  a  high  affinity 
binding interaction and that hSos-PFDN5 was expressed and the hSos moiety 
was functional. The negative control, pMyr LaminC, upon co-transformation with 
pSosPFDN5 did not result in yeast growth at 37 ° C for 240 hours of incubation 
on  the  selective  media.  These  data  demonstrate  that  hSos-PFDN5  did  not 
transactivate the system.For the protein interaction assay of PFDN5 with other 
proteins of interest, yeast cells were co-transformed with pSos-PFDN5 and the 
candidate interacting proteins in pMyr vector: Arl3, Arl2, Arl6 and RP2 (sections 
2.2, 2.1.8). The experiment showed that no growth at the restrictive temperature 
was observed and therefore no interaction occurred. The results of this analysis 
are represented in table 5.1. Chapter V 
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Figure 5.8. PFDN5 in the CytoTrap® system 
Illustration of positive and negative yeast growth of four different colonies from 
each transformation after 144 hours of incubation on galactose –UL selective 
media. The yeast were transformed with pSos-PFDN5 and pMyr Sos binding 
protein (SB) for a positive control, or pMyr Lamin C for a negative control. 
 
pSOS   pMyr   24° C (72h)  37° C (168h)  
Sos   Myr   +++  -  
Sos   PFDN5   +++  -  
RP2   Myr   +++  -  
RP2   PFDN5   +++  -  
PFDN5   Myr   +++  -  
PFDN5   Arl3   +++  -  
PFDN5   Arl2   +++  -  
PFDN5   RP2   +++  -  
PFDN5   SB   +++  +++  
PFN5   Arl6   +++  -  
 
Table 5.1. Summary of PFDN5 CytoTrap® results 
Growth was examined after incubation at 24ºC on glucose –UL selective media 
and  galactose  –UL  selective  media.  Positive  growth  is  labelled  “+++”  when 
yeast formed saturated colonies. Negative growth is indicated by “-“ in case no 
colonies were observed after 168 hours of incubation. The absence of growth 
suggests that no interaction occurred in this system. Chapter V 
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5.3. Discussion 
It was demonstrated in this chapter that sequence changes in the PFDN5 gene 
were  not  associated  with  severe  early  onset  retinal  degeneration  or  Bardet-
Bieldl syndrome. However, a mouse model with a homozygous point mutation 
in Pfdn5 was described with a syndromic form of retinal degeneration (Lee et 
al.,  ARVO  2005),  these  data  have  never  been  published  so  it  is  difficult  to 
discuss them in detail.  
However  studies  in  mice  deficient in  another  subunit  of  the  PFDN  complex, 
PFDN1, exhibited a syndrome with cilial dyskinesia and thus, support possible 
involvement  of  PFDN  in  retinal  degeneration  (Cao  et  al.,  2008).  The  mice 
developed hydrocephaly and respiratory mucus accumulation. Unlike PFDN5, 
the PFDN1 subunit has not been found to be crucial for the binding of the PFDN 
complex with tubulin (Simons et al., 2004).  
PFDN5 mutations would be predicted to affect cilia more severely than PFDN1. 
Our study demonstrated for the first time that PFDN5 was able to bind beta 
tubulin,  a  substrate  for  the  whole  PFDN  complex,  independently  from  other 
PFDN complex subunits. These data are supported by the previous finding that 
the PFDN complex with truncated PFDN5 failed to bind tubulin (Simons et al, 
2004). These new data indicate the importance of the PFDN5 subunit function 
of the PFDN complex. It is also possible that null-mutations in such an important 
subunit would be lethal and this could be one of the reasons why a mutation of 
this kind was not identified in this study. 
On the other hand, it has been previously reported that a sequence change in 
exon 6 (A157R) was associated with cancer in humans. PFDN5 was screened 
in 57 cultured cancer cells and 90 tissues from cancer patients. This sequence 
change was present in about 50–60 % of leukemia/lymphoma cells and in more 
than 75 % of squamous cell carcinomas of the tongue (Fujioka et al., 2001). 
This  sequence  change  was  not  found  during  our  screening  of  144  patients 
suggesting that it is more likely to be a mutation rather than a polymorphism. 
The A157R mutation abrogated the function of PFDN5 towards c-myc in vitro, 
proposing  that  it  could  be  a  tumor  suppressor  protein.  The  involvement  of Chapter V 
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PFDN5 in anti-oncogenic pathways has been shown previously (described in 
5.1.4) (Mori et al., 1998). PFDN5 is able to regulate several proto-oncogenes, 
such as c-myc, b-myc and c-fms directly, or via the wnt pathway. Thus, there is 
a possibility that amino acid substitution mutations in the C-terminus decrease 
the ability of PFDN5 to down regulate c-myc. 
The  DNA  sequence  changes  found  in  patients  with  EORD  were  located  in 
regions which are not predicted to directly affect the protein sequence. On the 
other hand, in our study, only PFDN5 exons and short regions of introns within 
60 bp from the acceptor/donor splice sites were screened. Therefore there is a 
possibility that large deletions or insertions within intronic regions could cause 
disease and would not be identified by this method. Intronic deletions/insertions 
have  been  shown  to  affect  protein  synthesis  e.g. in  the  Parkinson’s  disease 
causing gene NURR1 and in SCN5A that mutations result in Brugada syndrome 
(Hong et al., 2005; Nickols et al., 2004). However, such mutations are usually 
located  around  splice  sites  like  those  described  for  LCA5  and  TULP1 
(Ramprasad et al., 2008; Abbasi et al., 2008). Promoter region mutations can 
affect  the  binding  to  RNA  polymerase  II  or  numerous  regulatory  co-factors 
(Spek et al., 1995), and this region was not screened in our study either. Thus, 
these potential ways of affecting of the protein synthesis of PFDN5 could be 
investigated further by screening of promoter regions and all PFDN5 introns. 
The sequence changes found during the screening of PFDN5 in this study have 
not  been  described  in  the  SNP  database  and  therefore  are  likely  to  be 
mutations.  There  is  a  possibility  that  a  homozyous  sequence  change  at  a 
position 27 bp upstream from the splice site of exon 2 in DNA 55 in EORD 
panel could affect the protein synthesis if there was a potential cryptic splice 
site. However, sequence analysis does not support this hypothesis. 
Another  possibility  is  that  this  sequence  change  could  disrupt  a  potential 
interaction with DNA binding proteins, which could potentially modulate PFDN5 
splicing. In order to prove this hypothesis, the protein expression analysis of 
PFDN5 in blood samples from patient 55 could be used. To perform such a 
study it is essential to make an antibody to PFDN5, which is possible since a Chapter V 
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tag  free  protein  has  been  successfully  purified  and  is  ready  for  an  animal 
immunisation procedure.  
Investigation  of  PFDN5  interactions  with  other  proteins  important  for 
cytoskeleton biogenesis did not reveal any binding in CytoTrap®. This assay 
has  proved  useful  for  RP2  screening  for  novel interacting  partners.  Proteins 
tested  for  interaction  with  PFDN5  in  CytoTrap®  were  not  checked  for 
expression level, therefore it is possible that this method was not optimal. To 
investigate  interactions  further,  a  GST  pull-down  could  be  used  since  this 
affinity assay was efficient for identifying the binding of β-tubulin by PFDN5. 
Recently, an additional exon 2a was reported and this was not screened in this 
study since the reported mouse Pfdn5 mutation was in exon 4 which is absent 
in the PFDN5 δ isoform that contains exon 2a (figure 5.1) (Hagio et al., 2006). 
However, there is a possibility that this isoform is important for the retina and 
thus,  alterations  in  this  exon  would  be  crucial.  Therefore  a  study into  which 
isoform of PFDN5 is expressed in the retina using RT-PCR and isoform specific 
antibody would be informative. Thus, the importance of PFDN5 for the retina is 
yet to be revealed.  
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Chapter VI. Discussion and future work 
Inherited  retinal  dystrophies  represent  a  major  cause  of  blindness  of  which 
retinitis pigmentosa is the most prevalent. Retinitis pigmentosa is both clinically 
and  genetically  heterogeneous  and  the  pathogenesis  has  yet  to  be  clearly 
defined. The ultimate goal of studies into the disease associated genes is the 
possibility of developing new and effective therapies. However, before that may 
be achieved, the function of the causative gene and its role in the retina needs 
to be established.  
RP2 is a protein with a ubiquitous expression pattern and the reason why its 
mutations cause retinal degeneration is unknown (Schwann et al., 1998). RP2 
has been suggested to localise in the cilium (described in 1.5.3), a ubiquitous 
structure which dysfunction is known to cause mainly syndromic forms retinal 
degeneration  (reviewed  in  Klysik,  2008).  RP2  is  suggested  to  be  partially 
localised to the cilia (described in section 1.5.3). However RP2 mutations have 
not been shown to cause a cilia related disorder suggesting redundancy of RP2 
function  in  the  cilium.  Moreover,  the  RP2  plasma  membrane  localisation 
through  dual  acylation  has  been  shown  to  be  important  for  the  disease 
pathogenesis (Chapple et al., 2000; Chapple et al., 2002; Grayson et al., 2002). 
The possible clues to RP2 function may be in its interactions with other proteins. 
At the start of this study, RP2 was believed to have only one interacting partner, 
the ubiquitous cilia and microtubule localised ADP ribosylation factor-like Arl3 
(sections  1.6  and  1.7).  Recent  studies  revealed  several  other  potential 
interacting partners, suggesting the involvement of RP2 intracellular transport 
mechanisms and cell cycle regulation. All of them are ubiquitous proteins and 
bind to the C-terminus of RP2, presumably competing with each other (Evans, 
2007). 
In  this  study  two  proteins  taking  part  in  the  phototransduction  cascade,  rod 
arrestin and transducin-β, have been identified to bind to RP2. These two novel 
interacting partners, for the first time, provided a direct link between RP2 and 
retinal  physiology.  Moreover,  mutations  in  rod  arrestin  are  known  to  cause 
autosomal  recessive  retinitis  pigmentosa  (arRP)  and  Oguchi  disease Chapter VI 
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(Nakazawa et al., 1998), suggesting the similarity of pathogenic pathways with 
XLRP. Pathogenic RP2 mutations were demonstrated to disrupt both identified 
interactions, supporting their potential importance for XLRP pathogenesis.  
The  role  of  these  new  interactions  remains  to  be  elucidated.  Importantly, 
functional studies need to be performed to test whether RP2 is directly involved 
in  phototransduction  cascade  regulation.  Thus,  a  variety  of  experiments 
including studies of transducin complex dissociation by activated rhodopsin and 
PDE  complex  activation  in  the  presence  of  RP2  would  improve  our 
understanding of the role of RP2 interactions with transducin-β. Tests of the 
ability  of  rod  arrestin  to  quench  activated  phosphorylated  rhodopsin  in  the 
presence of RP2 could be performed to investigate the consequences of RP2-
rod  arrestin  interaction  for  the  phototransduction  cascade.  The  effect  of 
pathogenic mutants of RP2 in such studies could be also explored. 
Another  hypothesis  that  could  be  investigated  is  the  involvement  in  the 
phenomenon of light-dependent translocation that has been described for both 
rod  arrestin  and  transducin  (described  in  section  1.2.3.6).  Light  dependent 
translocation mechanism for another protein, recoverin, has been proposed to 
be connected with a calcium-myristoyl switch mechanism (Tanaka et al., 1995; 
Strissel et al., 2005), but the mechanism of translocation for rod arrestin and 
transducin  remains  to  be  elucidated.  RP2  may  be  one  of  the  proteins  that 
mediate such translocation (figure 6.1). 
It  is  unknown  if  RP2  itself  is  able  to  translocate  between  photoreceptor 
segments upon light exposure. This could be tested by staining of sections of 
the dark and light adapted retina with anti-RP2 antibody. It is possible to predict 
that this movement would be similar to the one described for recoverin from OS 
to IS upon light exposure due to their similarity in posttranslational modification. 
Therefore  the  hypothesis  of  calcium-myristoyl  switch  mechanism  should  be 
explored  as  RP2  was  suggested  to  bind  calcium  in  a  calcium  mobility  shift 
assay.  It  is  not  clear  which  residues  of  RP2  are  potentially  responsible  for 
calcium  binding,  whether  it  is  the  region  in  the  N-terminus  following  the 
myristoylation motif or it is the C-terminal residues that resemble an EF-hand. 
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In order to develop this hypothesis studies into the calcium binding ability of 
RP2 and its role in RP2 function could be explored. This question is especially 
important  for  the  retinal  specific  function  of  RP2  due  to  the  drop  in  calcium 
concentration  upon  phototransduction  cascade  activation.  Calcium 
concentration in the retina is known to regulate a variety of processes (section 
1.2.3.3). For example, other calcium binding proteins, centrins, recently have 
been suggested to be gatekeepers of transducin translocation (Wolfrum et al., 
2002; Giessl et al., 2006). Centrin isoforms are differently localised at the basal 
body  and  in  the  cilium.  When  activated  by  calcium,  centrin  isoforms  were 
demonstrated to bind transducin βγ, suggesting that the complex may regulate 
the transducin movement through the connecting cilium (Giessl et al., 2006).  
Another possible role of RP2 interaction with rod arrestin and transducin-β is 
their targeting to the membranes. This was demonstrated in this study, that in 
vitro RP2 localised transducin β to the plasma membrane. It is known that the 
transducin  β  subunit,  as  other  β  subunits  of  the  G  protein  family  of 
heterotrimeric proteins, does not undergo posttranslational modifications which 
would target it to the membrane. It is proposed that it is brought there by the 
prenylated  γ  subunit  (McGudden  et  al.,  2005).  However,  recent  data  argue 
against this hypothesis showing that a block of palmitoylation and myristoylation 
but not prenylation inhibited transducin-β membrane localisation (Saini et al., 
2007).  This  report  suggested  that  transducin-β  has  a  palmitoylated  and 
myristoylated adaptor that tethers it to the membrane. RP2 is known to have a 
dual acylation motif (Chapple et al., 2000) and thus, such a role for RP2 seems 
possible (figure 6.1). 
The consequence of RP2 interaction with rod arrestin and transducin β remains 
to be revealed. As proposed in this study, RP2 may bind to rod arrestin when it 
is a monomer but not a tetramer (Hanson et al., 2008). Therefore, elucidation of 
the effect of RP2 binding to rod arrestin could be investigated using mutants, 
which would support rod arrestin binding to a monomer state. It is important to 
confirm the hypothesis of the interaction of RP2 with the rod arrestin monomer 
as it is an active form quenching activated rhodopsin whereas the tetramer is 
considered to be a storage form (Hanson et al., 2007; Hanson et al., 2008).  Chapter VI 
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Interestingly,  both  transducin  and  isoform  44  of  rod  arrestin  are  found  in 
detergent resistant membranes (DRM) of photoreceptors upon light illumination 
and RP2 has been shown to localise to DRM in cells (Nair et al., 2002; Chapple 
et  al.,  2003).  Therefore,  the  experiments  that  would  show  whether  RP2  is 
present  in  DRM  of  the  photoreceptors  in  the  dark  adapted  or  light  adapted 
retina could be performed. In this aspect it is also important to test if RP2 binds 
to the p44 isoform of rod arrestin and whether this interaction is essential for 
p44 localisation in DRM. 
Another putative interacting partner of RP2, retina specific protein Unc119, was 
identified in this study using yeast two-hybrid screening with a retinal library. 
This finding complements the recent report of Veltel and colleagues (2008b) 
showing that RP2 is able to form a ternary complex with Unc119 via Arl3. Thus, 
the weak interaction observed in yeast two-hybrid may suggest that the system 
is able to detect even ternary complexes via endogenous yeast proteins.  
Another interacting partner that would put RP2 in a pathway with other retinal 
dystrophies  is  nucleolin  (NCL).  NCL  is  known  to  bind  the  lebercilin  protein 
(LCA5)  which  is  localised  to  the  connecting  cilium  and  which  failure  causes 
Leber Congenital Amaurosis (LCA, described in section 1.3.6) (den Hollander et 
al., 2007).  NCL is also reported to be involved in the pathogenesis of retinal 
dystrophies  caused  by  mutations  in  RPGR  via  the  interaction  of  the  cilia 
localised RPGR interacting protein (via RPGRIP1) with nucleophosmin (NPM) 
(Shu  et  al.,  2005).  Both  NCL  and  NPM  interact  with  each  other  and  are 
multifunctional chaperones that shuttle between the nucleoli and the cytoplasm 
and have been associated with centrosomal division (Ugrinova et al., 2007; Cha 
et al., 2004). Thus, cilia localised RP2, LCA5 and RPGR are put in one pathway 
not  only  by  their  localisation  but  by  shared  interacting  partners.  The 
physiological significance of NCL and NPM interaction for retinal dystrophies is 
unknown (figure 6.1).  
The interaction of RP2 with NCL can be hypothesised to be transient during cell 
cycle progression while NPM and NCL shuttle between the nucleus and the 
cytoplasm. It has been proposed that such nuclear proteins are released by 
importin  in  the  presence  of  centrosomal  RAN–GTP  (Cha  et  al.,  2004). Chapter VI 
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Moreover,  RPGR  is  known  to  have  RCC1  domain  in  its  structure  highly 
homologous to RCC1 protein, a GEF for RAN. Thus, there is a possibility that 
the interactions of RP2 with NCL and RPGR with NPM are a consequence of 
relationships with RAN. 
Other ubiquitous interacting partners of RP2 were identified using the yeast two-
hybrid approach. Among them were chaperones, a part of the substrate binding 
domain  of  Hsc70  and  a  subunit  of  cytosolic  chaperonin,  CCT6.  These  two 
interactors were identified during the screening with the N-terminal fragment of 
RP2  and  at  first  sight  this  data  suggested  that  the  fragment  used  for  the 
screening  was  at  least  partly  misfolded.  This  hypothesis  was  supported  by 
results  obtained  during  characterisation  of  interaction  with  CCT6,  which 
demonstrated binding of this chaperone subunit only to the fragment of RP2 
and  its  mutants.  However,  the  interaction  with  Hsc70  was  disrupted  with 
pathogenic mutations in RP2, suggesting that this interaction, unlike the one 
with  CCT6,  may  be  functional.  Moreover,  recently  the  interacting  partner  of 
RP2,  Arl3,  was  identified  as  one  of  the  proteins  of  the  Hsp90  interactome, 
providing another link between RP2 and chaperone machinery (McClellan et al., 
2007). 
The  role  of  the  RP2  interaction  with  Hsc70  is  to  be  elucidated.  Hsc70  is  a 
multifunctional protein and involved in a variety of cellular pathways (described 
in 1.4.1.1). One of them is the degradation by the proteasome and this function 
requires the assistance of co-chaperones such as CHIP. This study suggests 
that RP2 could be involved in 26S proteasomal degradation pathway due to one 
of the identified RP2 interacting partners being a non ATPase subunit 4 of 26S 
proteasome,  PSMD4.  Thus,  the  hypothesis  that  RP2  may  act  as  a  co-
chaperone of Hsc70 in protein degradation machinery could be explored.  
A  study  into  whether  mutation  in  another  putative  chaperone,  subunit  5  of 
prefoldin complex (PFDN5), could cause retinal degeneration was performed. 
The  trigger  for  this  project  was  a  conference  report  of  Lee  and  colleagues 
(2005) about a novel retinal dystrophy causing gene in mice, Pfdn5. However, 
upon screening of two panels of patients with syndromic and non-syndromic 
retinal degeneration no mutations were identified in this gene. There could be Chapter VI 
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several reasons for the absence of mutations. It has been three years since a 
point mutation in gene was first reported, however these data have not been 
published, arising a question whether data of Lee and colleagues (2005) was 
correct.  
There is another possibility that mutations in PFDN5 could be lethal in humans 
and therefore is not possible to identify in patients. This hypothesis is supported 
by the finding of this study demonstrating that PFDN5 protein is able to bind 
tubulin,  a  substrate  of  PFDN  complex,  independently  on  other  complex 
subunits.  Thus,  PFDN5  subunit  is  proposed  to  be  essential  for  the  complex 
function  and  therefore  correct  cytoskeleton  elements  folding  (described  in 
section 1.4.4).  
Thus, the aims of this study have been achieved. At least two retina specific 
putative interacting partners of RP2 protein have been identified; however the 
role of these interactions still remains to be elucidated. Other interactors of RP2 
were also identified suggesting its involvement in other cellular processes such 
as  26S  proteasomal  degradation  and  nuclear  transport  pathway  (figure  6.1). 
Therefore, this study suggested future ways of exploring of RP2 function in the 
retinal physiology. 
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Figure 6.1. A schematic of potential pathways where RP2 may function 
S – synapse, N – nucleus, ER – endoplasmic reticulum, M – mitochondrion, C – 
cilium, OS – outer segment, PM – plasma membrane.    References 
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General Reagents 
 
PCR Master Mix (ABgene, AB-0575/DC) 2 X 
 
1.3 units ThermoPrime DNA taq polymerase 
150 mM Tris-HCL  pH 8.8 
40 mM (NH4)2SO4 
3 mM MgCl2 
0.02 % (v/v) Tween20
® 
0.4 mM each dATP, dCTP, dGTP, dTTP 
 
 
siRNA buffer 5 X 
 
300 mM KCl, 
30 mM HEPES-pH 7.5  
1.0 mM MgCl2 
 
 
Resolving Gel for SDS-PAGE (10 %) 
1.5 M Tris-HCl pH 8.8      2.5 ml 
30 % Acrylamide:Bis      3.3 ml 
ddH2O            4.0 ml 
10 % (w/v) SDS        0.1 ml 
10 % (w/v) APS        0.1 ml 
Tetramethylethylenediamine  
(TEMED)          0.005 ml 
 
 
Stacking Gel for SDS-PAGE (3 %) 
0.5M Tris-HCl pH6.8      1.25 ml 
30 % Acrylamide:Bis      0.65 ml 
ddH2O            3.00 ml 
10 % (w/v) SDS        0.05 ml 
10 % (w/v) APS        0.05 ml 
TEMED          0.01 ml 
 
 
SDS-PAGE Running Buffer x1 in H2O 
Tris-HCl          25 mM 
Glycine          190 mM 
SDS            3.5 mM 
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Laemmli SDS-PAGE Sample Buffer x2 in H2O  
Tris-HCl (pH6.8)        125 mM 
Glycerol          20 % (v/v) 
SDS            4 % (v/v) 
2-β Mercaptoethanol      10 % (v/v) 
Bromophenol Blue        0.2 % (w/v) 
 
 
Western Blotting Transfer Buffer x1 in H2O 
Tris-HCl          25 mM 
Glycine           190 mM 
Methanol          20 % (v/v) 
 
 
Coomassie Gel Stain 
Methanol          25 % (v/v) 
Acetic acid          25 % (v/v) 
Coomassie brilliant blue (R-250)*   0.25 % (w/v) 
in H2O 
 
Coomassie De-Stain  
Methanol                                                  25 % 
Acetic acid                                               10 % 
in H2O 
 
Ponceau S Stain 
Trichloroacetic acid (TCA)     3 % (w/v) 
Ponceau S          0.2 % (w/v) 
in H2O 
 
Western Blotting Blocking Buffer 
“Marvel” milk powder      5 % (w/v) 
Tween-20®          0.05 % (v/v) 
In Phosphate buffered saline (PBS) 
 
 
LB Media 
Bacto®-tryptone        1 % (w/v) 
Bacto®-yeast extract      0.5 % (w/v) 
NaCl            1 % (w/v) 
up to 1 litre with H2O and autoclave 
 
 
LB Agar 
Bacto®-tryptone        1 % (w/v) 
Bacto®-yeast extract      0.5 % (w/v) 
NaCl            1 % (w/v) 
Bacto®-agar         1.5 % (w/v) 
up to 1 litre with H2O and autoclave, cool to 55ºC before adding antibiotic Appendix 
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Chloramphenicol Stock 
340mg in 10 ml ethanol 
Add 1 ml to 1 litre LB 
 
 
Ampicillin Stock 
1g in 20 ml water 
Add 1 ml to 1 litre LB before use 
 
 
TE Buffer in H2O 
Tris-HCl (pH 7.5)        10 mM 
EDTA           1 mM   
 
 
Phosphate-buffered Saline (PBS)  
NaCl            145 mM 
NaH2PO4          3.6 mM 
Na2HPO4          10.5 mM 
in H2O 
Autoclave before use 
 
 
TAE Buffer 
Tris-HCl          40 mM 
Acetic Acid          40 mM 
EDTA           1 mM 
in H2O 
 
 
RIPA buffer 
Tris-cl pH 7.4          50mM 
NaCl            150mM 
NP40            1 % (v/v) 
Na-deoxycholate        0.25 % (w/v) 
 
Yeast Specific Reagents 
 
LiOAc/TE Solution  
LiOAC            100 mM 
TE in H2O 
Filter sterilise 
 
 
40 % PEG LiOAc/TE Solution  
LiOAc           10 mM 
PEG4000          40 % (w/v) 
TE in H2O 
Filter sterilise Appendix 
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SU Buffer 
SDS            5 % (w/v) 
Tris-HCl (pH 6.8) in H2O      125 mM 
EDTA           0.1 mM 
Bromophenol blue        0.005 % (w/v) 
Urea            8 M 
Store at -20ºC.  Add DTT 15 mg/ ml prior to use. 
 
 
YPAD Broth 
Yeast extract         1 % (w/v) 
Bacto®-peptone        2 % (w/v) 
Dextrose          2 % (w/v) 
Adenine Sulfate        0.004 % (w/v) 
up to 1 litre with water and autoclave 
 
 
YPAD Agar 
Yeast extract         1 % (w/v) 
Bacto-peptone        2 % (w/v) 
Dextrose          2 % (w/v) 
Adenine Sulfate        0.004 % (w/v) 
Agar            15 % (w/v) 
Up to 1 litre with water and autovlave 
 
 
 
 
SD/Glucose Minimal Media 
Yeast nitrogen base without amino acids    0.17 % (w/v) 
Ammonium sulphate        0.5 % (w/v) 
Dextrose            2 % (w/v) 
Add Agar for plates, omit for media    15 % (w/v) 
Make upto 900 ml with water and autoclave 
Add 100 ml appropriate 10x dropout solution after cooling to 55° C 
 
 
SD/Galactose Minimal Media 
Yeast nitrogen base without amino acids    0.17 % (w/v) 
Ammonium sulphate        0.5 % (w/v) 
Galactose            2 % (w/v) 
Raffinose            1 % (w/v) 
Add Agar for plates, omit for media    15 % (w/v) 
Make upto 900 ml with water and autoclave 
Add 100 ml appropriate 10x dropout solution after cooling to 55° C 
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10x Dropout Solution in H2O      Weight (mg/litre) 
L-Isoleucine            300 
L-Valine            1500 
L-Adenine hemisulphate salt      200 
L-Arginine HCl          500 
L-Histidine HCl monohydrate      200 
L-Leucine            1000 
L-Lysine HCl           500 
L-Methionine           200 
L-Phenylalanine          500 
L-Threonine*           2000 
L-Tryptophan            500 
L-Tyrosine            500 
L-Uracil            200 
L-Glutamic Acid          1000 
L-Aspartic Acid*          1000 
L-Serine            400 
 
 
Reagents for general subcellular fractionation. 
 
Buffer C. 
HEPES pH 7.9          20 mM 
MgCl2              2 mM 
KCl              100 mM 
EDTA             5 mM 
Sucrose            250 mM 
Glycerol            10 % (v/v) 
 
 
 
Buffer N. 
HEPES pH 7.9          20 mM 
MgCl2             2 mM 
NaCl              50 mM 
EDTA             5 mM 
Glycerol            5 % (v/v) 
 
 
Buffer M. 
HEPES pH 7.9          20 mM 
MgCl2             2 mM 
KCl              100 mM 
EDTA             5 mM 
Sucrose            250 mM 
Glycerol            5 % (v/v) 
sodium deoxycholate         0,5 % (w/v) 
NP-40             1 % (v/v) 
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Buffer CS. 
PIPES pH 6.8          10 mM 
MgCl2             2 mM 
NaCl              150 mM 
EDTA             5 mM 
Sucrose            250 mM 
SDS              1 % (w/v) 
 
 
 